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PREFACE 
The three principle catecholamines in the mammahan body are dopamine, nor­
adrenaline and adrenaline (fig. 1). Traditionally, adrenaline is regarded as the 
major hormone secreted by the adrenal medulla, noradrenaline as the neuro­
transmitter of most of the postganglionic sympathetic neurones and dopamine as 
a precursor of the other two catecholamines in their biosynthesis. However, 
evidence has accumulated that all three catecholamines have an additional func­
tion, ι e. they may act as neurotransmitter substances in the mammalian central 
nervous system (CNS). 
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FIG 1 Chemical structures of the three principle catecholamines in the mammalian body 
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Vogt (1954) was the first to suggest that a catecholamine might function as a 
central neurotransmitter in a study in which she reported that the regional 
distribution of brain noradrenaline and adrenaline ("sympathin") is uneven and 
bears no obvious relation to the distribution of sympathetic innervation of brain 
blood vessels. Similar evidence led to the suggestion that brain dopamine might 
act as a neurotransmitter (Carlsson et al., 1958). Further studies on central 
catecholamines during the last two decades have mostly concentrated on the two 
most conspicuous catecholamines in the mammalian CNS: dopamine and norad-
renaline. 
Fluorescence histochemical methods for the visualization of catecholamines have 
shown that dopamine and noradrenaline are highly localized within the cell 
bodies, axones and terminals of specific populations of neurones (Fuxe, 1965; 
Ungeistedt, 1971; see fig. 2). Moreover, there is abundant evidence now to 
support a central neurotransmitter role for these two catecholamines (reviews: 
Homykiewicz, 1966; Salmoiraghi, 1966; Bradley, 1968; Axelrod, 1974). How-
ever, fluorescence histochemical methods cannot differentiate between norad-
renaline and adrenaline contaimng neurones. Hokfelt et al. (1974) have recently 
by using immunohistocheimcal techniques succeeded to map central neurones 
containing phenylethanolamine-N-methyltransferase, the enzyme converting 
noradrenaline into adrenaline. Gass chromatographic-mass spectrometnc 
methods have confirmed the presence of relatively high amounts of adrenaline in 
brain regions in which phenylethanolamine-N-methyltransferase containing 
neurones were found, suggesting that adrenaline might indeed be the neurotrans-
mitter of these neurones (Koslow and Schlumpf, 1974, see fig. 2). 
As central neurotransmitter substances the catecholamines play an important 
role in the language of the brain: they transmit mformation between neurones. 
This transmission of information is achieved primarily by interaction of the 
neurotransmitter with a sensitive post-synaptic site called receptor. The neuro-
transmitter-receptor interaction triggers a cascade of chemical events that 
FIG. 2: Horizontal representation of the most conspicuous ascending dopamine, norad-
renaline and adrenaline containing neuron groups in the rat brain (Modified from 
Ungerstedt, 1971 and Hokfelt et al., 1974). Left. Dopamine containing nerve fibres origi-
nate from cell bodies located m the substantia nigra (A 8 and A 9), cell bodies surrounding 
the interpeduncular nucleus (A 10) or cell bodies m the arcuate nucleus of the hypo-
thalamus (A 12). The fibres innervate the amygdala and caudate nucleus, the nucleus 
accumbens and olfactory tubercle and the median eminence. Middle Noradrenaline con-
taining nerve fibres originate from several structures in the lower brainstem (A 1, A 2, A 4, 
A 5, A 6 and A 7) and terminate in several regions of the CNS, e.g the spinal cord, the 
lower brainstem, the central grey matter, the hypothalamus, the amygdala and the septum. 
Right. Adrenaline contaimng neurones have been proposed by Hokfelt et al (1974) on the 
basis of the immunohistochemical demonstration of neurones containing phenylethanol-N-
methyltransferase, the enzyme converting noradrenaline mto adrenaline. The cell bodies of 
these neurones are located m the lower brainstem and the nerve terminals in the spinal cord, 
the lower brainstem and the hypothalamus. 
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ultimately causes a change in the bioelectric activity of the post-synaptic mem-
brane This possibility of changing membrane bioelectric activity is the basis of 
the dynamic synaptic communication between neurones 
During the last two decades much has been revealed concerning a number of 
aspects of the process of catecholamine neurotransmission in the mammalian 
brain, e.g. catecholamine biosynthesis and degradation, catecholamine neuronal 
storage and uptake and catecholamine release mechanisms Also the way in 
which a number of drugs interact with these elements of the catecholamine 
neurotransmission process has been the subject of a great number of molecular 
pharmacological studies. However, up to now relatively little attention has been 
given to the molecular pharmacological analysis of central catecholamine re-
ceptors. In this respect it may be illustrative that in a recent important book 
entitled "Frontiers in Catecholamine Research" (eds. Usdin and Snyder, 1973) 
of the total of 220 papers dealing with catecholamines in the nervous system 
only very few were armed at an analysis of central catecholamine receptors, 
whereas at least 50 papers dealt with catecholamine synthesizing or degrading 
enzymes. Of course, the reason for this could quite well be that analysis of 
central catecholamine receptors does not belong to the frontiers of the cate-
cholamine research. However, a more likely explanation is the complexity of 
measuring central drug-receptor interactions 
For an operational analysis of receptors in general one must be able to measure 
some of the biological effects produced by the drug-receptor interaction More-
over, for a molecular pharmacological analysis of receptors drugs must be 
administered as close to the receptor as possible and the effect measured must be 
linked to the drug-receptor interaction as much as possible e g for the analysis 
of vascular adrenergic receptors it is better to measure drug-induced effects at 
the level of an isolated vascular strip than to measure blood pressure changes in 
the entire organism. Molecular pharmacological analysis of peripheral catechol-
amine receptors has largely been performed in such isolated smooth muscle 
preparations, in which the drug-receptor interaction leads to easily measurable 
graded responses It is obvious that a similar approach can hardly be used for 
central nervous system catecholamine receptors In the latter case drug-induced 
effects must ultimately be analyzed at the level of single mammalian CNS 
neurones. Present neurophysiological techniques allow such analysis only to 
some extent since these techniques have not been developed well enough to 
allow close comparison of the effects caused by different doses of one or several 
drugs (cf Bloom, 1974) 
One way to tackle this problem is the study of catecholamine synaptic receptors 
in a (non-mammalian) preparation allowing such analysis and then use the results 
of such analysis as a model for mammalian CNS catecholamme receptors 
Section I of this thesis contains such approach In that section the pharmacology 
of dopamine receptors in the isolated ganglia of the snail Helix aspersa will be 
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presented. This preparation was chosen in view of the following: (I)Helix 
aspersa ganglia can be isolated and — if kept in a proper Ringer solution — 
remain electrophysiologically active for several hours; (2) Helix aspersa neuron 
cell bodies are relatively large; some of them have a diameter of more than 100 
μτη, thus allowing intracellular recording of their electrophysiological activity; 
(3) Dopamine is the only catecholamine present in the ganglia of this snail. 
Moreover, its neurotransmitter role is well documented, thus the presence of 
dopamine receptors can be anticipated. 
Another approach in the operational analysis of synaptic catecholamine re­
ceptors in the mammalian CNS is to study drug-induced effects on a level some­
what more complex than that of a single neuron. In that case special care has to 
be taken that all secondary processes that could influence the drug-induced 
effect apart from its receptor interaction are accounted for, e.g. drug inter­
action with other receptors, effects caused by metabolites of the drug, indirect 
effects due to interaction with neurotransmitter release, synthesis etc. Section II 
of this thesis contains a series of experiments performed along these lines. In 
that section experiments will be presented that are aimed at an operational 
analysis of hypothalamic adrenergic receptors in the control of arterial blood 
pressure and heart rate in the rat. In these experiments cardiovascular effects of 
drugs have been measured after the stereotactic injection of drugs into circum­
scribed noradrenaline and adrenaline sensitive regions of the hypothalamus. Such 
approaches are defenitely less precise in terms of receptor analysis than those at 
the level of the single neuron, but they gain in relevance as a consequence of the 
fact that they can reveal how CNS catecholaminergic synaptic mechanisms 
participate in the normal — or abnormal — functioning of the entire organism. 
Therefore, section I will be purely directed at a molecular pharmacological 
analysis of catecholamine (i.e. dopamine) receptors, whereas in section II more 
attention will be given to the functional significance of mammalian CNS cate­
cholamine receptors in the control of cardiovascular activity. 
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SECTION I 
DOPAMINE RECEPTORS 
17 

CHAPTER I MODELS IN THE STUDY OF DOPAMINE RE-
CEPTORS 
Introduction 
The first concepts of the unique physiological role of dopamine apart from its 
function as a precursor of noradrenaline and adrenaline were put forward some 
20 years ago (Carlsson et al., 1958; Carlsson, 1959; Holtz, 1959; Ehringer and 
Hornykiewicz, 1960). These studies all dealt with the distribution pattern of 
dopamine in the mammalian body, specially in the central nervous system where 
dopamine was shown to occur in relatively high amounts in the extrapyramidal 
system. Evidence in favour of a neurotransmitter role for dopamine at this level 
of the brain has been reviewed by Hornykiewicz (1966). 
The antiparkinson agent levodopa is the first drug of which the therapeutic 
effectiveness was related specifically to dopaminergic mechanisms (Birkmayer 
and Hornykiewicz, 1961 ; Barbeau et al., 1962). This drug is believed to exert its 
therapeutic action by elevating the extrapyramidal amount of dopamine that is 
subnormal in a number of parkinsonian patients (Barbeau et al., 1962; Davidson 
et al., 1967; Cotzias et al., 1967). 
However, in these early studies a dopamine-specific receptor at the level of these 
brain structures was not implicated. Van Rossum was the first to suggest that 
dopamine-specific receptors may be involved in the behavioural mode of action 
of several groups of drugs (van Rossum and Hurkmans, 1964; van Rossum, 1965, 
1966, 1967). This was proposed to be specially the case for amphetamine (van 
Rossum and Hurkmans, 1964) and several neuroleptic drugs (van Rossum, 1965, 
1966, 1967). These latter agents were suggested to act as antagonists at the 
central dopamine receptors, thereby causing an inhibition of the behavioural 
effects of dopamine at its central receptors (van Rossum, 1967; Cools and van 
Rossum, 1970). 
In 1965 Ernst suggested that apomorphine may cause its behavioural effects by an 
agonistic interaction with central dopamine receptors. Some effects of a number 
of other drugs, e.g. ergot alkaloids, piribedil, amantadine, are now primarily 
explained on the basis of an interaction with central dopaminergic mechanisms. 
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Conclusions concerning the mode of interaction of these drugs with central 
dopamine receptors almost invariably come from studies in which drugs were 
injected peripherally and in which behavioural phenomena were used as para-
meters to measure drug-induced effects This approach creates a very complex 
drug-effect relationship in the pharmacological action of these drugs, thereby 
hampering molecular pharmacological characterization of the central dopamine 
receptor. In the adrenergic receptor pharmacology similar complexities in drug-
effect relationships have been greatly reduced by the use of isolated organs. 
Therefore studies in isolated organ systems were clearly also indicated for the 
dopamine receptor pharmacology (cf. van Rossum, 1965). 
Over the last ten years several approaches have been put forward in the study of 
dopamine receptor pharmacology A number of effects of dopamine have been 
used as the basis of such approaches. However, a dopamine-induced effect does 
not necessarily imply the existence of a dopamine-specific receptor. To show 
such existence two important entena have to be fulfilled (aj the dopamine-
induced effect must be antagonized by drugs that at a dose range in which they 
block dopamine effects do not block the effects of agonists at other (e.g. ad-
renergic, cholinergic) receptors, (b) the dopamine-induced effect must be 
mimicked by a set of compounds with a relative potency that differs from that 
at other (e.g. adrenergic, cholinergic) receptors. 
The following effects of dopamine have been used as a basis for the characteriza-
tion of dopamine receptors pharmacologically (1) dopamme causes a number of 
cardiovascular effects in mammals some of which have been proposed to be 
mediated by dopamine-specific receptors, (2) dopamme causes a number of 
effects in evertebrates, mainly in their nervous system. Again, some of these 
effects have been suggested to be mediated by dopamine-specific receptors, (3) 
in contrast to the previous two functional approaches also a biochemical ap-
proach has been used for investigating dopamine receptor pharmacology 
dopamine stimulates adenylate cyclase isolated from various parts of the 
mammahan body. It has been proposed that a dopamine-specific receptor is 
involved m the mediation of this response, (4) dopamine causes a number of 
electrophysiological effects when administered onto mammalian central 
neurones lontophoretically. Agam, some of these effects seem to be mediated by 
dopamine-specific receptors 
The rest of this chapter will be devoted to a discussion of the data obtained 
using these approaches. In the last paragraph of this chapter some recent ad-
vances in the behavioural models m the study of central dopamine receptors will 
be discussed. 
Finally, a frequently used approach in the classification of centrally acting, 
putatively dopaminergic drugs is the study of the changes in dopamine turnover 
after the administration of these drugs. The hypothesis underlying this approach 
is that drugs interacting with postsynaptic dopamme receptors will cause a com-
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pensatory change in dopamine turnover presynaptically as a consequence of a 
neuronal feedback mechanism (cf. Andén, 1973). This approach will not be 
further discussed here in view of the fact that the drug-effect relationship under-
lying such biochemical changes is still too much under debate to allow strict 
conclusions concerning a possible dopamine receptor involved and its pharma-
cological nature. 
1.1. The vascular dopamine receptor 
Dopamine exerts a number of dose-dependent effects upon the mammalian car-
diovascular system including positive inotropic and positive chronotropic effects 
on the heart, vasoconstriction and vasodilation (McDonald and Goldberg, 1963; 
Allwood et al., 1963; McNay and Goldberg, 1966). The first three of these 
effects are easily antagonized by classical adrenergic receptor blockers and are 
therefore most likely due to an action of dopamine on adrenergic receptors 
(further references: Goldberg, 1972, 1975). However, there is evidence for the 
involvement of dopamine-specific receptors in the vasodilatory effect. 
In species such as the rabbit and guinea pig dopamine causes a pure fall in 
arterial blood pressure after intravenous administration (Holtz and Credner, 
1942; Burn and Rand, 1958; Holtz et al., 1963). In the dog small doses cause 
depressor, larger doses pressor effects (McDonald and Goldberg, 1963; McNay 
and Goldberg, 1966). The depressor action cannot be blocked by a or β ad­
renergic receptor blockers; after a adrenergic receptor blockade the depressor 
action is even more prominent (Burn and Rand, 1958; Vanov, 1963; Holtz et al., 
1963; McDonald and Goldberg, 1963; Eble, 1964; van Rossum, 1965, 1966). In 
a series of studies in dogs, Goldberg and associates and Eble demonstrated that 
dopamine-induced depressor effects are due to a vasodilation of the renal and 
mesenteric vascular beds (Eb le,1964; McNay et al., 1965; McNay and Goldberg, 
1966; Meyer et al., 1967). Recently dopamine-induced vasodilation of coronary 
and cerebral vessels has been described as well (Schuelke et al., 1971: Cobb et 
al., 1972; Goldberg, 1972; von Essen, 1972; von Essen and Roos, 1974). Evi­
dence has also been presented for the existence of dopamine receptors that 
mediate renal artery vasodilation in man (McDonald et al., 1964; Breckenridge et 
al., 1971). Moreover, dopamine causes a substantial degree of diuresis and 
natriuresis in man (McDonald et al., 1964; Breckenridge et al., 1971). Recent 
studies have indicated that besides enhancing total renal blood flow, dopamine 
changes the renal cortical : medullary perfusion ratio (Espíritu et al., 1972; 
Hardaker and Wechsler, 1973). This effect of dopamine on the distribution of 
renal blood flow rather than on total flow is supported by the absence of 
dopamine receptors from both extrinsic and interlobular renal arteries 
(Zaroslinski and Browne, 1971 ; Kelly, 1972; Strandhoy et al., 1972). Up to now 
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there is not much evidence on the role of endogenous dopamine in autonomic 
control of the kidney vasculature. Bell and Lang (1973) have suggested that 
renal vasodilation is mediated by nerves that release dopamme as a transmitter 
In autonomic ganglia there is evidence for the existence of dopaminergic 
neurones (Koslow, 1973). Dopamme has been shown to inhibit ganglionic trans­
mission by causmg hyperpolanzation of the postsynaptic membrane (Libet and 
Tosaka, 1970, Willems and Bogaert, 1975, Kalix et al, 1974) Actually such a 
ganglionic effect of dopamine has been suggested to be involved in its vasodila-
tory effects (Bogaert and De Schaepdryver, 1967, Willems, 1974, Willems and 
Bogaert, 1975). However, a presynaptic inhibition of sympathetic nerve activity 
has recently also been proposed (Ilhan et al., 1974, Long et al, 1975) 
Eble (1964), McKay et al (1965) and van Rossum (1966) were the first to 
propose that specific receptors for dopamine mediate the effects of dopamine in 
the renal vascular bed This hypothesis was based upon the fact that a and β 
adrenergic receptor blocking agents as well as anticholinergic and antihistamin-
ergic agents are not able to antagonize dopamine-induced depressor and renal 
vasodilatory effects. In 1966 van Rossum showed that the neuroleptic agents 
spiramide and halopendol act as antagonists of dopamine depressor actions. A 
few years later Yeh et al (1969) and Goldberg and Yeh (1971) were able to 
show that halopendol as well as a number of neuroleptics of the phenothiazme 
type antagonize the renal and mesenteric vasodilation caused by dopamine. 
However, in contrast to the long-lasting effects of the neuroleptics on the central 
nervous system, the antagonism at the level of the renal dopamine receptors only 
lasts 1 - 2 minutes. Bell et al (1974; have reported that ergometnne, an ergot 
alkaloid without a adrenergic blocking activities, produces a powerful and long-
lasting antagonism of the renal effects of dopamme So, although a number of 
neuroleptic agents appear to act as selective antagonists of dopamine-vasodila­
tion, ergometnne is a better antagonist Recently, also the alkaloid bulbocapnine 
was shown to antagonize dopamine-induced depressor responses in the dog and 
the cat (Seller et al., 1975, Pendleton et al, 1975) 
Apart from selective antagonists a pharmacological receptor should also be char­
acterized by a specific order of activities of a series of closely related analogs of 
the natural agonist With respect to the renal dopamine receptor Goldberg et al 
(1968) investigated the activities of 44 phenylethylamines related to dopamine. 
Of this series only the N-methyl analog of dopamine, epinine, possesses unequi­
vocal dopamine-hke activity. Amines with other substitutions on either the ben­
zene ring or the side chain of the dopamme molecule do not exhibit such 
activity Apart from these phenylethylamines Goldberg and co-workers also 
studied the effects of apomorphine This drug was found to exert weak 
doparmne-hke activity, but it also possesses antagonistic properties (Goldberg et 
al, 1968, Goldberg and Musgrave, 1971, Bell et al, 1974) Recently the 
N-propyl derivative of apomorphine was found to be a more potent renal vaso-
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dilator than apomorphine, but still less effective than epinine and dopamine 
(Crumley et al., 1974). 
Goldberg et al. (1973, 1975) and Toda and Goldberg (1975) have recently used 
isolated canine renal, mesenteric and coronary artery strips to study the pharma­
cological nature of dopamine effects. After pretreatment with an α adren­
ergic blocker dopamine causes relaxations of such strips. Again, as was the case 
in intact animals, structural requirements for dopamine-like action are very 
specific. Dopamine-induced relaxation was not blocked by β adrenergic blockers; 
however, haloperidol also failed to antagonize the relaxation caused by dopa­
mine. It might be of great interest to test the effects of ergometrine in this 
set-up. 
The lack of activity of haloperidol in these isolated renal artery strips may 
indicate that in the intact organism the attenuation of dopamine effects on renal 
blood flow by haloperidol is caused by an action elsewhere in the body. In this 
respect the interesting experiments of Willems (1974) and Willems and Bogaert 
(1975) indicating that haloperidol very effectively blocks dopamine effects at 
the level of the lumbar paravertebral ganglia of the dog seem to be of import­
ance. This may imply that in the intact animal dopamine receptors at two levels 
— the renal and the ganglionic — are involved in the vasodilatory effects of 
dopamine, as was suggested by Willems (1974). This may also explain why van 
Rossum (1966) found a much longer lasting antagonism of dopamine-depressor 
effects with neuroleptic agents than the 1 - 2 minutes reported by Yeh et al. 
(1969) and Goldberg and Yeh (1971) at the level of the renal artery. 
In summary, the selective renal vasodilation caused by dopamine appears to be 
mediated via a dopamine-specific receptor. The structural requirements for dopa­
mine-like activity are more specific than those for a and β adrenergic activity 
(Ariens, 1967). Neuroleptic drugs may act as antagonists at the level of this 
dopamine receptor, although ergometrine seems to be a better antagonist. More­
over, dopamine receptors at two levels of the autonomic system may participate 
in the cardiovascular actions of dopamine and recent data indicate that these 
receptors may be pharmacologically distinct. This will be further discussed in 
chapter 3. 
From a pharmacological point of view the cardiovascular effects of dopamine 
have stressed the potential importance of dopamine receptors in the mode of 
action of certain drugs. 
Clinically, the presence of dopamine-specific receptors in certain parts of the 
cardiovascular system could be of future interest. A drug that would have a 
positive inotropic action on the heart without causing a significant peripheral 
vasoconstriction, and that would increase the blood flow to the kidney and 
splanchnic regions has potential value in the treatment of shock (McCannel et 
al., 1966). Moreover, an agent causing a specific increase in renal blood flow and 
an accompanying natriuresis could be an important adjunct in drug treatment of 
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hypertension and acute renal shutdown. Such a drug has not been found up to 
now; potential drugs in this sense are either too unstable metabolically (dopa­
mine and epininej or have too many central side effects (apomorphine). It might 
be of interest to explore imidazoline or tetrahydronaphthalene derivatives as 
some of these seem to have interesting dopaminomimetic activity as will be 
discussed in chapter 3. 
1.2. Evertebrate dopamine receptors 
Dopamine has been shown to affect a number of non-neuronal tissues of everte-
brates. Among these actions are: inhibition of the stretch receptor of the 
crayfish (McGeer et al., 1961; McLennan and Hagen, 1963); inhibition of the 
electrically induced contraction of the isolated cardiac intestine of Tapes 
watlingi (Dougan and McLean, 1970) and hyperpolarization of cockroach salivary 
gland cells (House et al., 1973). However, none of these effects has been 
analyzed pharmacologically in any detail, therefore conclusions concerning 
possible involvement of dopamine receptors cannot be made. 
Dopamine has also been shown to affect neurones in evertebrate ganglia. The 
advantages of studies on evertebrate neurones and the occurrence and neuro­
transmitter role of dopamine will be dealt with in chapter 2. In the following 
paragraphs the results of pharmacological studies with respect to dopamine ef­
fects on evertebrate neurones will be discussed. These studies have been perform­
ed in the phylum of molluscs mostly, because of the extraordinary size of 
molluscan neuron cell bodies which easily allows experimentation at the level of 
single neurones. 
In 1961 Kerkut and Walker showed that dopamine mainly causes hyperpolariza­
tion and inhibition of spontaneous activity of Helix aspersa neurones, although 
some cells were excited. The hyperpolarization was either brought about by an 
increase in K+permeability (Kerkut et al., 1969a) or by stimulation of an elec-
trogenic sodium pump (Kerkut and Thomas, 1965; Kerkut et al., 1969b). In a 
series of papers the Southampton group has described the pharmacology of 
dopamine inhibitory actions on snail neurones (Walker et al., 1968; Woodruff 
and Walker, 1969; Woodruff et al., 1970; Walker et al., 1971; Woodruff et al., 
1971 ; Woodruff, 1971 ; Pinder et al., 1972). From these studies it has become clear 
that the receptors involved in dopamine-induced inhibitions of Helix aspersa 
neurones are quite distinct from classical α or 0 adrenergic receptors, in the sense 
that dopamine actions can be blocked by selective antagonists and are mimicked by 
a specific series of dopamine-like drugs. With respect to agonistic activity only 
phenylethylamines with both a 3- and 4-hydroxyl substitution of the benzene 
ring are active. Furthermore, in contrast to the situation at α and /3 adrenergic 
receptors, the presence of a hydroxyl group at the carbon atom β to the nitrogen 
24 
reduces dopamme-like activity Finally, as is the case for α adrenergic activity, 
substitution of the terminal nitrogen with more than one methyl group greatly 
reduces agonistic activity (Woodruff and Walker, 1969, Woodruff, 1971). One 
drug notably without agonistic activity is apomorphine (Woodruff and Walker, 
1969, Pinder et al., 1972). Recently, a rigid analog of dopamine — 2-amino-
6,7-dihydroxy-l ,2,3,4 tetrahydronaphthalene - (A-6,7-DTN) was shown to have 
powerful agonistic activity, whereas rigid analogs with a isoquinone structure are 
without effect (Pinder et al., 1972). This indicates that the conformation of 
dopamine at the receptor site is trans rather than gauche in contrast to previous 
suggestions made by Kier and Truitt (1970) 
With respect to antagonistic activity dopamine receptors mediating neuronal 
inhibition also differ from α and β adrenergic receptors. The β blocker 
propranolol as well as the anticholinergic agent atropine are without effect 
(Walker et al., 1968). The alpha adrenergic blockers phentolamine and phenoxy-
benzamine both antagonize the effects of dopamine, but fairly high concentra­
tions are required (Walker et al., 1968) Ergometrine — an ergot alkaloid without 
adrenergic receptor blocking activity — turned out to be a very potent anta­
gonist, having a pA2 value of 8 - 9 (Walker et al., 1968, Woodruff et al., 1970). 
Related ergot alkaloids, such as ergotamine, ergotoxine and also LSD, are also 
effective antagonists of dopamme-induced inhibitions (Walker et al., 1968, 
Woodruff et al., 1971). A remarkable finding has been the lack of dopamine 
antagonistic properties of the neuroleptics with respect to this inhibitory action 
of dopamine (Woodruff et al, 1970, 1971) whereas these agents are selective 
dopamine antagonists with respect to dopamme-induced behavioural effects (van 
Rossum, 1967). 
In summary, dopamme-induced inhibition of Helix aspersa neurones seems to be 
mediated by a doparmne-specific receptor. Structural requirements for agonistic 
activity are very strict, whereas also with respect to antagonism a considerable 
degree of selectivity is found. Interestingly, drugs suspected to interfere with 
mammalian dopamine receptors, such as apomorphine and the neuroleptics, are 
ineffective. 
However, not every molluscan neuron is inhibited by doparrune many neurones 
are not affected while others are even excited. In chapter 3 a pharmacological 
analysis of dopamme-induced excitations will be presented. 
In other molluscs, Aplysia cahfornica and Planorbis corneus, dopamme has 
similar effects as in Helix aspersa Ascher (1972) and Faber and Klee (1974) 
have studied dopamme-induced inhibitions and excitations of Aplysia neurones 
These studies have indicated that these two effects can be antagonized differ­
entially by some blocking drugs strychnine and tubocuranne — at relatively 
high doses — blocked the dopamme excitatory responses without affecting the 
inhibitory ones which were selectively blocked by ergot derivatives (Ascher, 
1972, Faber and Klee, 1972) 
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Recently Berry and Cottrell (1973a, 1975) studied dopamine neurotransmission 
in Planorbis corneus They found that by stimulating the so-called giant dopa-
mine-contaimng cell (GDC) postsynaptic inhibition as well as excitation could be 
obtained Both effects were postulated to be mediated by dopamine as a trans-
mitter (Berry and Cottrell, 1973a, 1975) Ergometnne and 6-hydroxydopamine 
specifically blocked the electrically induced inhibitory postsynaptic potentials 
(IPSP's) and the inhibition caused by exogenous dopamine administration 
Tubocurarme — at high doses — blocked the excitatory postsynaptic potentials 
(EPSP's) and dopamine-induced excitation However, at these doses also post-
synaptic effects of acetylcholine were blocked by tubocurarme (Berry and 
Cottrell, 1973b, 1975, Berry et al, 1974) This latter finding implies that at least 
in the case of dopamine-induced excitation a transmitter role for dopamine has 
not been proved formally. It would be interesting to test the effects of neuro-
leptic agents in both Aplysia and Planorbis in view of the postulated dopamine 
receptor blocking activities of these drugs (van Rossum, 1966) 
In conclusion, although both in the case of Aplysia and Planorbis neurones the 
dopamine-induced effects were not analyzed very thoroughly with respect to the 
pharmacological mechanisms involved, these studies contain indications that 
there may exist pharmacological differences in the receptors mediating dopa-
mine-induced inhibition and excitation This will be further explored in chapter 
3 
1.3. Adenylate cyclase as a model for the dopamine receptor 
It has been shown during the last decade that homogenates of tissues containing 
dopaminergic synapses respond to low concentrations of dopamine by an in-
creased production of cyclic AMP These areas include the bovine superior 
cervical ganglion (Greengard et al, 1972), the mammalian retina (Brown and 
Makman, 1972, Bûcher and Schorderet, 1974), basal ganglia (Kebabian et al, 
1972), olfactory tubercle, nucleus accumbens (Horn et al, 1974) and cortex 
(von Hungen and Roberts, 1973) Also in rat erythrocytes and mouse neuro-
blastoma cells the existence of a dopamine sensitive adenylate cyclase has been 
measured (Sheppard and Burghardt, 1970, Prasad and Gilmer, 1974) 
The presence of a dopamine-sensitive adenylate cyclase in a certain tissue does 
not necessarily imply that such an adenylate cyclase is involved in the process of 
neural transmission However, Greengard and associates (Greengard et al, 1972, 
McAfee and Greengard, 1972, Kalix et al , 1974) have provided fairly strong 
evidence for an endogenous role of dopamine-sensitive adenylate cyclase in the 
hyperpolanzation of the superior cervical sympathetic ganglia Thus stimulation 
of the preganglionic nerve leads to an increased concentration of cyclic AMP in 
isolated ganglia, and cyclic AMP can mimic the hyperpolanzing effects of dopa-
mine when applied to ganglionic neurones Moreover, phosphodiesterase in-
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hibitors potentiate the hyperpolanzation and the increase in ganglionic cyclic 
AMP induced by stimulation of the preganglionic nerve and they also potentiate 
the hyperpolanzation after exogenous dopamine. A recent study by Siggins et al 
(1974) provides some electrophysiological evidence for the involvement of an 
adenylate cyclase in dopamine responses of rat caudate neurones. They showed 
that cyclic AMP mimics the inhibitory effects of doparrune and that the phos­
phodiesterase inhibitor methyl-isobutyl-xanthine potentiates doparmne-induced 
inhibitions However, this is no solid proof for the involvement of adenylate 
cyclase in the endogenous process of synaptic transmission at the level of the 
caudate nucleus as the lontophoretic applications of the drugs were not com­
bined with stimulation of the dopamme cell bodies in the substantia nigra. 
Dopamine-stimulated adenylate cyclase as a model for the dopamme receptor 
has attracted considerable interest from pharmacologists (review Iversen, 1975) 
In some cases, such as in rat erythrocytes, the effects of dopamine have later 
been interpreted as effects on an adrenergic rather than a dopamine receptor 
(Sheppard and Burghardt, 1974a, b). However, there is good evidence now that 
in the case of homogenates of the retina and the mammalian striatum one is 
dealing with a dopamine-specific effect As is the case with the vascular dopa­
mine receptor and the e vertebrate neuronal dopamme receptors there is a high 
degree of structural specificity for agonists at this adenylate cyclase dopamine 
receptor. Among the phenylethylamme analogs of dopamine only the N-methyl 
derivative epinine is equipotent with the parent compound. 1-Noradrenaline is 
some 20 times less potent and also the α-methyl derivative of dopamine is far 
less potent Compounds lacking the catechol hydroxyl groups and substances in 
which the side chain contains one or three carbon atoms instead of the usual two 
are without activity (Brown and Makman, 1972, Kebabian et al, 1972, Forn et 
al, 1974, Miller et al., 1974a, Makman et al, 1975) The aporphine alkaloids 
apomorphine and N-propylnorapomorphine are also effective, although the 
maximal degree of stimulation of eyebe AMP production by these agents is only 
0 3 — 0.5 of that of dopamme, i.e. these agents have low intrinsic activities 
(Kebabian et al., 1972, Forn et al, 1974, Miller et al, 1974, Bûcher and 
Schorderet, 1975). Aporphine alkaloids with the catechol group in a different 
position, such as (—)isoapomorphme or (—)l,2-dihydroxyaporphine, or those 
lacking one or both the hydroxyl groups, as in (-l-)lO-hydroxy-N-propylnorapo-
morphine or (-)aporphine, were found to be inactive in stimulating adenylate 
cyclase (Miller et al, 1974, Kelly et al, 1975). 
A number of tetrahydroisoquinolines - rigid analogs of dopamine in which the 
dopamine side chain is locked in a folded rather than an extended conformation 
- are ineffective as dopamine agonists (Sheppard and Burghardt, 1974a, b, 
Miller et al., 1974a) In contrast, 2-amino-6,7-dihydroxy-l,2,3,4-tetrahydro-
naphthalene, which represents a fully extended conformation of the dopamine 
side chain is equipotent with dopamme as an agonist (Miller et al , 1974a) These 
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data indicate that the preferred conformation of dopamine at its receptor is such 
that the side chain is in the fully extended trans form. 
Interestingly, the antiparkinson agent amantadine which has been suggested to 
be a dopamine receptor stimulant on the basis of behavioural studies (Papeschi, 
1974), is ineffective with respect to stimulation of dopamme-sensitive adenylate 
cyclase in the rat caudate nucleus (Karobath, 1974). Also the antiparkinson 
agent pinbedil is ineffective (Miller and Iversen, 1974). However, its catechol 
analog — S 584 — was shown to be active, although with low intrinsic activity 
(Miller and Iversen, 1974). 
Recently also the ergot derivatives d-LSD and ergometnne were shown to poss-
ess slight agonistic properties (von Hungen et al., 1974, Spano et al., 1975, 
Woodruff et al., 1975). Their intrinsic activity, however, is quite low and apart 
from agonistic properties LSD also has antagomstic properties, antagonism has 
not yet been tested for ergometnne. 
One very remarkable property of the dopamme-sensitive adenylate cyclase of the 
retina and the mammahan CNS is that it is extremely sensitive with respect to 
blockade by antipsychotic neuroleptic agents (Kebabian et al., 1972, Brown and 
Makman, 1973; Clement-Courmer et al., 1974, Karobath and Leitich, 1974, 
Miller et al., 1974b, Lippmann et al., 1975). The antagonism is competitive with 
dopamine and seems to be rather specific since antiadrenergic as well as anti-
cholinergic and antihistaminergic agents are ineffective. From the extensive stu-
dies by Iversen and associates (review. Iversen, 1975) it has become evident that 
antipsychotics from different chemical classes — e.g. phenothiazines, butyro-
phenones, thioxanthenes and dibenzazepines — share this ability to inhibit dopa-
mme-induced stimulation of adenylate cyclase. The phenothiazines are generally 
the most active compounds. 
Recently an important advance has been made in the study of the dopamine 
receptor pharmacology after the introduction of antipsychotic agents showing 
chemical isomerism, both geometrical isomers — cis and trans flupentixol — and 
stereoisomers — (+) and (—)butaclamol. In both cases the antipsychotic activity 
of the one isomer is higher than that of the other one, the active agents being 
cis-flupentixol and (+)butaclamol, respectively. Interestingly, in the adenylate 
cyclase studies the same isomers proved to be far more potent inhibitors of 
dopamine-induced production of cyclic AMP (Lippmann et al., 1975, Miller et 
al., 1975). The existence of a stereochemically specific antagonist could prove a 
valuable tool in the isolation of a dopamine receptor 
In summary, the dopamine-stimulated adenylate cyclase in a number of tissues — 
specially in the CNS and the retina — has properties showing that a dopamine-
specific mechanism is present there Requirements for agonistic and antagonistic 
activity are rather strict This adenylate cyclase is most certainly a useful bio-
chemical test preparation for systematic studies of the pharmacological 
specificity of central dopamine receptors However, there is no real evidence yet 
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that an adenylate cyclase is involved in endogenous dopaminergic neurotrans-
mission or how it would relate to a putative dopamine receptor 
1.4. Microiontophoresis in the mammalian CNS as a tool in the study of central 
dopamine receptors 
The development of a sensitive histochemical fluorescence method for the direct 
visualization of catecholamines by Falck, Hillarp and associates has led to a 
detailed chemical mapping of specific neuronal catecholaminergic pathways. 
There are at present a number of reviews dealing with these studies (Fuxe et al., 
1970, Ungerstedt, 1971; Livett, 1973). With respect to the dopamine pathways 
it has become evident that there are several important dopamine neuron 
systems (1) the mgro-stnatal dopamine fibres, originating in the substantia nigra 
and innervating the neostriatum, (2) the mesolimbic dopamine fibres, originating 
in the cell bodies surrounding the interpeduncular nucleus and innervating the 
limbic forebrain, (3) the tubero-infundibular dopamine fibres, originating in the 
arcuate nucleus of the hypothalamus and innervating the median eminence, (4) 
the midbrain-cortical dopamme fibres, originating in the midbrain at the level of 
the area ventrahs tegmenti and diffusely innervating the cerebral cortex (Berger 
et al., 1974), and (5) a only recently described incerto-hypothalaimc dopamine 
neuron system (Bjorklund et al., 1975). 
There is good evidence that dopamine acts as a neurotransmitter substance at the 
level of the nerve terminals of these neuron systems. One may therefore expect 
the presence of dopamine-specific receptors in these regions of the brain From 
methodological point of view it is a difficult matter to study pharmacological 
properties of these potential receptors as was mentioned before in the introduc-
tion to this chapter. However, the technique of microiontophoretic drug applica-
tion, whereby effects of drugs can be related to changes in electrophysiological 
activity at the cellular level, has added to the knowledge of central dopamine 
mechanisms The advantages and disadvantages of this technique have recently 
been reviewed (Bloom, 1974). 
Only with respect to the mgro-stnatal neuron system such studies have been 
performed in any detail. In the original studies concerning the effects of lon-
tophoretic application of dopamine to single nerve cells in the caudate nucleus 
of cats and rabbits the predominant effect found was reduction of artificially 
induced unit discharge activity (Bloom et al., 1965, Herz and Zieglgansberger, 
1966, McLennan and York, 1967, Feltz, 1969, Connor, 1970). However, in each 
of these studies a proportion (10 - 2Q/o) of the neurones affected by dopamme 
were excited by this compound. Spencer and Havlicek (1974) have pointed out 
that the nature of the anaesthetic agent used is of great importance m deter-
mining the effects of lontophoretic applications of drugs whereas only 2% of 
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striatal neurones of allobarbital-anaesthetized rats were excited by dopamine, in 
the case of methoxyflurane anaesthesia this percentage was increased to 36%. 
Bloom et al. (1965) and Feltz and Albe-Fessard (1972) have also stressed this 
problem. 
In the cat globus pallidus and putamen the predominant effect of dopamine is 
neuronal excitation. Moreover, there is a good correlation between the dopa-
mine-induced excitations of these neurones and their orthodromic activation by 
electrical stimulation of the substantia nigra (York, 1970). Upon electrical 
stimulation of the substantia nigra two types of effects are found in the cat 
caudate nucleus: certain cells are excited, others inhibited (Frigyesi and Purpura, 
1967; Albe-Fessard et al., 1967; McLennan and York, 1967; Connor, 1968; 
Feltz and Albe-Fessard, 1972). There is a good correlation between the neurones 
inhibited by stimulation of the substantia nigra and those inhibited by dopamine 
(Connor, 1970). The neurones excited by substantia nigra stimulation are mainly 
found in the medial two thirds of the cat caudate nucleus, whereas inhibitory 
effects are found scattered throughout the whole caudate nucleus (Feltz and 
Albe-Fessard, 1972). Specially the data of York (1970) question the original 
ideas (Bloom et al., 1965; Herz and Zieglgänsberger, 1966; Connor, 1970) con-
cerning the purely inhibitory role of dopamine at the level of the terminals of 
the nigro-striatal neurones. Actually the recent work of Hull et al. (1970, 1974) 
and Kitai et al. (1975) has also thrown doubt on this concept of a purely 
inhibitory role of dopamine. Firstly, these authors when measuring the activity 
of striatal neurones of cats intracellularly nearly always found an initial exci-
tation in response to electrical stimulation of the substantia nigra (Hull et al., 
1970; Kitai et al., 1975). Secondly, they showed that lesions of the substantia 
nigra or medial forebrain bundle drastically reducing caudate dopamine quantit-
ies hardly influence the firing rate of caudate neurones (Hull et al., 1974). 
Similar findings were reported by Feltz and de Champlain (1972) using 
6-hydroxydopamine-induced degenerations of the nigro-striatal dopamine 
neurones of cats. There is, however, only a poor correlation between ortho-
dromically induced EPSP's in the caudate nucleus and dopamine effects in this 
brain region. One explanation for this poor correlation could be the use of 
anaesthetics as described above. Another explanation, which was recently put 
forward by several authors (Feltz and de Champlain, 1972; Hull et al., 1974; 
Feltz, 1974; Cools and van Rossum, 1975), is that apart from the inhibitory 
substantia nigra-neostriatal dopaminergic fibres there is a non-dopaminergic 
nigro-striatal neuron system. This latter fibre system then would excite small 
interneurones which have an inhibitory output within the caudate nucleus (Feltz 
and Albe-Fessard, 1972). It has been indicated by Frigyesi and Purpura (1967) 
already that it may be very difficult to record from these neurones in view of 
their small size. An interesting addition to this hypothesis was recently given by 
Feltz (1974), Cools and van Rossum (1975) and Cools et al. (1976b). These 
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authors suggested that the caudate neurones excited by substantia nigra fibres 
are also under an inhibitory control of neurones containing gamma-aminobutync 
acid (GABA) as transmitter substance. The transmission at the terminals of these 
neurones is according to the hypothesis of Cools and van Rossum (1975) 
controlled by presynaptically located dopamine receptors, stimulation of which 
leads to a reduction in the release of GABA and consequently to an excitation of 
the caudate interneurones and blockade of which leads to an enhanced release of 
GABA. This hypothesis could explain the lack of excitatory actions of lonto-
phoretically applied dopamine in animals under certain types of anaesthesia as 
dopamine will only cause effects when there is a relatively high degree of activity 
in the GABA-containing neurones. Moreover, this hypothesis explains the earlier 
finding by Feltz (1971) that the neuroleptic agent halopendol inhibits the exci-
tation of caudate neurones after stimulation of the non-dopammergic excitatory 
substantia mgra-caudate nucleus pathway. Further evidence in support of this 
hypothesis can be found in papers of Cools et al. (1976b) and Cools and van 
Rossum (1975). 
In summary, with respect to the nigro-stnatal pathways there is evidence for the 
existence of two types of dopaminergic fibre systems from the substantia nigra 
to the putamen: one excitatory, one inhibitory (York, 1970). With respect to 
the caudate nucleus there seems to be one dopaminergic nigro-stnatal pathway, 
inhibitory in nature, and one non-dopammergic pathway, excitatory in nature. 
Moreover, at the level of the caudate nucleus there are two distinct dopaminergic 
mechanisms, one inhibition-mediating, acting via postsynaptically located dopa-
mine receptors diffusely distributed throughout the caudate nucleus, the other 
excitation-mediating via presynaptically located dopamine receptors mainly in 
the medial parts of the caudate nucleus. The papers of Cools et al. (1975, 
1976b) and Cools and van Rossum (1975) present a further discussion of this 
concept. 
Up to now the lontophoretic effects of dopamine have not been analyzed in 
great pharmacological detail. With respect to the effects in the putamen York 
(1970, 1972) has indicated that receptors mediating dopamine-induced excita-
tions and inhibitions, respectively, show pharmacological differences. First of all, 
after repeated dopamine injections the excitation-mediating type shows a higher 
degree of tachyphylaxis than the inhibition-mediating one. Secondly, mono-
amine oxidase inhibitors potentiate the dopamine-induced excitations without 
affecting, or even blocking the inhibitions. Thirdly, a variety of a adrenergic 
blockers such as phentolamine, phcnoxybenzamine and chlorpromazine block 
dopamine-induced excitations without affecting the inhibitions (York, 1970). 
However, in a later stud> York (1972) reported that chlorpromazine is a com-
petitive antagonist of both inhibitions and excitations induced by dopamine. 
With respect to dopamine effects on caudate neurones, Feltz (1971) reported 
that halopendol does not antagonize dopamine-induced inhibitions but is effec-
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tive in antagonizing the excitations induced by substantia nigra stimulation as 
was mentioned before. Recently Ben-Ari and Kelly (1974) also found that the 
potent neuroleptic a-flupentixol only poorly antagonizes dopamine-induced in-
hibitions of cat putamen neurones. Papaverine and bulbocapnine, however, when 
applied iontophoretically or given intravenously, effectively block the inhibitory 
effects of substantia nigra stimulation as well as that of dopamine (Gonzalez-
Vegas, 1974). 
Amphetamine has a biphasic action on the firing rate of rat caudate neurones 
consisting of an initial increase followed by a prolonged depression (Groves et 
al, 1974, 1975; Rebec and Groves, 1975). Interestingly, lesioning the nigro-
striatal bundle producing a marked decrease in forebrain dopamine levels, 
abolishes the depressive effect without changing the initial activation (Groves et 
al., 1975). 
Recent reports on the effects of apomorphine indicate that this drug mimics 
dopamine-induced inhibitions of caudate neurones in rats (Grossman et al., 
1974; Siggins et al., 1974). Also the previously mentioned dopamine analog 
A-6,7-DTN mimics these dopamine effects (Woodruff et al., 1974). 
The ergot alkaloid ergometrine does not mimic dopamine-induced inhibitions of 
caudate neurones (Grossman et al., 1974), although this agent and its structural 
analog agroclavine seem to be able to mimic dopamine-induced inhibitions of rat 
cortical neurones (Grossman et al., 1974; Stone, 1974). It is not certain, how-
ever, that in the case of cortical dopamine effects dopamine-specific receptors 
are involved. 
One final interesting electrophysiological study on central dopamine effects has 
recently been published by Moss et al. (1975) and relates to the iontophoretic 
effects of dopamine on tubero-infundibular neurones. 30% of the neurones in-
vestigated were activated by dopamine and 38% were depressed. Pimozide 
effectively blocked the excitations; Moss et al. (1975), however, did not report 
on the effects of pimozide on the inhibitory responses. 
In summary, the classical view of dopamine as a purely inhibitory transmitter is 
no longer tenable. In the putamen, and possibly also in the hypothalamus, 
available evidence indicates both an inhibitory and an excitatory role of dopa-
mine. In the caudate nucleus, the picture is somewhat more complicated. There, 
apart from an inhibitory role, dopamine also seems to mediate neuronal exita-
tion possibly by a presynaptic action. Although pharmacological aspects of these 
different actions have not been analyzed in detail, there is evidence indicating 
that more than one type of dopamine receptor may be involved in these res-
pective dopamine effects. 
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1.5. Behavioural models in the study of central dopamine receptors 
The original concept of the role of dopamine-specific receptors in the mode of 
action of certain drugs was based upon behavioural studies (cf. van Rossum, 
1967, 1970). Also, by far the most commonly used models now to evaluate the 
possible dopaminergic or antidopaminergic activity of drugs are derived from 
behavioural studies. 
A number of models are based upon the assumption that apomorphine is a 
prototype of a dopaminomimetic drug (Ernst, 1965). Already in 1874 Harnack 
reported that apomorphine systemically injected in rodents induces a compulsive 
sniffing, licking and biting stereotypy (1). A number of experiments have 
confirmed these findings and the main site of action has been shown to be 
located in the neostriatum (for references: Cools, 1973a; Costali and Naylor, 
1973; Wolfarth, 1974; Pijnenburg et al., 1975b). In a number of species, 
specially the dog, apomorphine has a strong emetic action (2), possibly by an 
action in the chemoreceptor trigger zone in the medulla oblongata. Finally, 
apomorphine has a marked antitremor activity (3) in rats pretreated with 
reserpine and o-chloralose (Roos and Steg, 1964) or in monkeys with ventro-
medial tegmental lesions, possibly also by an action in the striatum (Porier and 
Sourkes, 1965; Goldstein et al., 1969). An extension of the apomorphine-in-
duced stereotyped behaviour model has been made by Andén et al. (1966, 1967) 
and Ungerstedt (1968, 1971). These authors disrupted the dopamine balance 
between the two neostriata by means of unilateral ablation of one neostriatum 
or by means of unilateral 6-hydroxydopamine-induced degeneration of the 
nigro-neostriatal fibres. After such a disruption apomorphine induces stereo-
typed turning towards the side of the body on which the neostriatum is removed 
(4).These four effects of apomorphine - stereotypy, emesis, antitremor activity 
and postural asymmetries - are generally believed to be indicative for central 
dopamine receptor stimulation. 
The behavioural effects of many groups of drugs have been compared over the 
last 10 years with that of apomorphine and such studies have led to a pro-
portional amount of conclusions concerning the dopamine receptor stimulating 
activity of these drugs. Based on these models the following drugs are nowadays 
considered to be dopamine receptor stimulants: the antiparkinson agent piribedil 
and its metabolite S 584 (Corrodi et al., 1971 ; Costali and Naylor, 1973; Creese, 
1974);the antiparkinson agent amantadine and its derivate D-154 (Svensson, 
1973; Papeschi, 1974; a number of apomorphine analogs (Hensiak et al., 1965; 
Koch et al., 1968; Cannon et al, 1972a; Neumeyer et al., 1973; Burkman et al., 
1974; Costali et al., 1975a); a number of tetrahydronaphthylamines and 2-in-
danamines (Sprenger et al., 1969; Cannon et al., 1972b; Burkman, 1973; 
McDermed et al., 1975; Elkhawad and Woodruff, 1975); a number of 
benzhydryl dérivâtes (van Beek and Timmerman, 1974); a number of piperazine 
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dérivâtes (Costali et al., 1975b), the ergot alkaloids ergometrine, agroclavine, 
2-bromo-a-ergocryptme, ergocornine and the related drug LSD (Stone, 1973, 
Corrodi et al., 1973, Miyamoto et al., 1974, Pieri et al, 1974, Woodruff et al, 
1974), the antidepressant agent quipazine (Grabowska et al, 1974, the drug 
nomifensine (Costali et al., 1975c) and the imidazoline derivative 
2-(p-nitrobenzylthio)-imidazoline (3H) HCl (Menon et al., 1972). 
One must inevitably conclude on the basis of this hst of so-called "dopamine 
receptor agonists" that the dopamine receptor is a very "permissive" one, enab-
ling so many diverse groups of drugs to act as agonists The value of the models 
with which these conclusions were derived will be discussed below. 
Another drug beheved to act at least partly as a dopaminomimetic agent is 
amphetamme, although its interaction with dopaminergic mechanisms is regard-
ed to be of indirect nature it is bebeved to release endogenous dopamine and to 
block its re-uptake (van Rossum, 1970, Taylor and Snyder, 1971). The stereo-
typed behaviour and increase in locomotor stimulation seen after amphetamme 
administration in rodents is generally related to an action of amphetamine in the 
neostriatum and nucleus accumbens (Pijnenburg et al, 1975a, b). This effect of 
amphetamine and also the above mentioned effects of apomorphine are import-
ant in the behavioural models for testing the potential dopamine receptor block-
ade by drugs. In such models a drug is considered to be a dopamme receptor 
blocker if it antagonizes the effects of amphetamine and apomorphine (Andén et 
al., 1966, 1970, Janssen et al., 1965, 1967, Malier-Nielsen et al, 1973). Special-
ly the so-called "turning model" (postural asymmetries as a consequence of 
disrupting the dopamine balance between the two neostnata) is frequently used 
as such. It has become evident that drugs from several chemical classes, e.g. 
phenothiazmes, butyrophenones and thioxanthenes, share an ability to block 
these actions and are therefore considered to be dopamme receptor blockers 
(van Rossum, 1967, Andén et al., 1970, Miller-Nielsen et al., 1973). 
There is a close parallel between the anti-apomorphine and anti-amphetamme 
effects of drugs and their clinical activity as antipsychotic neuroleptic agents 
(Janssen et al., 1965, 1967, Snyder et al., 1974). Recently, however, a few 
exceptions to this parallelism have been described, eg clozapine (Stille et al., 
1971), metoclopramide and sulpiride (Dolphin et al., 1975, Gessa et al, 1975). 
However, the value of the behavioural models for testing dopaminomimetic or 
dopaminolytic activity must be senously doubted. Firstly, apomorphine — as 
studied in other models — is only a very poor dopamine receptor stimulant in 
terms of its intrinsic activity. Moreover, in these models it was shown that it has 
antagonistic properties as well. Therefore apomorphine cannot be regarded as a 
very good prototype of a dopamine receptor agonist. Secondly, other neuro-
transmitters than dopamine located in different parts of the CNS play an indis-
pensable role in the organization of the above-mentioned types of behaviour, e g. 
serotonin. A behavioural effect of apomorphine such as turning behaviour can be 
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caused by manipulations of other transmitter mechanisms as well (for a detailed 
discussion Cools and Janssen, 1974). Also so-called antagonists may cause their 
effects by acting on other neurotransmitter systems. Thirdly, conclusions about 
the mechanism of action of the above-mentioned drugs are usually derived from 
experiments in which the drugs were injected peripherally. The disadvantage of 
the systemic route of administration in the study of central dopamine receptors 
are (a) drugs can be metabohzed before reaching the putative dopamme re-
ceptors, (b) they have to pass several physico-chenucal barners and (c) they can 
easily influence other neurotransmitter systems than the dopaminergic as well. 
One way to overcome these problems is to use the technique of stereotactic 
injections of drugs into circumscribed parts of the brain. Several groups have 
recently used this technique with remarkable results From these studies it has 
become evident that several parts of the forebram such as the caudate nucleus, 
the putamen, the globus palbdus and the nucleus accumbens, are involved in the 
behavioural mode of action of drugs like apomorphme, amphetamine and the 
neuroleptics (cf. Cools, 1973a, Costali and Naylor, 1973, Pijnenburg et al., 
1975a, b). In two recent papers concerning structure-activity-relationship studies 
for dopaminomimetic activity measured as behavioural changes after intrastnatal 
injections into rats and guinea pigs it was found that (1) the 3,4-dihydroxy-
phenyl moiety of dopamine is essential for doparmne-like activity and (2) altera-
tions in the length of the side chain and substitution at the a- or/3C-atom or 
N-atom markedly reduce or even abolish activity (Costali et al., 1974, 1975b). 
Moreover, dihydroxy-tetrahydroisoquinolme derivatives are inactive, in contrast 
to the dihydroxy-tetrahydronaphthalene-ammo denvate A-6,7-DTN, suggesting a 
trans rather than a gauche conformation of dopamine at its receptor (Costali et 
al., 1974, 1975b). 
Very interesting results on the basis of stereotactic injections into the caudate 
nucleus of cats were recently reported by Cools (1973a, b), Cools and van 
Rossum (1975) and Cools et al. (1975) As was mentioned under 1.4. already 
these authors provided evidence for the existence of 2 functionally, anatomically 
and pharmacologically distinct dopamine mechanisms in the cat caudate nucleus. 
One of these is mainly located in the centromedial part of the caudate nucleus 
and mediates a behavioural syndrome indicated by dopamine-induced con-
tralateral turning of the head and limbs, the other is located more diffusely 
throughout the caudate nucleus and mediates the so-called ipsilateral turning 
syndrome after dopamine injections. These two mechanisms have different phar-
macological characteristics, apomorphme being a specific agonist of the first 
type and 3,4-dihydroxy-phenylamino-2-imidazoline (DPI) of the second type. 
With respect to antagonists, halopendol is a selective blocker of the first type 
and ergometnne of the second one. For a further discussion of these data, 
specially with respect to their clinical implications, the reader is referred to two 
recent reviews (Cools et al., 1975, Cools and van Rossum, 1975) 
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TABLE I 
Effects of dopamine suggested to be mediated by dopamine-spccffic receptors and actions of the putative dopamine receptor 
agonist apomorphine and the putative dopamine receptor blockers haloperidol and ergometrine. 
Preparation Effect Apomorphine Haloperidol Ergometrine References 
Isolated dog renal, mesenteric and 
femoral artery strips (contracted Relaxation 
with prostaglandin F2a> pretreatment 
with phenoxybenzamine). 
Ineffective Ineffective Not tested 
Goldberg et al., 
1973, 1975; Toda 
and Goldberg, 1975. 
Dog kidney (pretreatment with 
phenoxybenzamine or phentolamine 
Vasodilation Partial agonist Antagonist with Antagonist with Y eh et al., 1969; 
and antagonist short duration long duration Bell et al., 1974. 
of action of action 
Cat blood pressure (pretreatment 
with yohimbine) Depressor Not tested Antagonist Not tested van Rossum, 1966. 
Dog paravertebral ganglion Inhibition Agonist Antagonist Ineffective 
Willems, 1973, 1974; 
Willems and Bogaert, 1975. 
Helix aspersa neurones Inhibition Ineffective Ineffective Antagonist Woodruff and Walker, 1969; Woodruff, 1971. 
Aplysia californica and Planorbis 
corneus neurones 
Inhibition Not tested Not tested 
Ascher, 1972; Faber and 
Antagonist
 К 1 е е > 1 9 7 4 ; B e f r y a n d 
Cottrell, 1973b, 1975. 
Adenylate cyclase (mammalian retina 
and striatum) c-AMP production Partial agonist Antagonist 
Partial agonist Iversen, 1975; 
not tested as Woodruff et al., 1975. 
antagonist 
Rat and guinea pig striatum (stereo- Stereotyped 
tactic injection) behaviour Agonist Antagonist Not tested Costali et al., 1975. 
Cat caudate nucleus (stereotactic in- Contralateral 
jcction into the centromedial part) turning Agonist 
Cat caudate nucleus (stereotactic in- IpsUateral 
jection into the remaining part) turning 
Antagonist 
Ineffective Ineffective 
Ineffective 
Antagonist 
Cools and van Rossum, 
1975; Cools et al., 
1975. 
In summary, behavioural models using peripheral routes of drug administration, 
are poor models to test central dopamine receptor pharmacology. These models 
may be very useful in studying some of the behavioural effects of drugs, but if 
conclusions are to be made concerning the nature of the receptor involved in 
these effects, models in which drugs are injected stereotactically should be pre-
ferred, given that attention is paid to solvent effects, diffusion of the drugs and 
dose-response characteristics. 
Conclusion 
Dopamine is an important endogenous compound in the mediation of a number 
of functions of the central and possibly also of the peripheral mammalian ner-
vous system. At several levels in the mammalian body dopamine-specific re-
ceptors have been proposed. Moreover, early evidence has indicated that these 
dopamine-specific receptors are relevant in the mode of action of several drugs, 
e.g. the neuroleptics which have been proposed to act as antagonists at these 
receptors (van Rossum, 1966, 1967) and apomorphine, a proposed agonist at 
these receptors (Ernst, 1965). 
Over the last ten years a number of approaches have emerged in the study of the 
dopamine receptor pharmacology. These have been reviewed in this chapter. In 
the studies performed according to these approaches the original views of the 
mechanism of action of the neuroleptics (van Rossum, 1967) and apomorphine 
(E-nst, 1965) have been confirmed partly. However, in some models for the 
dopamine receptor the original classification of apomorphine as an agonist and 
the neuroleptics as antagonists at dopamine receptors could not be confirmed 
(cf. table I). This was specially the case for the renal dopamine receptor and the 
dopamine receptors mediating neuronal inhibition in the snail Helix aspersa and 
the cat caudate nucleus. This discrepancy indicates that there may exist more 
than one type of dopamine receptor. 
In the evertebrate nervous system dopamine can mediate neuronal inhibition as 
well as excitation. As such divergency was also indicated to exist in the cat 
caudate nucleus (Cools, 1973a and b), it seemed attractive to analyse these two 
effects in more pharmacological detail and to investigate whether this electro-
physiological distinction of dopamine effects runs parallel with a pharmacologic-
al distinction of the respective dopamine receptors involved. Results of such 
experiments are reported in the next two chapters. 
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CHAPTER 2 HELIX ASPERSA NEURONES: ANALYSIS OF 
DOPAMINE-INDUCED INHIBITION AND EXCI-
TATION 
2.1. Dopamine as a neurotransmitter in evertebra tes 
Experimental studies on evertebrates have contributed greatly to the knowledge 
of the nervous system, one very important example being the neurophysiological 
studies of the giant synapse and axones of cephalopod molluscs. During the last 
two decades another class of the phylum of the molluscs, the Gastropoda, has 
proved to be of great utility for neurobiological research. One of the most 
important reasons for this utility is the size of the neuron cell bodies of many 
Gastropoda (e.g. Helix, Aplysia and Pfonorbis). In addition, unlike in vertebrate 
cell preparations, the neurones retain their functional activity after dissection 
and survive for several hours or even days. The functional activity of the neur-
ones can be tested under direct inspection by means of either intra- or extra-
cellular recording. Furthermore, the environment of the cell can be changed by 
adding or substituting ions or by adding metabolites, inhibitors, drugs etc. in 
known concentrations. Another advantage is the relative constant location of the 
neuron somata on the surface of the ganglia and their often distinctive pigmen-
tation, thus allowing easy recognizability in different preparations. Neuron 
constancy extends to the level of input and axonal distribution as confirmed 
both by electrophysiological techniques and single cell staining with procion 
yellow and cobalt chloride. Finally, it has now become possible to investigate in 
individual neurones, the occurrence and metabolism of an ever increasing 
amount of different substances such as small inorganic ions, amino acids, amines, 
proteins etc. There are a number of excellent reviews dealing with several of these 
aspects of the use of evertebrate neurones in neurobiological research (Florey, 
1967; Taue, 1967; Cottrell and Laverack, 1968; Gerschenfeld, 1973; Osborne 
and Neuhoff, 1973;Kerkut, 1973, Willows, 1973). 
There is considerable evidence now to support the transmitter role of acetyl-
choline, dopamine and serotonin in evertebrate ganglia, and to a lesser degree 
also that of the amino acids glutamic acid and GABA. In the following para-
graphs evidence for such a role for dopamine will be reviewed. With respect to 
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the other putative neurotransmitters the reader may consult previous reviews: 
acetylcholine (Taue, 1967; Cottrell and Laverack, 1968; Gerschenfeld, 1973; 
Kehoe, 1972); serotonin (Gerschenfeld, 1973; Gerschenfeld and Paupardin-
Tritsch, 1974; Cottrell and Macon, 1974); amino acids (Pitman, 1971; 
Gerschenfeld, 1973). 
With respect to dopamine, evidence for a transmitter role has been gathered 
mostly in the ganglia of the molluscs Aplysia, Helix and Planorbis. Early bio-
chemical studies have indicated that dopamine occurs in high concentrations in 
these ganglia and is localized particularly in neurones (Sweeney, 1963; Dahl et 
al., 1966; Kerkut et al., 1966; Cottrell and Laverack, 1968; Osborne and 
Cottrell, 1970; Carpenter et al., 1971), in contrast to noradrenaline and adre-
naline which are absent (Kerkut and Walker, 1961; Sweeney, 1963) or present 
only in slight amounts (Osborne and Cottrell, 1970). Histochemical studies with 
the Falck-Hillarp technique show many green fluorescent neurones and axones 
interpreted as likely to contain dopamine (Dahl et al., 1966; Sedden et al., 1968; 
Marsden and Kerkut, 1970). In all these observations fluorescent varicose fibres 
of various lengths and diameters have been described in ganglionic neuropiles 
and peripheral nerves. Reserpine causes a fall in dopamine content of the ganglia 
and a fading of the green fluorescence of nerves and axones (Dahl et al., 1966; 
Kerkut et al., 1966; Cottrell, 1967; Sedden and Walker, 1967). A relation be-
tween the dense-core granulated synaptic vesicles and dopamine occurrence has 
been postulated on the basis of alterations in their size and content under the 
effect of reserpine (Narahashi, 1963; Curtis and Kerkut, 1969). 
With respect to the synthesis and degradation of dopamine the picture is some-
what different from that of mammalian nervous tissue. Similar to mammalian 
neurones snail neurones can convert L-DOPA to dopamine (Kerkut et al., 1966; 
Sweeney, 1969). A recent study in characterized Planorbis neurones has indi-
cated that only dopamine-containing neurones contain the enzymes to form 
dopamine from tyrosine (Osborne et al., 1975). However, as far as degradation is 
concerned in contrast to the mammalian brain the monoamine oxidase activity 
in snail brain appears to be low (Blaschko and Hope, 1957; Cardot, 1963; 
Kerkut et al., 1966). Moreover, monoamine oxidase inhibitors are not very 
effective in changing dopamine concentration in snail ganglia (Cardot, 1963; 
Kerkut et al., 1966). However, there seems to be a significant amount of cate-
chol-O-methyl-transferase activity in snail ganglia, so dopamine is probably 
mainly metabolized via this route. The presence of some acid metabolites such as 
3,4-dihydroxyphenylacetic acid and homovanillic acid has been shown (Osborne 
and Cottrell, 1970). These metabolites are probably formed by an action of 
monoamine oxidase in the liver (Kerkut et al., 1966; Jurio and Killich, 1972), 
although a recent study in single neurones has indicated that dopamine-
containing neurones also show some monoamine oxidase activity, in contrast to 
non-dopamine-containing neurones (Osborne et al., 1975). 
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Another important way of dopamine inactivation is uptake by tissue elements 
Such an uptake has been shown to exist in the snail brain (Carpenter et al, 
1971, Myers and Sweeney, 1973) 
Another prerequisite for an agent to be considered to be a neurotransmitter is 
that it must be released following presynaptic stimulation and consequently 
cause an effect upon the postsynaptic membrane Moreover, there must exist 
specific antagonists of the transmitter and of the natural response following 
presynaptic stimulation and a similar reversal potential for the natural response 
and for the transmitter These prerequisites have been worked out for Helix, 
Aplysia and Planorbis dopamine neurones There is abundant evidence now that 
dopamine can mediate inhibitory, excitatory or biphasic responses (Kerkut and 
Walker, 1962, Gerschenfeld and Taue, 1964,Glaizner, 1967,Walker etal , 1968, 
Woodruff and Walker, 1969, van Wilgenburg and van Leeuwen, 1971, Ascher, 
1972, Berry and Cottrell, 1973a, 1975, Loker et al., 1975) The hyperpolariza-
tion is blocked effectively by ergometrme and related compounds (Walker et al , 
1968, Woodruff et al , 1970, Ascher, 1972, Berry and Cottrell, 1973a, 1975), 
whereas the depolarization is blocked by d-tubocurarme and strychnine (Ascher, 
1972, Berry and Cottrell, 1973a, 1975, Faber and Klee, 1974) However, these 
latter antagonists are not very selective as they also block acetylcholine effects in 
the doses required to antagonize dopamine-induced excitations These studies 
indicate that different receptors may be involved in dopamine-mduced excita-
tions and inhibitions of neuronal activity. Actually this seems to be quite a 
general principle in nervous tissue, as a similar pharmacological distinction has 
also been reported for acetylcholine (Kehoe, 1972), serotonin (Gerschenfeld and 
Paupardm-Tntsch, 1974), G ABA (Aranza and Walker, 1975, Walker et al, 
1975), glutamate (Piggott et al., 1975) and noradrenaline (Boakeset al., 1971). 
2.2. Materials and methods used in the Helix aspersa dopamine receptors studies 
Expenments were performed on neurones of the isolated suboesophageal gang-
lionic mass of the garden snail Helix aspersa, which was imported from England. 
The advantage of this snail in comparison with Helix pomatia is that the con-
nective tissue over the brain is not so well developed, therefore allowing removal 
more easily. The snail was removed from its shell, pinned out and dissected to 
display the ganglionic mass. The gut and reproductive system were removed or 
deflected to one side. The ganglionic mass was dissected free and the connective 
tissue covering the ganglia was removed carefully. The ganglia were mounted in a 
bath of 17 ml volume allowing direct vision by a binocular microscope (Zeiss) 
with maximal magnification of a factor 80 The bath was filled with a snail 
Ringer solution of the following composition 80 mM NaCl, 4 mM KCl, 7mM 
CaCl2, 5mM MgCl2 and 5 mMTns-HCI The pH of this Ringer solution is 7 8 -
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8.0. Unless otherwise stated the bath was perfused with the snail Ringer at a rate 
of about 2 ml/min. 
Intracellular recordings were made using Pyrex glass micro-electrodes. These 
micro-electrodes were pulled on a vertical electrode puller constructed at the 
department of Medical Physics of the University of Nijmegen. The tips of these 
electrodes were checked under a microscope. Only micro-electrodes with a tip of 
ca. 0.5 μτη were used. The micro-electrodes were filled with a 1 M potassium 
acetate solution. The resistance of the tips of the electrodes used ranged from 5 
ίο30ΜΩ. 
The micro-electrode was brought into the neighbourhood of the neurones using 
a micro-manipulator (Leitz) under visual inspection through the binocular. The 
tip was then placed onto the cell body of the neuron planned to study. By 
gently turning the micro-manipulator vertical knob the electrode was inserted 
into the cell. The membrane potential and action potentials of the cell were 
amplified using a negative capacitance amplifier (constructed by the Technical 
Services of the Science Faculty of the University of Nijmegen; for a detailed 
description: van Huet et al., 1971). The resistance of the micro-electrodes was 
also measured via this amplifier. The amplifier has an output to a Tektronix 502 
A oscilloscope (Tektronix Holland N.V.). From there the signal was transmitted 
to a UV recorder (S.E. Laboratories) via a special pre-amplifier (constructed by 
the Technical Services of the Science Faculty of the University of Nijmegen). 
Permanent recordings were made on standard Linagraph Direct Print paper 
(Eastman-Kodak). The signal from the oscilloscope was also transmitted to a 
microphone and in a number of experiments also to a Philips Analog 7 (Philips) 
for permanent storage. The recordings presented in this and the next chapter 
were drawn from the Linagraph record:ngs. 
Drugs were solved freshly in snail Ringer unless otherwise stated. Doses are 
expressed as concentrations of the salt in the bath. 0.1 ml quantities of drug 
solutions were injected into the bath over a period of 3 - 15 seconds. In the case 
of testing potential agonists this injection was performed while the bath was 
perfused with snail Ringer at the normal rate of 2 ml/min. In the case of testing 
antagonism perfusion was stopped just before injecting the potential antagonist. 
Perfusion was stopped until just before adding an agonist again. 
When comparing the effect of a potential agonist with that of dopamine at least 
two different doses of dopamine were injected both before and after the addi­
tion of each of at least two different doses of the potential agonist. Potency of 
an agonist is expressed as the equipotent molar ratio (e.p.m.r.) according to 
Woodruff and Walker (1969), i.e. the ratio: 
bath-concentration of compound (M) 
bath-concentration of dopamine (M) 
producing the same degree of inhibition or excitation. In a few cases a more 
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complete dose-response relationship was studied allowing to express the potency 
of an agent in terms of intrinsic activity (i.a.) and affinity (expressed as рОг : 
negative logarithm of the dose — ED;,, — needed to obtain half of its maximal 
effect) according to van Rossum (1963). This latter approach, however, was not 
used generally in view of the fact that only a limited (10 - 15) number of 
injections can be made without irreversibly changing the membrane properties of 
the cell bodies. 
An analogous approach was used in assessing potentially antagonistic properties 
of drugs, i.e. the effect of 1 or 2 doses of dopamine was tested twice before 
injecting the antagonist and twice or more after having injected the antagonist 
depending upon the duration of antagonism. Potency of an antagonist is then 
expressed as the minimal amount needed to reduce the effect of a standard dose 
of dopamine with a factor 2. This standard dose was always a sub-maximal dose, 
usually it was 3 χ 10"7M dopamine, which is a dose close to the ED S 0 of 
dopamine at both the inhibition-mediating and excitation-mediating dopamine 
receptor. In a few cases more complete dose-response curves were made to allow 
conclusions concerning the nature of the antagonism and the pA2 of the anta­
gonist (negative logarithm of the concentration of the antagonist which causes a 
shift of a factor 2 in the dose-response curve for the agonist) according to van 
Rossum (1963). Again, this approach has not been used in each case due to 
considerations already mentioned. 
Chemicals used in this study: sodium chloride, potassium chloride, magnesium 
chloride 6 H 2 0 , calcium chloride 2 H 2 0 , potassium acetate, l,l,l,-tris(hydroxy-
methyl) methylamine (all Merck, analytical grade). 
Drugs used in the experiments described in chapter 2: 
The drugs used in the experiments described in this chapter were: dopamine 
hydrochloride (Koch-Light, Fluka, Calbiochem), acetylcholine iodide (Fluka), 
serotonin Creatinin sulphate (Koch-Light), atropine sulphate (Ned. Farm.), 
phentolamine methanesulphonate (CIBA) and (d,l) propranolol hydrochloride 
(Sigma). The chemical structures of the last three compounds are given in fig. 8. 
The names and chemical structures of the drugs used in the experiments des­
cribed in chapter 3 wiU be given in that chapter. 
Dopamine, serotonin, acetylcholine, atropine and propranolol were dissolved in 
the snail Ringer solution; phentolamine was dissolved in distilled water. In con­
trol experiments it was found that using distilled water instead of snail Ringer 
does not influence drug effects. Doses given in the text refer to the bath concen­
tration of the drugs calculated as their salt. 
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2.3. Identification of the neurones 
There are a number of entena which can be used to identify a single nerve cell in 
snail ganglia (Walker et al., 1970, Loker et al., 1975,Kerkut et al., 1975) 
1. Position of the cell body within the ganglion 
2 Size and colour of the cell body 
3 Membrane resting potential 
4 Action potential shape and duration 
5. Spontaneous activity pattern of the neuron 
6 Response of the neuron to stimulation of nerve bundles 
7. Presence in the neuron of substances like dopamine, serotonin or acetyl­
choline 
8. Responses of the neuron to applied drugs such as dopamine, serotonin, 
acetylcholine or certain amino acids 
9. Marking of the cell body with cobalt or procion yellow which penetrate the 
cell axones and indicate the track of the axones across the ganglia and into 
nerves 
With respect to Helix aspersa ganglia several mapping-studies have been publish­
ed in which combinations of these criteria were used for identification (Loker et 
al., 1975, Walker et al., 1970;Glaizner, 1967; Parmentier, 1973, Kerkut et al., 
1975). 
In the expenments reported below, studies were made of effects on 9 neurones. 
We have also used several of the above mentioned entena in a number of 
preliminary studies intended to identify these neurones The relative positions of 
the cell are indicated in figure 3 (criteria 1 and 2). 
П С . 3 Relative position of the 9 neurones in the subocsophageal ganglionic mass of Helix 
aspersa used in this study The suboesophageal ganglionic mass conbists of several ganglia, 
but in this study only neurones from the right parietal and visceral ganglion were used 
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TABLE II 
Electrophysiological characteristics of a number of neurones in the brain of the snail 
Helix aspersa 
CeUno. (*) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
No. of 
trials 
11 
21 
9 
10 
15 
9 
17 
26 
3 
Average resting 
potential (range) 
mV 
45 (34^9) 
44(37-51) 
52 (44-55) 
52 (42-55) 
50 (39-59) 
46(38-51) 
50(42-60) 
43 (34-50) 
55 (49-58) 
Total action 
potential height 
(range) mV 
76 (65-82) 
78 (65-90) 
72(61-79) 
82(71-98) 
78 (69-87) 
76(57-81) 
80(62-91) 
72(54-83) 
68 (59-79) 
Action potential 
frequency per second 
(range) 
1.5 (0 8-2 0) 
1 0 (0.7-3.2) 
0.6(0 -0.9) 
0.4(0 -0 8) 
1 0 ( 0 5-1.2) 
1 3(1.0-1.6) 
0 5 (0.4-0 8) 
1.1 (0.7-1.4) 
0.2(0 -0 3) 
(*) The number of the cell refers to the designation as given in figure 1. 
In table II some electrophysiological characteristics of these neurones are given 
as they were determined in a number of experiments (criteria 3,4, 5). 
In table III the responses of these cells to dopamine, acetylcholine and serotonin 
are given (criterion 8). 
In this study, criteria 6, 7 and 9 were not used for identification. We have 
attempted to compare our identification with that of Loker et al. (1975) and 
Walker et al. (1970) who used comparable criteria in their respective studies 
(table IV). These authors, however, have not extensively studied neurones in the 
left part of the visceral ganglion (our cells 6 - 9). Therefore no companson could 
be made with respect to these cells. 
TABLF III 
Responses of the cells to the application of dopamine, acetylcholine and serotonin 
H hyperpolanzation, D depolarization, D-Η depolarization at low doses, hyperpolanza-
tion at high doses, О no response 
C e l l n o O 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Dopamine 
H 
H 
H 
H 
H 
H 
D 
D 
D 
Acetylcholine 
D 
D 
D 
D 
D 
D 
H 
H 
H 
Serotonin 
D-H 
D 
О 
D-H 
D 
О 
H 
H 
D 
(*) The number ot the cell refers to the designation as given in figure 1 
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TABLE IV 
Comparison of our identification of neurones 1 - 9 with that as described in previously 
published maps of Helix aspersa ganglia. 
This study (*) Designation by Designation by 
Walker et al. (1970) Loker et al. (1975) 
1 12 F 6 o r F 7 
2 19 Fl 
3 17 
4 25 E6 
5 16 E5 
6 22 (? ) 
7 -
8 -
9 -
(*) The number of the cell refers to the designation as given in figure 1. 
2.4. Effects of dopamine on Helix aspersa neurones 
The spontaneous activity of cell 1 - 6 was inhibited by dopamine (DA-I-neur-
ones). This inhibition was usually accompanied by a hyperpolarization of the 
cellular membrane (figure 4A). Cells 7 - 9 were excited by dopamine (DA-E-
neurones). This excitation was usually accompanied by a depolarization of the 
cellular membrane (figure 4B). 
3xio-7M 
FIG. 4: Effects of dopamine (DA) on Helix aspersa neurones. A. Inhibitory effect of 
dopamine (3 χ IO"7 M) on cell 5. B. Excitatory effect of dopamine (3 χ IO"7 M) on cell 7. 
DOPAMINE-INDUCED INHIBITIONS (cell 1 - 6) 
The pattern of inhibition induced by dopamine was very constant over the 
different cells used. When dopamine was injected into the bath, cells stopped 
firing within a few seconds and the neuronal membrane usually hyperpolarized 
M ,,^/Ζ/λΜ 
DA. 
ЗхЮ-
7
М 
30 sec 
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rapidly. In a few cases the inhibition of activity was not accompanied by such 
hyperpolanzation, specially not after repeated injections of dopamine. Such 
tachyphylaxis with respect to the hyperpolanzation was also reported by Walker 
et al. (1968). 
Maximal hyperpolanzation was usually reached within 1 0 - 2 0 seconds after 
adding dopamine. The period of time in which a cell stopped firing or fired at a 
rate lower than that before injection was always related to the dose added. A 
typical dose-response curve for dopamine-induced inhibition is given in figure 5. 
Length of inhibition 
(mm) 
3 -
2 · 
Hyperpolanzation 
(mV) 
H G 5 Dose-response relationship for dopamine-induced inhibition of spontaneous activity 
(cell 5) A Dose-response curve for the duration of the inhibition induced by dopamine В 
Dose-response curve for the degree of hyperpolanzation induced by dopamine 
The dose-related inhibition of dopamine can either be measured as the duration 
of the inhibition (figure 5A) or as the degree of hyperpolanzation (figure 5B) 
The duration of the effect is not a very good parameter if one wants to interpret 
the dose-response relationship m terms of intrinsic activity and affinity of the 
agonistic drug, because of the fact that distribution and drug-elimination factors 
— tissue uptake, metabolism — play an important role in determining the dura­
tion of an effect apart from the intrinsic activity and affinity of the drug In this 
respect the degree of hyperpolanzation probably is a better parameter, although 
it cannot always be used as such because of the already mentioned tachyphylaxis 
which occurs sometimes. If hyperpolanzation is used as parameter, the pD2 
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value of dopamine in the experiment shown in figure 5 would be about 7.0, 
which is in agreement with the value found in several other experiments where 
the pD2 of dopamine with respect to hyperpolarization was 7.1 ± 0.5 (Mean ± S.D., 
N=7). 
DOPA MINE-IN DU CED EXCITATION (cell 7 - 9 ) 
The excitation induced by dopamine is relatively slow in onset. Whereas acetyl-
choline-induced excitation of snail neurones was maximal already 3 - 20 seconds 
after injection (Struyker Boudier and van Rossum, 1974), in the case of dopa­
mine maximal increase in action potential frequency and maximal depolarization 
only occurred 30 - 60 seconds after injection depending upon the dose of dopa­
mine (fig. 6). 
Act on potent als 110 sec 
44 · 
Λ0 
36 
32 
2 8 
24 
20 
16 
12 
8 
FIG. 6: Excitatory responses to three different concentrations of dopamine (Λ : 3 χ 10"7 M; 
О : IO- 6 M; D : 3 χ ІО^ M) measured on cell 7. The ordinate indicates time in intervals of 10 
seconds, t : Moment of injection of dopamine. 
The increase in action potential frequency was usually accompanied by a de­
polarization of the cellular membrane. Again, as was the case for dopamine-
induced hyperpolarization, tachyphylaxis with respect to the change in mem­
brane potential sometimes occurred after repeated dopamine injections. Similar 
effects were reported by Ascher (1972). 
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A typical dose-response curve for dopamine-induced excitation is given in figure 
7. The dose-related effect of dopamine in the case of excitation can be measured 
as: (A) the increase in action potential rate; (B) the amount of depolarization of 
the membrane; and (C) the duration of the excitation. As was argued above, the 
duration of the effect is not a good tool if intrinsic activity and affinity are to be 
determined. Also the amount of depolarization is not an ideal parameter because 
of the sometimes occuring tachyphylaxis. The increase in action potential rate is 
probably the best parameter in the case of excitatory effects. In the example 
given in figure 7A the pD2 value of dopamine measured as effect on the action 
potential rate is approximately 6.2, again in good agreement with pD2 values 
found in similar experiments (рОг: 6.8 ± 0.4, N=8). 
Increase in action 
potential r a t e per 10sec 
4 2 
3 6 
3 0 
2 4 
18 
12 
6 
i_ength of 
excitation (mm) 
Depolarization (mV) 
10 10 10 
FIG. 7: Dose-response relationship for dopamine-induced excitation of spontaneous activity 
(cell 7). A. Dose-response curve for the increase in action potential rate per 10 seconds. B. 
Dose-response curve for the excitation induced by dopamine. C. Dose-response curve for the 
degree of depolarization induced by dopamine. 
2.5. Antagonistic activities of atropine, propranolol and phentolamine 
The effects of the three classical autonomic antagonists atropine (an acetyl­
choline — muscarinic — receptor blocker), phentolamine (an α-adrenergic re­
ceptor blocker) and propranolol (a jS-adrenergic receptor blocker) were invest­
igated to test the specificity of the dopamine effects and the receptors involved. 
The chemical structures of these agents are given in figure 8. 
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Atropine 
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00 і н 
Propranolol 
FIG. 8: Chemical structures of the classical autonomic antagonists used in this study. 
It was already reported by Walker et al. (1968) that atropine and propanolol do not 
influence the inhibitory effects of dopamine on Helix aspersa neurones. We 
could confirm these findings in this study in which effects of atropine and 
propranolol were tested on 6 neurones inhibited by dopamine. Neither atropine 
(in doses up to 5 χ 10 ' s M) nor propranolol (in doses up to IO 5 M) produced 
any reduction of dopamine-induced inhibitions. 
With respect to excitatory effects of dopamine, it was found in 5 experiments 
that atropine in doses up to ΙΟ"5 M did not affect excitatory effects of dopa­
mine (3 χ 10"7 M). At much lower doses (10"7 M) atropine already completely 
blocked acetylcholine-induced inhibitions of the same neurones. With propranol­
ol a somewhat more complicated picture was obtained. In 2 of the 5 dopamine-
excited neurones studied propranolol was totally ineffective in doses up to IO 5 
M. The spontaneous activity of the three remaining cells was depressed by 
propranolol at doses of 5 χ ΙΟ"6 M or higher. Also the excitatory effect of 
dopamine was attenuated at these doses, whereas acetylcholine inhibitions were 
not influenced. This may indicate a dopamine receptor blockade by propranolol. 
However, more work with other /3-adrenergic receptor blockers, specially those 
without local anaesthetic activity, will be necessary to allow more definite con­
clusions on the possible interactions of /3-adrenergic receptor blockers with the 
dopamine receptor mediating neuronal excitation. 
The α-adrenergic receptor blocker phcntolamine blocked both dopamine-in­
duced inhibitions and excitations (5, resp. 4 neurones were tested), although 
relatively high doses, 2 - 5 χ ΙΟ"6 M, were needed to reduce the effect of 
но 
N-CH 2 -/ Ί 
I 4N -1 
CH3 
Phentolamme 
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dopamine with a factor 2 or more. At these doses phentolamine did not in-
fluence acetylcholine- or serotonin-induced changes of the firing rate of these 
neurones, indicating a specific interaction of phentolamine with the dopamine 
receptors. 
In summary, these data with the anticholinergic and antiadrenergic drugs indi-
cate the specificity of the dopamine effects and the receptors involved. The 
anticholinergic agent atropine does not influence the dopamine effects at all and 
the anti-adrenergic agents are only active at relatively high doses. The ß-adren-
ergic receptor blocker propranolol is inactive as antagonist of dopamine-induced 
inhibitions, whereas it causes only slight blockade of the excitatory effects. This 
latter action may be due to an interaction with the dopamine receptor. Phentol-
amine, finally, possesses antagonistic properties both with respect to dopamine-
induced inhibitions and excitations. The effects appear to be due to a specific 
interaction with the dopamine receptor. The potency of phentolamine, however, 
is rather low when compared with that of some of the blockers that will be 
described in the next chapter (see also table VI). 
In conclusion, the neurones of the snail Helix aspersa provide an excellent test 
system to study dopamine receptor pharmacology. First of all, there is abundant 
evidence to prove the role of dopamine as a neurotransmitter in this preparation. 
Secondly, both inhibitory and excitatory effects of dopamine can be measured. 
Experiments with classic autonomic blocking agents indicate the specificity of 
the receptors involved. This will be further evaluated in the next chapter. Third-
ly, the preparation has great experimental advantages of which the most import-
ant ones are: (1) the possibility to work at the level of single neurones and still 
keeping the preparation functionally intact; (2) the reproducibility of the effects 
obtained throughout different preparations and (3) the possibility to work with 
precisely known concentrations of drugs in the organ bath, thereby allowing 
dose-response studies. A disadvantage of perfusion as the way of administration 
is that drugs may cause their effects indirectly: they may act on elements differ-
ent from the postsynaptic membrane. Therefore, such approach does not allow 
conclusions on the localization of the dopamine receptors. To allow such con-
clusions experiments using the iontophoretic route of administration should be 
performed (cf. Ascher, 1972). 
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CHAPTER 3 TWO TYPES OF DOPAMINE RECEPTORS IN THE 
GANGLIA OF HELIX ASPERSA 
Introduction 
In this chapter experiments will be reported that were intended to further 
characterize the dopamine receptore mediating neuronal inhibition and excita-
tion pharmacologically. Several groups of drugs have been used to enable such 
characterization: a series of dopamine-related phenylethylamine derivatives, a 
number of imidazolines, two drugs of which earlier studies had indicated a 
possible dopaminomimetic activity: apomorphine and piribedil, a number of 
ergot alkaloids and a number of neuroleptic drugs. The effects of these groups of 
drugs will be treated separately in the following paragraphs. In the last paragraph 
of this chapter the implications of the results found in the experiments described 
in this chapter will be discussed. 
DRUGS USED IN THE EXPERIMENTS DESCRIBED IN CHAPTER 3 
Phenylethylamines: 
dopamine hydrochloride (Koch-Light, Fluka, Calbiochem) 
N-methyldopamine hydrochloride (epinine, Burroughs-Wellcome) 
(—) noradrenaline hydrogentartrate (Fluka, Philips-Duphar) 
(+) noradrenaline hydrogentartrate (Philips-Duphar) 
(—) adrenaline bitartrate (Boehringer-Ingelheim) 
(—) phenylephrine hydrochloride (Boehringer-Ingelheim) 
(—) isoprenaline sulphate (Sigma) 
5-methyldopamine hydrobromide (Philips-Duphar) 
p-tyramine hydrochloride (Koch-Light) 
3-methoxy-4-hydroxy-phenylethylaiTiine hydrochloride (Calbiochem) 
3,4-dmiethoxy-phenylethylamine hydrochloride (Sigma) 
dexamphetamine sulphate (Sigma) 
p-oxedrine tartrate (Koch-Light) 
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Imidazolines: 
Clonidine hydrochloride (Boehringer-Ingelheim) 
naphazoline hydrochloride (CIBA) 
3,4-dihydroxy-phenylamino-2-imidazoline hydrochloride (Wander) 
Ergot derivatives: 
ergometrine maléate (Haiewood Chemicals) 
ergotamine tartrate (GynergeenR, Sandoz) 
dihydroergotamine methanesulphonate (Dihydergot11, Sandoz) 
dihydroergotoxine (Hydergine1*, Sandoz) 
Neuroleptic drugs: 
haloperidol (Serenase R , Janssen Pharmaceutica) 
droperidol (DehydrobenzperidolR, Janssen Pharmaceutica) 
chlorpromazine hydrochloride (SPECIA) 
fluphenazine dichloride (Schering) 
trifluperazine hydrochloride (Théraplix) 
thioproperazine bismethanesulphonate (SPECIA) 
Other compounds: 
apomorphine hydrochloride (Brocades) 
piribedil methanesulphonate (ET 495, Servier) 
acetylcholine iodide (Fluka) 
serotonin Creatinin sulphate (Koch-Ught) 
The chemical structures of these compounds are given on the following pages: 
phenylethylamines in table V, imidazolines in figure 10, apomorphine and 
piribedil in figure 12, ergot derivatives in figure 15, and neuroleptic drugs in 
figure 19. All drugs were dissolved in snail Ringer, except apomorphine, 
piribedil, chlorpromazine, fluphenazine, trifluperazine and thioproperazine that 
were dissolved in distilled water and haloperidol (SerenaseR), droperidol (Dehy-
drobenzperidolR), ergotamine (GynergeenR), dihydroergotamine (Dihydergot11) 
and dihydroergotoxine (HydergineR) of which commercially available solutions 
were used that were diluted with Ringer to obtain the dose needed. 
In the cases of the phenylethylamines, apomorphine and (3,4-dihydroxy-phenyl-
ammo)-2-imidazoline a few milligrams ascorbic acid were added as an anti-
oxidant. This manipulation only caused a slight drop in the pH of the Ringer 
solution. In control experiments it was shown that neither the use of distilled 
water instead of Ringer as a solvent nor the addition of ascorbic acid to a drug 
solution influenced the effect of the drug. With respect to the use of com-
mercially available solutions care had to be taken that the pH of the final 
solution added to the bath did not get lower than about 4. Solutions with pH 
lower than 4 usually caused unspecific changes in the membrane properties of 
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the cell, such as a change in resting membrane potential, changes in action 
potential height and shape Solutions with a pH 4 - 9 could be used safely 
3.1. Phenylethylamine derivatives 
The chemical structure of the phenylethylammes used in this study are given in 
table V. 
DOPAMINE 
The effects of dopamine have been described extensively under 2.4 The thresh­
old amount to induce either inhibition or excitation with dopamine was 0.01 -
0.1 nmol, which corresponds to a minimal bath concentration of 0.6 - 6 χ 10 9 
M. 
N-METHYLDOPAMlNb (EPININb) 
Epinine was applied to 4 neurones that could be inhibited by dopamine (DA-I-
neurones) and 3 cells that could be excited by this compound (DA-E-neurones). 
Epinine mimicked the dopamine effects in each experiment with an average 
e.p.m J. of about 1 both for inhibitory and excitatory effects. 
( - ) NORADRENALINt 
The effect of (—) noradrenahne was tested on 12 DA-I-neurones and on 9 
DA-E-neurones. In each case ( -) noradrenaline mimicked the effects of dopa­
mine. Its average e.p.m.r. with respect to inhibitory activity is 18 with a range of 
4 - 2 8 . The mean e.p.m.r of (—) noradrenaline for excitations was found to be 4 
(range 2 - 10). In the case of (—) noradrenaline complete dose-response curves 
were made (figure 9). From these dose-response curves it appeared that the 
intrinsic activity of (—) noradrenaline when compared with dopamine is equal to 
1, both in case of inhibitory and excitatory activity. 
( + ) NORADRENALINL 
The effect of (+) noradrenaline was tested on 6 DA-I-neurones and 5 DA-E-
neurones (+) Noradrenaline mimicked the effects of dopamine with a mean 
e ρ m.r. for inhibition of 94(range 70-140) and for excitation of 9 (range 6-15). 
53 
Increase in action 
potential rate per 10 sec 
36 -
30 
24 -
18 
12 
6 
10 ' e 10"7 10"6 10"5 10"4 
M 
FIG. 9: Dose-response relationship for dopamine and (-) noradrenaline-induced excitation 
of cell 8. 
(-) ADRENALINE 
(—) Adrenaline was applied to 4 DA-I-neurones and 5 DA-E-neurones. (-) 
Adrenaline mimicked dopamine effects, except for one cell excited by dopa­
mine. On this cell adrenaline was not active in doses up to 10"s M. The mean 
e.p.m.r. of adrenaline for excitatory activity at the remaining four cells was 13 
(range: 7 - 30). Its e.p.m.r. for inhibitory activity was found to be 80 (range: 60 
-100). 
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A Dopamine 
о (-) Noradrenaline 
S-METHYLDOPAMINE 
The effect of 5-methyldopamine was tested on 4 DA-I-neurones and 4 DA-E-
neurones. S-Methyldopamine mimicked the effect of dopamine in each case, its 
e.p.m.r. for excitatory activity being 28 (range: 18 - 40) and for inhibitory 
activity 16 (range: 12 - 20). 
( - ) ISOPRENALINE 
(—) Isoprenaline was tested on 4 DA-I-neurones and 7 ¿DA-E-neurones. (—) 
Isoprenaline did not mimic the inhibitory effects of dopamine in concentrations 
up to 10"s M (e.pjn.r. > 2000). In 2 of the 7 neurones that could be excited by 
dopamine it was inactive in doses up to 10"s M. The other 5 cells were slightly 
excited by isoprenahne at relatively high doses. The e.p.m.r. of isoprenaline on 
these 5 neurones was about 300 (range: 100 - 400). 
( - ) PHENYLEPHRINE, p-TYRAMINE, 3-M ETHO X YTYRAMINE, 3,4,-DIME-
THOXY-PHENYLETHYLAMINE, p-OXEDRINE AND DEX AM PHETAMINE 
AH these agents were tested at least on 4 DA-I-neurones and 4 DA-E-neurones. 
In none of these experiments these agents mimicked the effects of dopamine in 
doses up to 0.3 - 5 χ 10"5 M. 
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Compound 
dopamine 
cpmine 
(- ) noradrenaline 
(+) noradrenaline 
(-) adrenaline 
(-) isoprcnalinc 
p-tyramine 
(-) phenylephrine 
p-oxedrinc 
5-mcthyldopamine 
3-methoxyty ramine 
3,4-dimcthoxyphenylethylamine 
dexamphetamine 
2 
Η 
Η 
Η 
Η 
Η 
II 
Η 
Η 
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Η 
3 
но 
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II 
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Η 
но 
СНзО 
4 
но 
но 
но 
но 
но 
но 
но 
Η 
но 
но 
но 
СНзО CHjO 
Η Η 
5 
Η 
II 
Η 
Η 
Η 
II 
Η 
Η 
Η 
енз 
II 
Η 
Η 
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ines for inhibitory and excitatory effects on Helix aspersa neurones. 
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II 
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e.p.m.r. inhibition 
1 
1 
18 
94 
80 
> 2 0 0 0 
> 2 0 0 0 
> 2 0 0 0 
> 2 0 0 0 
16 
> 2 0 0 0 
> 2 0 0 0 
> 2 0 0 0 
e.p.m.r. exci 
1 
1 
4 
9 
13 
300 
> 2 0 0 0 
> 2 0 0 0 
> 2 0 0 0 
28 
> 2 0 0 0 
> 2 0 0 0 
> 2 0 0 0 
DISCUSSION 
The results reported above are in good agreement with those obtained by 
Woodruff and Walker (1969) who only studied structure-activity-relationship 
(S.A R.) characteristics of a senes of phenylethylammes with respect to dopa-
mine-like inhibitory activity of Helix aspersa neurones. From the results report­
ed above and those of Woodruff and Walker (1969) the following general con­
clusions can be made regarding the characteristics for dopamine-bke activity (1) 
the presence of both 3- and 4-hydroxyl substitution in the phenyl moiety of the 
dopamine molecule is essential for dopamine-like inhibitory and excitatory 
activity as indicated by the complete lack of activity of compounds lacking one 
or both of these hydroxyl groups p-tyramine, (—) phenylephrine, p-oxedrine 
and dexamphetamine, or compounds in which one or both hydroxyl groups is 
methylated 3-methoxytyramine and 3,4-dimethoxy-phenyIethylamine, (2) the 
presence of a hydroxyl group at the C-atom in the β position with regard to the 
terminal nitrogen causes a marked reduction in activity (—) and (+) noradren­
aline and (—) adrenaline are less active than dopamine and epimne, (3) a methyl 
substitution at the terminal nitrogen of the dopamine molecule does not in­
fluence activity if the /}-carbon atom contains no substituent (epimne), but 
reduces activity if there is a hydroxyl group in the /3 position, adrenahne being 
less potent than noradrenaline. The larger isopropyl substituent (isoprenaline) 
even abolishes inhibitory activity completely, whereas excitatory activity is 
greatly reduced; (4) the presence of a methyl substituent in the 5 position of the 
phenyl moiety of the dopamine molecule reduces activity, (5) both with respect 
to excitatory and inhibitory activity (+) noradrenaline is less active than (—) 
noradrenaline. This difference is larger in case of inhibitory activity (a potency 
ratio of 5.2) than in the case of excitatory activity (a potency ratio of 2 3). 
The most important features distinguishing this S.A.R. pattern from that for a-
or ^-adrenergic activity of analogous phenylethylammes are (a) dopamine — 
together with epimne — is the most potent agonist of this senes of phenylethyl­
ammes, (b) both the 3- and 4-phenobc hydroxyl groups are essential for dopa-
minomimetic activity. These groups are relatively unimportant for α-adrenergic 
activity for which an unsubstituted amino terminal group is of special signific­
ance for agonistic activity. For /3-adrenergic activity the presence of the two 
phenolic hydroxyl groups is somewhat more important (Anens, 1967, Pratesi 
and Grana, 1967, Pratesi et al., 1975), but there are also ß-adrenergic agonists 
lacking the 3-OH group that still have high intnnsic activity and affinity (Anens, 
1967), (c) the presence of a hydroxyl group at the 0-carbon atom reduces 
dopaminergic activity, in contrast to the a- and ^-adrenergic activity where the 
|3-hydroxyl group is an activity enhancing factor (Anens, 1967), (d) the differ-
ence in potency of (+) and (—) noradrenaline as dopamine receptor agonists is 
much smaller than in the case of a- or j3-adrenergic receptor agonistic activity of 
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these agents, where differences in relative affinities of factors 20 - 200 are 
reported (Ariens, 1963, 1967; van Rossum, 1965; Patii et al., 1972, 1974). One 
notable exception in this respect is the a-adrenergic receptor of the vas deferens. 
In this preparation the potency ratio (—)/(+) noradrenaline is only 4 (van 
Rossum, 1965). Interestingly, dopamine has a relatively high affinity for the rat 
vas deferens a receptor and this receptor also shows a difference with other α 
receptors in the sense that the neuroleptic butyrophenones haloperidol and 
droperidol are much more potent antagonists at the level of this receptor than at 
the level of other α-adrenergic receptors (van Rossum, 1965). These observations 
led van Rossum in 1965 already to suggest that there may be a smooth scale of α 
receptors with at one end receptors which are best fitted for noradrenaline and 
at the other end receptors which are best fitted for dopamine. However, 
formally speaking, receptors best fitted for dopamine — as is the case for Helix 
aspersa neurones — may not be α-noradrenergic receptors but rather true dopa­
mine receptors. 
These data for the phenylethylamines do not indicate very pronounced differen­
ces in the S.A.R. profiles for agonistic activity at inhibition-mediating and exci­
tation-mediating dopamine receptors. Only slight differences were found, e.g. 
the somewhat greater potencies of (—) and (+) noradrenaline and (—) adrenaline 
with respect to excitatory actions; the larger potency ratio for (—)/(+) noradren­
aline for inhibitory activity and the slight excitatory actions of isoprenaline in 
the absence of an inhibitory effect. As will be reported below, really significant 
differences were found with antagonists or with structurally more divergent 
agonists. 
3.2. Imidazoline derivatives 
The chemical structures of the 3 imidazolines used in this study are given in 
figure 10. 
H /CI Η HCX Η 
H 2 4 N N ] C h N -О "олУ- N -O V l Η Η 
Naphazoline Clonidine DPI 
H G . 10: Chemical structures of the three imidazoline derivatives used in the Helix aspersa 
dopamine receptor study. 
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These agents were chosen in view of their interesting α-adrenergic receptor 
agonistic properties (Mujic and van Rossum, 1965; Struyker Boudier et al., 
1975; see also chapter 7). From these studies it appears that naphazoline is a 
potent and specific stimulant of peripheral α-adrenergic receptors in contrast to 
its weak central α-adrenergic receptor stimulating properties (Mujic and van 
Rossum, 1965; Struyker Boudier et al., 1975). Clonidine was found to be a 
potent stimulant of central α-adrenergic receptors with little peripheral a-adren-
ergic receptor activity (Struyker Boudier et al., 1975). DPI, finally, was shown 
to be a stimulant of both central and peripheral α-adrenergic receptors (Struyker 
Boudier et al., 1975). Specially this last agent looked an interesting one to test 
for dopaminomimetic properties as it contains a 3,4-dihydroxyphenyl moiety. 
NAPHAZOLINE AND CLONIDINE 
The effects of naphazoline and Clonidine were tested on a minimum of 4 neur­
ones that could be inhibited by dopamine and 4 neurones that could be excited 
by dopamine. Unless high doses were used (>10"5 M) these two compounds did 
not affect the activity of these neurones. At high doses a short inhibition of 
activity was observed in a few cases. This inhibition occurred both in cells that 
could be inhibited by dopamine and cells that could be excited by this com­
pound, so there seems to be no relation with the effect of dopamine itself. 
(3,4-DIHYDROXY-PHENYLAMINO)-2-IMIDAZOLINE (DPI) 
The effects of DPI were tested on 13 DA-I-neurones and 6 DA-E-neurones. In 4 
of the 6 cells excited by dopamine no appreciable effect could be obtained with 
DPI in doses up to 10"5 M, in 1 case the neuron was inhibited by DPI and in 1 
case it was excited. However, these effects only occurred at concentrations 
between I O 6 - IO 5 M, which is 30 - 100 times higher than those needed to 
obtain effects with dopamine on these neurones. 
DPI mimicked dopamine-induced inhibitions in 11 of the 13 cells tested. The 
duration of the inhibition depended upon the dose of DPI injected with dose-
response characteristics similar to those of dopamine. 
The mean e.p.m.r. of DPI with respect to inhibitory activity was about 1 (range: 
0.2 - 3). There were slight differences with dopamine in the sense that dopamine-
induced inhibitions were usually accompanied by a hyperpolarization of the 
cellular membrane (2 - 18 mV), whereas the degree of hyperpolarization after 
DPI was usually smaller (0 - 7 mV): figure 11. 
The inhibitory effects of DPI were blocked by ergometrine — an antagonist of 
dopamine-induced inhibitions of the same neurones — which strengthens the 
support of a common mode of action of dopamine and DPI in causing neuronal 
inhibition. 
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FIG. 11 ; Effects of dopamine (DA) and (3>4-dihydroxyphenylamino)-2-imida7oline (DPI) on 
Helix aspersa neurones. A. Effects of dopamine (3 χ IO"' M) and DPI (3 χ IO"7 M) on cell 3. 
В. Effects of dopamine (3 χ IO"7 M) and DPI (3 χ IO"6 M) on cell 7. Note that DPI only 
mimics dopamine-induced inhibitions. 
DISCUSSION 
The results obtained with these three imidazolines support the previously 
derived conclusion that the presence of a 3,4-dihydroxy-phenyl moiety is an 
essential prerequisite for a drug to be able to act as an agonist at dopamine 
receptors: Clonidine and naphazoline, agents lacking such moiety, are ineffective. 
However, it is surprising that DPI, the imidazoline containing this 3,4-dihydroxy-
phenyl moiety, only acts as an agonist at the inhibition-mediating dopamine 
receptor. At this receptor it is a potent agonist. 
This result strongly indicates that there may be differences in the pharmacologic­
al receptors mediating inhibition and excitation by dopamine. More work should 
be done with other 3,4-dihydroxy-phenyl dérivâtes to elucidate what chemical 
features are essential in determining the specific requirements for activity at 
dopamine-inhibition-mediating receptors. 
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3.3. Apomorphine and piribedil 
The chemical structures of apomorphine and piribedil are given in figure 12. 
These drugs were chosen in view of their possible dopaminergic activity as 
described by several authors (cf. chapter 1). 
Apomorphine Piribedil 
FIG. 12: Chemical structures of the putative dopaminergic agents apomorphine and piri­
bedil. 
APOMORPHINE 
The effect of apomorphine was studied on 14 DA-I-neurones and 16 DA-E-
neurones. None of the 14 neurones that could be inhibited by dopamine was 
inhibited by apomorphine in doses up to 1 - 5 χ IO"5 M (figure 13A). This is in 
agreement with the lack of dopaminergic agonistic activity previously reported 
by Woodruff and Walker (1969) and Pinder et al. (1972). 
In a number of cells (N=8) inhibited by dopamine the possible antagonistic 
activity of apomorphine was tested. At relatively high doses (> I O 6 M) apo-
morphine blocked the inhibitory actions of dopamine (figure 13A). This 
antagonism may be competitive as higher doses of dopamine can cause inhibition 
again. 
12 of the 16 neurones that could be excited by dopamine were also excited by 
apomorphine. In the other 4 no appreciable effect was seen in doses up to 10's 
M. The pattern of excitation induced by apomorphine on the 12 cells on which 
it was active was somewhat different from that of dopamine (figure 13B). First, 
the degree of depolarization induced by apomorphine (2 - 7 mV) was lower than 
that of dopamine (4 - 20 mV) and, secondly, its effect lasted longer than that of 
dopamine. In figure 14 dose-response curves for dopamine and apomorphine on 
cell 8 are given. From these curves it can be seen that the intrinsic activity of 
apomorphine is only 0.3 of that of dopamine. This is in agreement with other 
experiments where intrinsic activities of 0.2 - 0.5 were found. The average 
e.p.m.r. of apomorphine with respect to excitatory activity was found to be 18 
(range: 10-60). 
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Зх10- 7 М 5 x 1 0 - 6 M 
FIG. 13: Effects of dopamine (DA) and apomorphine (APO) on Helix aspersa neurones. A. 
Effects of dopamine ( 3 χ 10"^ M) and apomorphine (10"5 M) on cell 2. B. Effects of 
dopamine (3 χ 10"^ M) and apomorphine (5 χ ΙΟ'*· M) on cell 7. Note that apomorphine 
only mimics dopamine-induced excitations, whereas it blocks the inhibitions. 
In 3 cells Haloperidol (an antagonist of dopamine excitatory effects, see para­
graph 3.5.) was given before apomorphine. Haloperidol (10 "б M) completely 
abolished the excitatory effects of apomorphine in all 3 cases, which is 
additional evidence in favour of a common mode of action of apomorphine and 
dopamine in inducing neuronal excitation. 
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FIG. 14: Dose-response relationship for dopamine or apomorphme induced excitation of 
cell 8. Note that the intrinsic activity of apomorphme is considerably lower than that of 
dopamine. 
PIRIBEDIL 
The effect of piribedil was tested on 4 DA-I-neurones and 6 DA-E-neurones. In 3 
of the 4 neurones inhibited by dopamine piribedil at relatively high doses (5 χ 
1 0 " 6 M - 5 x l O " s M ) caused a short (15 - 60 seconds) lasting inhibition of 
spontaneous activity of which the duration was not clearly related to the dose. 
The fourth neuron was not affected by piribedil. Piribedil did not influence the 
effect of dopamine at these neurones, not even at the high dose of 5 χ 10"s M. 
With respect to the excitatory effects of dopamine, piribedil in doses up to 5 χ 
10"s M did not mimic dopamine, neither did it influence the excitations induced 
by dopamine. 
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о Apomorphme 
DISCUSSION 
Apomorphme and pinbedil were studied in view of their putative dopaminergic 
receptor stimulating activity (cf. chapter 1). The data obtained with 
apomorphme in this study provide another strong indication that dopamine 
receptors mediating neuronal inhibition differ from those mediating excitation 
Apomorphme behaves as an antagonist of dopamine-induced inhibitions, where­
as it mimics the excitations caused by dopamine. However, on the dopamine-
mhibition-mediating receptor apomorphme only has weak intrinsic activity and 
an e.p.m.r. of 18, so it cannot be regarded to be an extremely potent agonist at 
this receptor. The low intrinsic activity of apomorphme is not very surprising in 
view of the strict structural requirements for dopamine-hke activity and the 
rather bulky structure of this agent. It would be of importance to investigate 
other aporphine alkaloids or related conformationally rigid analogs to see 
whether a more potent agonist can be obtained (for further discussion of this 
matter see conclusion). 
The data obtained with pinbedil give little support for a dopaminergic effect of 
this drug. It was totally inactive on the cells excited by dopamine and on the 
cells inhibited by dopamine, it only caused inhibition at relative high doses. 
Moreover, this inhibition only lasted very short and the duration was not related 
to the dose, so an effect on the dopamine receptor does not seem very likely 
However, more experiments with this agent and its catechol metabolite S 584 
should be performed to allow more definite conclusions 
3.4. Ergot alkaloids 
The chemical structure of the ergot alkaloids used in this study are given in 
figure 15. 
ERGOMFTRINF 
The effects of ergometnne were tested on 22 DA-I-neurones and 8 DA-E-
neurones Ergometnne caused no change in the spontaneous activity of the 
neurones that could be inhibited by dopamine It blocked the inhibitory effects 
of dopamine at very low doses (figure 16) Optimal antagonism of dopamine-
induced inhibitions occurred already 0 5 - 5 minutes after injecting ergometnne 
into the bath and lasted 1 - 2 hours when the bath was perfused at a rate of 2 
ml/min. 
The minimal amount of ergometnne required to reduce the effect of 3 χ 10 1 M 
dopamine by a tactor of 2 or more was 2 - 5 χ 10 9 M At this low dose 
ergometnne did not influence acetylcholine and serotonin effects on these 
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Ergometnne 
Ergotamine 
Dihydroergotamine 
9-10 
unsaturated CH3 СН
г
 С 6 Н 5 
saturated СН3 СН2 С 6 Н 5 
I Dihydroergocornine saturated CHtCHj^ СН (СН3)2 
Dihydroergocnstine saturated СЖСНз^ СН
г
 С 6 Н 5 
Dihydroergokryptine saturated CI-KCl ·^ СН2 СН(СНз)г FIG. 15: Chemical structures of the ergot alkaloids used in this study. 
ЗхКГ'М 3x10" 7 M 
2 0 m V 
20 sec 
PIG. 16. Antagonism of dopamine-induced inhibition of cell 2 by ergometnne. 
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neurones. At higher doses ergometnne (> 2 χ 10 8 M) also blocked serotonin-
induced excitations or inhibitions of these neurones Ergometnne never in­
fluenced acetylcholine effects, not even at concentrations as high as 10 6 M. 
In 4 neurones the dose-response characteristics of dopamine effects measured as 
duration of inhibition were determined both before and after the addition of 
ergometnne (1 - 5 χ ΙΟ"8 M). From these experiments it appeared that the 
antagonism caused by ergometnne may be competitive as the antagonism is 
surmountable by higher doses of dopamine. An example of such dose-response 
studies is given in figure 17. 
(m 
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FIG. 17 Dose-response curves for dopamine-induced inhibition of cell 3 before and after 
the addition of ergometnne (10"8 M) 
The effects of ergometnne on the DA-E-neurones are somewhat more com-
phcated. In 6 of the 8 neurones the addition of ergometnne in doses of 5 - 50 χ 
ΙΟ"
7
 M caused a slight, gradual increase in action potential rate over a prolonged 
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oí ergometnne (10 8 M) 
period of time. In 3 cases this effect was measured over a period of 30 minutes 
without injecting any other drug in that period. Perfusion was left off; in 3 
control experiments similar measurements were made without adding ergo-
metrine. The results of these experiments are summarized in figure 18. 
Act ion potentials / 1 0 ьес 
2C ι 
Γ-ΙΓ 1 no crug 
t = 0 t - 5 t=10 t = 15 t = 2C t = 3 0 
MG. 18: Mean action potential rate per 10 seconds after prolonged exposure of ergometnne 
(10"6 M) to three neurones that can be excited by dopamine (all three times cell 8). 
compared with the mean action potential rate m 3 cases (cell 8) when no drug was added. 
The ordinate indicates the number of action potentials per 10 seconds. The abscissa 
indicates time in minutes. Lrgometnne was added at t = 0. I· urther details, sec text. 
As can be seen in figure 18, the increase in action potential rate caused by 
ergometrine only developed very slowly reaching maximum after about 20 
minutes. The increase in action potential rate never was more than a factor 2. 
Ergometrine also blocked the dopamine-induced excitations of these neurones. 
The minimal amount of ergometnne required to reduce the effects of 3 χ ΙΟ"7 M 
dopamine by a factor 2 or more was 3 - 6 χ ΙΟ"8 M. At these doses ergometrine 
did not influence acetylcholine- and serotonin-induced inhibitions of these 
neurones. At higher doses of ergometrine a reduction of the effect of acetyl­
choline was observed sometimes. It was not possible to determine the nature of 
the antagonism induced by ergometrine or its pA2 value in view of the too 
limited amount of experiments allowing such measurements. However, on the 
basis of the threshold doses given above it can be concluded that ergometrine is 
at least 10-15 times less active as antagonist of dopamine-induced excitations 
than as antagonist of the inhibitions induced by dopamine. 
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ERGOTAMINE, DIHYDROERGOTAMINE, DIHYDROERGOTOXINE 
Walker et al. (1968) and Woodruff et al. (1971) already reported on the effects 
of three structural analogs of ergometrine, viz. ergotamine, ergotoxine and LSD. 
All three agents behaved as antagonists of dopamine-induced inhibitions 
although their relative potencies are some 10-100 times lower than that of 
ergometrine. 
In this study this finding was confirmed with respect to ergotamine which was 
tested on 4 neurones inhibited by dopamine. It acted as dopamine receptor 
blocker at minimal doses of 3 - 8 χ ΙΟ"8 M. Also the dihydroergot derivatives 
were effective antagonists of dopamine-induced inhibitions as tested on 4 
neurones each. 
The minimal dose required to reduce the effects of 3 χ ΙΟ"7 M dopamine by a 
factor 2 or more were 1 - 3 χ ΙΟ'7 M for dihydroergotamine and 2 - 7 χ ΙΟ"7 M 
for dihydroergotoxine (see also table VI). 
In this study the effects of these 3 ergot alkaloids with respect to excitatory 
actions of dopamine have not been studied. 
DISCUSSION 
These data obtained with ergometrine and its structural analogs indicate that 
several of these ergot alkaloids can be regarded as relatively potent dopamine 
receptor antagonists. Especially ergometrine is very powerful in this respect. 
Ergot alkaloids have complex pharmacological properties in mammals (Dale, 
1906; Cerletti, 1959). They can cause a great number of effects due to a direct 
action on smooth muscle (Cerletti, 1959; Brazeau, 1970), blockade of adrenergic 
and serotonergic receptors in the periphery (Rothlin, 1957; Cerletti and 
Doepfner, 1958; Nickerson, 1970) and a number of central nervouw system 
actions (Brawley and Duffield, 1972). These drugs can therefore not be regarded 
as very attractive drugs for the classification of pharmacological receptors. It is 
interesting, however, that ergometrine — the- most potent dopamine receptor 
blocker found in this study — is a drug without α-adrenergic properties, whereas 
ergotamine and even more so the dihydro derivatives are very potent in this 
respect (Nickerson, 1970). This clearly distinguishes the dopamine receptors 
described in this chapter from the classical adrenergic receptors studied in the 
past. 
Ergometrine as well as ergotamine and the dihydro derivatives, have considerable 
antiserotonergic activity (Cerletti and Doepfner, 1958). In this study we also 
found considerable antiserotonergic activity with these agents. Actually, the 
dose region in which these drugs only produced antidopaminergic activity is 
quite small. This may indicate some relationship between the dopamine and the 
serotonin receptor in the snail brain (for detailed discussion: Woodruff, 1971). 
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However, it is also quite well possible that more distinction between dopamine 
and serotonin receptors can be obtained with the design of more specific 
antagonists. It has already been reported by Woodruff (1971) that cypro­
heptadine is a drug that blocks the actions of serotonin without affecting those 
of dopamine. 
It was observed in this study that ergometrine blocks both inhibitory and 
excitatory effects of dopamine, although it seems to be 10 - 15 times more 
potent with respect to blockade of inhibitory actions The slight and gradual 
excitation of DA-E-neurones after the administration of ergometnne remains 
puzzling. It remains to be established whether this effect of ergometnne is due 
to a stimulation of the excitation-mediating dopamine receptors, an interaction 
with serotonergic receptors or another effect. On smooth muscle ergometnne 
causes a similar gradual effect., viz. a prolonged increase in resting tonus. It has 
been suggested that this effect is due to a partial agonistic action of ergometnne 
οηα-adrenergic receptors (Innes, 1962) 
3.5. Neuroleptics 
In this study a number of neuroleptic drugs have been included in view of their 
putative dopaminolytic properties reported by several authors (see chapter 1) 
Neuroleptics of two different chemical classes have been included the butyro-
phenone denvatives halopendol and dropendol and the phenothiazine den-
vatives chlorpromazine, fluphenazine, tnfluperazine and thioproperazine The 
chemical structures of these drugs are given in figure 19. 
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П С 19 Chemical structures of the neuroleptiu drugs used in this study Halopendol and 
dropendol belong to the group of the neuroleptic butyrophenoncs Chlorpromazine, 
fluphenazine, thioproperazine and tnfluperazine belong to the group ot the neuroleptic 
phenothiazincs. 
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HALOPERIDOL AND DROPLRÍDOL 
The effects of haloperidol and droperidol have been studied on 16 respectively 5 
DA-I-neurones. With respect to excitatory dopamine effects these drugs were 
tested on 13 respectively 4 neurones. 
Haloperidol and droperidol in doses up to Ι Ο 5 M did not affect the spontaneous 
activity of the DA-I-neurones. At higher doses they usually caused aspecific 
changes in the membrane activity, such as rapid depolarization and changes in 
the action potential shape and height. These changes are most likely due to 
solvent effects as the pH of the solutions was 4 or even lower. Similar changes 
are obtained if Ringer solutions acidified to pH values lower than 4 are ad­
ministered. At doses up to ΙΟ'5 M neither haloperidol nor droperidol significant­
ly reduced dopamine-induced inhibitions (figure 20A). Also acetylcholine-
induced excitations and serotonin-induced excitations or inhibitions were not 
significantly altered at these doses of haloperidol or droperidol. 
On cells excited by dopamine a somewhat more complicated picture was 
obtained with the butyrophenones. At doses of 5 χ ΙΟ'7 M - 1 0 s M these 
butyrophenones in a number of cases caused cessation of firing for periods of 1 -
4 minutes (figure 20B). At higher doses (5 χ Ι Ο 6 M — 5 χ ΙΟ"4 M) increases in 
firing rate were observed a few times; this is probably due to solvent effects as 
was reported before in the case of dopamine-inhibited neurones. 
DA. H A L D A 
3x10-7M 10- 5 M 3x10-7M 
D A . H A L . D A . 30sec 
3x10-7M 3x10-6M 3x10-7M 
HG. 20; Effects of dopamine (DA) and haloperidol (HAL) on Helix aspersa neurones. A. 
Fffects of dopamine (3 χ 10"^ M) and haloperidol (10"5 M) on cell 5. B. Effects of 
dopamine (3 χ 10"^ M) and haloperidol (3 χ 10"" M) on cell 7. Note that haloperidol only 
blocks dopamine-induced excitations. 
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Haloperidol and droperidol both antagonized the excitatory effects of 
dopamine. This antagonism started within 2 minutes after the addition of the 
neuroleptic drugs, but optimal antagonism did not occur until 10 - 20 minutes 
after adding halopendol or dropendol to the bath. The blockade was reversible 
after perfusing the preparation for 1 - 2 hours with snail Ringer at a rate of 2 
ml/mm dopamine again caused complete excitation of these neurones. The 
threshold concentration of halopendol required to reduce the effect of 3 χ IO"7 
M dopamine by a factor 2 or more was 6 - 20 χ 10 8 M. Dropendol was effective 
at minimal doses of 3 - 6 χ 10"7 M, so it is about 4 times less active than 
halopendol (see also table VI). 
In three cases complete dose-response curves of dopamme-induced increase in 
action potential rate were determmed both before and after the addition of 
halopendol (IO'6 M). An example is given in figure 21. 
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flG 21 Dose-response curves for dopamme-induced excitation of cell 8 before and after 
the addition of halopendol ( ΙΟ - 6 M) 
From these three expenments it appears that the antagonism is of competitive 
nature. The pA2 value of halopendol in these 3 experiments is 6.8 ± 0.3 (mean ± 
SD.) 
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At doses of 10"8 - 5 χ IO"6 M haloperidol and droperidol did not influence 
acetylcholine and serotonin effects on these neurones which is a strong 
indication for the specificity of their interaction with the dopamine receptor at 
these doses. Higher doses sometimes reduced both acetylcholine and serotonin 
effects. Apart from their dopamine receptor blockade the butyrophenones 
probably also have other — unspecific — membrane effects which could explain 
this general reduction of effects obtained by transmitter substances. 
CHLORPROMAZINE, FLUPHENAZINE, TRIFLUPERAZINE AND 
THIOPROPERAZINE 
The effects of the four phenothiazines were tested on a minimum of 4 DA-I-
neurones. At doses of I O 8 - Ι Ο 5 M these agents did not affect the spontaneous 
activity of these neurones. The inhibitory effects of dopamine were also not 
influenced at these doses, apart from 2 cases in which fluphenazine at a dose of 
ΙΟ"
5
 M reduced the effect of dopamine ( 3 χ ΙΟ-7 M) if dopamine was adminis­
tered within 3 minutes after the addition of fluphenazine. If dopamine was 
added later than 3 minutes after the addition of fluphenazine no appreciable 
reduction of its inhibitory effect was observed. The effects of acetylcholine and 
serotonin on these neurones were not influenced by the phenothiazines in doses 
up to I O 5 M. 
With respect to dopamine excitations only chlorpromazine and fluphenazine 
were tested on 4 and 3 neurones respectively. Both chlorpromazine and 
fluphenazine blocked the excitatory effects of dopamine ( 3 χ ΙΟ"7 M). The 
threshold doses required were 3 - 6 χ ΙΟ'7 M and 2 - 6 χ IO"8 M respectively (see 
also table VI). At these doses chlorpromazine and fluphenazine did not influence 
the acetylcholine and serotonin effects on these neurones. 
DISCUSSION 
These data found with the neuroleptic agents are an additional support to the 
concept of two pharmacologically distinct dopamine receptors. In general , the 
neuroleptics tested in this study were without effect on dopamine-inhibition 
mediating receptors, whereas they did antagonize dopamine-excitatory effects. 
This antagonism of dopamine-excitatory action seems to be due to a specific 
dopamine receptor blockade as acetylcholine and serotonin effects were not 
influenced in a dose range in which dopamine effects were already significantly 
reduced. However, the concentrations at which the neuroleptics block 
dopamine-excitatory effects are not very low, in contrast to ergometrine 
blockade of inhibitory dopamine effects. It is quite well possible, however, that 
more potent blockers can be found among the other neuroleptics. 
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TABLE VI 
Summary of the data obtained in chapter 3 with respect to the minimal concentrations (M) 
of putative dopaminolytic agents needed to reduce inhibitory or excitatory effects of 
dopamine (3 χ ΙΟ""7 M) by a factor 2 or more. Also relative potencies are indicated with the 
potency of phentolaminc taken as 1. 
Drug 
ergometrine 
crgotamine 
dihydrocrgotamme 
dihydroergotoxinc 
phentolamine 
propranolol 
Haloperidol 
dropendol 
chlorpromazine 
fluphcnazine 
thioproperazine 
tnfluperazine 
Dopamme-mduced 
inhibition 
2 - 5 x 10· 9 
3 - 8 x IO"8 
1 - 3 x IO"7 
2 - 7 xlO" 7 
2 - 5 χ IO"6 
>io-s 
>io-s 
>io- s 
>io-s 
>io- s 
>io-s 
>io- s 
Relative 
potency 
1000 
60 
18 
8 
1 
< 0 . 3 
< 0 . 3 
< 0 . 3 
< 0 . 3 
< 0 . 3 
<о.з· 
< 0 . 3 
Dopamme-mduced 
excitation 
3 - 6 x l 0 - 8 
Not tested 
Not tested 
Not tested 
2 - 5 χ 10-6 
5 χ 10-6 
6 - 20 χ IO'8 
3 - 6 χ IO"7 
3 - б х І О " 7 
2 - 6 χ IO"8 
Not tested 
Not tested 
Relative 
potency 
80 
-
-
-
1 
0.7 
30 
8 
8 
90 
-
— 
Conclusion: Implications of the existence of two types of dopamine receptors 
From the results reported in this chapter three major conclusions can be drawn: 
1. Dopamine receptors in Helix aspersa ganglia are dopamine-specific receptors, 
that is to say, their pharmacological properties are completely different from 
those of other aminergic receptors and dopamine itself is the natural and most 
potent agonist. The specificity in the pharmacological profile of dopamine 
receptor activity is found both for agonistic and antagonistic activity at these 
receptors. Requirements for agonistic activity are very strict, as was revealed in 
the study of the phenylethylamines and the imidazolines. This agrees very well 
with the study of Goldberg et al. (1968) concerning dopamine-like vasodilatory 
activity and the study of Miller et al. (1974) concerning dopamine-like stimu­
lation of adenylate cyclase. The essential features for dopaminomimetic activity 
have been discussed already under 3.1. and can be summarized as: (a) the pre­
sence of a 3,4-dihydroxyphenylethylamino moiety is indispensable for agonistic 
activity; (b) substitution at the a - or ß-carbon atoms or substituents lager than 
methyl at the terminal nitrogen greatly reduces activity. 
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The antagonists studied in this chapter were of quite divergent chemical nature 
Their pattern of action, however, still indicates considerable selectivity. The 
most potent antagonist found — ergometrme — is a drug lacking antiadrenergic 
activity. Also the activities of the neuroleptics when compared with those of 
phentolamine and propranolol are indicative for the specificity of the dopamine 
receptors However, none of these antagonists can be regarded as very pure 
dopamine receptor blockers as they also have some antiserotonergic properties 
(ergometrme) and antiadrenergic properties (ergotamine, neuroleptics) It would 
be of theoretical and possible clinical — interest to develop new dopamine 
receptor blockers along more rational lines taking into consideration the very 
specific requirements for dopamine like activity Probably such drugs have been 
developed already but their activity may have remained hidden because of the 
relatively poor test-models used up to now for testing antidopaminergic activity. 
2. Dopamine receptore mediating neuronal inhibition and excitation have 
distinct pharmacological properties They will therefore be called DA-I- and 
DA-b-recepiors from here on Apart from possible experimental and clinical 
importance (see below) this distinction is also of theoretical interest The exist-
ence of specific agonists and antagonists may reveal some of the characteristics 
of the respective receptors involved as has been possible for the a-and 
/3-adrenergic receptors, the H, and H2 histammergic receptors and the nicotinic 
and muscarinic cholinergic receptors 
Dopamine itself is a conformationally very flexible molecule, so one can easily 
imagine a multiple receptor interaction of this agent During the last few years a 
number of authors have made conformational analyses of the dopamine mole-
cule using several quantum-chemical methods such as extended Huckel calcula-
tions (Kier and Truitt, 1970, Bustard and Egan, 1971, Rekker et al, 1972), 
CNDO calculations (Complete Neglect of Differential Overlap, Katz et al , 1973) 
or PCILO calculations (Perturbative Configuration Interaction using Localized 
Orbitals, Pullmann et al, 1972) or by performing crystallographic X-ray analysis 
of the dopamine molecule (Bergin and Carlstrom, 1967, Horn and Snyder, 
1972). Although it is extremely difficult to compare results obtained with such 
diverse techniques it has become evident that there are at least three almost 
equivalent energy minima for the dopamine molecule, one associated with the 
extended (trans) form of the phenylethylamino moiety and two with the folded 
(gauche) forms However, such calculations can only present very rough 
estimations of the conformation of dopamine at its receptor site where very 
special forces due to the drug-receptor interaction may play a decisive role In 
this respect it is much more worthwhile to study conformational aspects of 
molecules in which the phenylethylamino moiety is contained in a rigid 
structure Such molecules much less likely undergo conformational changes 
under the influence of the drug-receptor interaction. Some of such rigid 
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dopamine analogs have been studied pharmacologically and it is intriguing that 
they show very specific activities. First of all, it has been shown that agents 
having a dihydroxytetrahydroisoquinoline structure — corresponding to the 
gauche conformation of dopamine — (see figure 22) have no dopaminomimetic 
activity when tested on the adenylate cyclase dopamine receptor (MiHer et al., 
1974a; Sheppard and Burghardt, 1974a and b), the striatal dopamine receptor 
(Costall et al., 1975b), the vascular dopamine receptor (Goldberg et al., 1969) or 
the DA-I-receptors of Helix aspersa (Woodruff, 1971). It has not yet been 
possible to test any isoquinoline derivative on neurones excited by dopamine, 
but in view of the marked similarity between the adenylate cyclase dopamine 
receptor and the DA-E-receptor it seems unlikely that these compounds would 
exert dopamine-like activity.
, . . -n h 2
/NH, 
Dopamine ( t r a n s )
’xrH O
Dopamine (g a u c h e )
h° —r°^Sr"
Apomorphine
h o —t r ^
HO
A -  6.7- DTN
Tetrahydroisoquinolines
/ ^ N H 2
- r VH O - 
H O ^ ^
A -  5 ,6 -DTN
FIG. 22: Upper row: trans and gauche representation of the conformations of the dopamine 
molecule. Middle row: Apomorphine is an example of a dopamine analog in which the 
dihydroxyphenylethylamino moiety is contained in a rigid, trans conformation. Dihydroxy- 
tetrahydroisoquinolines are dopamine analogs in which the dihydroxyphenylethylamino 
moieties are locked in a folded, gauche conformation. Lower row: 2-amino-6,7-dihydroxy- 
1,2,3,4-tetrahydronaphthalene (A-6,7-DTN) and 2-amino-5,6-dihydroxy-l,2,3,4-tetrahydro- 
naphthalene (A-5,6-DTN) are examples of dopamine analogs in which the dihydroxyphenyl­
ethylamino moieties are locked in an extended, trans conformation, although the respective 
conformations of these two molecules differ slightly. Further details: see text.
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On the other hand, rigid analogs containing the phenylethylamino moiety in its 
extended (trans) conformation seem to interact much more easily with 
dopamine receptors. Several of such drugs have been studied, e.g. apomorphine, 
2-amino-5,6-dihydroxy-l ,2,3,4-tetrahydronaphthalene (A-5,6-DTN) and 2-amino-
6,7-dihydroxy-l,2,3,4-tetrahydronaphthalene (A-6,7-DTN). Chemical structures 
of these agents are indicated in figure 22. As was pointed out by Woodruff 
(1971) and Pinder et al. (1972) a]ready apomorphine and A-6,7-DTN have dif-
ferent conformations. Interestingly on snail neurones A-6,7-DTN is a stimulant 
at DA-I-receptors (Pinder et al., 1972) whereas apomorphine stimulates DA-E-
receptors and blocks the DA-I-receptors. This may be a first clue into revealing 
the different properties of the two dopamine receptors. In this respect it is 
highly interesting that in behavioural studies (Burkman, 1973) both apomor-
phine and A-5,6-DTN have been shown to produce strong emesis in dogs, where-
as only apomorphine induces compulsive gnawing and convulsant activities in 
mice and stereotyped pecking in pigeons: behaviours that cannot be induced by 
A-5,6-DTN. This indicates a pharmacological dissociation between emetic and 
compulsive behavioural effects. It would be of interest to test the effects of 
A-5,6-DTN on DA-E-receptors as this drug can be predicted to be an agonist 
with higher intrinsic activity than apomorphine at these receptors. 
3. Helix aspersa dopamine receptors provide a model for the classification of a 
number of drugs. In such classification it is of extreme importance to define the 
properties of a drug in terms of its interaction with both DA-I- and DA-E-
receptors. Such classification is presented for a number of drugs in table VII. 
TABLE vu 
Classification of some drugs on the basis of their interaction with DA-I- and DA-E-re-
ccptors in Helix aspersa. 
Drug 
Dopamine 
Apomorphine 
Pinbedil 
DPI 
Phentolaminc 
Propranolol 
brgometnne 
Haloperidol 
Droperidol 
Huphcnj/ine 
Chlorpromjzinc 
DA-I-receptors 
Full agonist 
Antagonist 
Ineffective 
hull agonist 
Weak antagonist 
Incltective 
Antagonist 
Ineftectivc 
Inettective 
Incftective 
Ineffective 
DA-E-receptors 
Full agonist 
Partial agonist 
Ineffective 
Ineffective 
Weak antagonist 
Weak antagonist 
Antagonist 
Antagonist 
Antagonist 
Antjgomst 
Antagonist 
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This classification has a number of implications as it differs from that obtained 
in studies where other models for dopamine receptors are used. In chapter 1 these 
models - the vascular dopamine receptor, evertebrate dopamine receptors, 
adenylate cyclase dopamine receptor and the central nervous system dopamine 
receptor — have been reviewed. In the following paragraphs the implications of 
the concept of the two types of DA receptors for each of these models will be 
mentioned. 
With respect to the mammalian vascular dopamine receptor it was mentioned in 
paragraph 1.1. that most likely dopamine receptors at two different peripheral 
levels participate in the depressor effects induced by dopamine. The first of 
these is located at the level of the renal vasculature. At this receptor neuroleptic 
drugs are not or only very poorly active as antagonists of dopamine in contrast 
to ergometrine; remarkably apomorphine has antagonistic properties too. It also 
has agonistic properties, but that effect may also be due to an action at 
ganglionic level, unless it could be shown that apomorphine acts on isolated 
artery strips. Still on the basis of these pharmacological aspects this receptor can 
be classified as DA-I-receptor. This would imply that A-6,7-DTN and DPI should 
be potent renal vasodilators. The second dopamine receptor involved in the 
cardiovascular actions of dopamine has been described at the level of the para-
vertebral ganglion (Willems, 1974). This receptor can be classified as a typical 
DA-E-receptor in view of the good agonistic activity of apomorphine, the anta-
gonism by haloperidol and the relative lack of effect of ergometrine. 
With respect to the evertebrate dopamine receptors described in paragraph 1.2. 
there is very clear evidence for the existence of both DA-I- and DA-E-receptors. 
In Helix aspersa both receptors exist, but there is also good evidence to support 
this existence in Aplysia (Ascher, 1972) and Planorbis (Berry and Cottrell, 
1973a, 1975). 
With respect to the adenylate cyclase-coupled dopamine receptor the situation is 
more complicated. Neuroleptic drugs are good antagonists of dopamine and 
apomorphine behaves as a partial agonist, which would suggest the involvement 
of DA-E-receptors. However, the slight stimulatory effect of ergometrine is 
somewhat puzzling. In view of the reported heterogeneity of adenylate cyclase 
dopamine receptors (Spano et al., 1975) further experiments using more 
selective agonistic drugs should be awaited before definite conclusions can be 
made. 
In the mammalian CNS finally, there is accumulating evidence for the existence 
of two types of dopamine receptors. The iontophoretic experimental data of 
York (1970) and Feltz (1971) can be interpreted on the basis of this concept, 
although these authors have not yet used the critical drugs to make this 
distinction clear. However, Cools et al. (1975,1976) and Cools and van Rossum 
(1975) have provided strong evidence in favour of the existence of both DA-I-
and DA-E-receptors in the striatum of the cat on the basis of the behavioural 
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effects obtained by DPI and ergometrme on the one side and apomorphine and 
Haloperidol on the other side The data of Pijnenburg et al (1976) who used the 
same drugs indicate the presence of both DA-I- and DA-E-receptors in the rat 
accumbens as well. 
The existence of both these receptors in the mammalian brain has implications 
for the interpretation of the behavioural effects observed after treating mammals 
with drugs interfering with central dopaminergic mechanisms. One example is 
the behavioural effect seen after the administration of apomorphine Apomor-
phine has a number of behavioural effects which are all generally considered to 
be a consequence of dopamine receptor stimulation. However, it has become 
evident in this study that apomorphine is a stimulant of only the one type of 
dopamine receptor and a blocker of the other type This may imply that some of 
its effects are due to its stimulatory properties and others to its blocking proper-
ties. This possible divergency can be further explored by the use of drugs inter-
fering more specifically with only one type of dopamine receptor as have been 
described in this study. 
In conclusion, the existence of two pharmacologically distinct types of 
dopamine receptors involved in a number of behavioural and cardiovascular 
functions creates an interesting concept for medicinal chemists to design new 
types of drugs interacting specifically with one of these types An interesting 
example of such a drug is DPI, whereas also some of the amino-tetrahydro-
naphthalene derivatives could be of interest. 
Helix aspersa neurones are a very useful model to test such specific activity 
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SECTION II 
CENTRAL NERVOUS SYSTEM ADRENERGIC RECEPTORS 
AND CARDIOVASCULAR CONTROL 

CHAPTER 4 CENTRAL NERVOUS SYSTEM CONTROL OF 
CARDIOVASCULAR ACTIVITY 
Introduction 
The cardiovascular system is aimed at supplying adequate bloodflow to the 
brain, kidney, lungs, vegetative organs, muscles, skin and other tissues of the 
body In some of these tissues e.g. the kidney — local autorcgulatory mechan-
isms are in operation to preserve a relative constant local bloodflow. The flow 
requirements for several other tissues may vary greatly, for instance, during 
exercise the bloodflow through the muscles may increase 1 0 - 2 0 fold Such 
acute changes in bloodflow in individual organs and tissues are achieved mainly 
by a change in cardiac output and a change in the peripheral resistance of each 
individual organ or tissue at the expense of others. This implies that integrated 
responses of the heart and the peripheral vascular beds must occur to provide 
individual tissues with an adequate bloodflow. 
The bloodflow requirements for specific tissues and consequently the blood-
flow distribution to different tissues - often changes when an organism reacts to 
cope with a number of environmental disturbances (challenges) The cardio-
vascular changes during several of these challenges have now been investigated in 
detail, eg changes in environmental temperature (Kullmann et al , 1970, 
Schonung et al, 1971, Iriki et al , 1971 b, Rowell, 1974), behavioural alerting 
(Abrahams et al, 1964, Pribram and McGuinness, 1975), emotional stimuli 
(Abrahams et al., 1960, Pinotti, 1970, Zanchetti et al., 1970, Adams et al., 
1971, Folkow and Neil, 1971, Humphrey and Joels, 1972), changes in body 
posture (Gauer and Thron, 1965, Doba and Reis, 1972 a and b 1974 a, Lisander 
and Mariner, 1971), muscular exercise (Rushmer and Smith, 1959, Vatner et al., 
1970, Freyschuss, 1970, Borst et al., 1972, Rowell, 1974) and changes in 
oxygen content of the blood (Korner et al., 1969 and 1973, Utheret al., 1970, 
Iriki et al., 1971 a, Inki and Kozawa, 1975). From these studies it has become 
evident that the circulatory responses evoked by each of these challenges are 
distinctive and result from an interaction of specific, local humoral effects with 
distinctive changes in autonomic — mostly sympathetic - nerve discharge 
patterns to the heart and the vasculature An example of such distinctive 
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patterns of change in autonomic activity is the response to the assumption of an 
upright body posture; this type of challenge is accompanied by elevation of 
systemic blood pressure, tachycardia and vasoconstriction of arteries in limbs, 
kidney and abdominal viscera (Gauer and Thron, 1965; Doba and Reis, 1972 a 
and b). 
Electrophysiological studies during the last decade have greatly contributed to 
the insight that the CNS contains mechanisms which are capable of initiating the 
distinctive patterns of sympathetic nerve discharge during the above mentioned 
challenges (reviews: Körner, 1971 ; Hudlicka, 1973; Smith, 1974; Hilton, 1974, 
1975; Körner and Uther, 1975; Ninomiya and Irasawa, 1975; Pribram and 
McGuinness, 1975; Simon and Riedel, 1975). These patterns of sympathetic 
nerve discharge have been shown to be the autonomic component of complex 
somatovisceral adjustments in which autonomic as well as somatomotor re-
actions are taking part to cope with the particular challenge imposed upon the 
organism by environmental stimuli (Smith et al., 1974; Smith, 1974; Hilton, 
1974, 1975). 
Another major contribution of these electrophysiological studies is that they 
have shown that the CNS mechanisms initiating such differentiated patterns of 
sympathetic discharge are located at several, mostly suprabulbar levels of the 
brain: e.g. the mechanisms operating during thermal challenges are located in the 
hypothalamus (Bligh, 1973); those active during emotional stimuli and muscular 
exercise in both the hypothalamus and the cerebral cortex (Hilton, 1966; 
Folkow and Neil, 1971; Smith, 1974); those mediating cardiovascular adjust-
ments during hypoxia and hypercapnia in the hypothalamus as well as in the 
lower brainstem (Uther et al., 1970; Korner, 1971; Iriki and Kozawa, 1975; 
Komer and Uther, 1975) and those active during changes in body posture in the 
fastigial nucleus in the cerebellum and in the lower brainstem (Doba and Reis, 
1974 a). 
Apart from these largely suprabulbar mechanisms capable of influencing cardio-
vascular activity there are important bulbar mechanisms that play a role in the 
regulation of cardiovascular parameters. These bulbar mechanisms are mainly 
involved in the integrative proprioceptive cardiovascular control, for instance, 
the control of arterial blood pressure via baroreceptor reflex mechanisms 
(Alexander, 1946; Bard, 1960; Uvnäs, 1960; Folkow et al., 1965; Humphrey, 
1967; Seller and Illert, 1969; Komer, 1971; Koizumi and Brooks, 1972;Spyer, 
1975). Recent evidence has indicated that suprabulbar, especially hypothalamic 
regions may also be involved in the complete integration of the baroreceptor 
reflex as well as the chemoreceptor reflex (Komer et al., 1969; Uther et al., 
1970; Komer, 1971; Hilton and Spyer, 1971; Komer et al., 1972; Iriki and 
Kozawa, 1975). Especially the experiments of Hilton and Spyer(197I) in which 
small lesions in the anterior hypothalamus of cats diminished cardiovascular 
responses to baroreceptor afferent stimulation have provided strong evidence for 
such direct hypothalamic involvement. 
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In summary, although the major mechanisms for proprioceptive neural cardio­
vascular control are located in the bulbar region of the brain, there are important 
suprabulbar mechanisms capable of influencing cardiovascular activity The 
primary importance of these latter mechanisms seems to be that they can initiate 
patterns of somatovisceral adjustments to challenges imposed upon the organism 
by the environment 
Although the precise interrelation between the vanous brain centres in the cere­
bral organization of these somatovisceral action patterns is still largely unknown, 
available data suggest a wide range of control of cardiovascular parameters by 
structures at different levels of the CNS, eg spinal cord, lower brainstem, 
cerebellum, hypothalamus and even the cerebral cortex Moreover, recent studies 
have added to this concept of direct neural control a possible role of the CNS in 
the control of hormonal factors that influence cardiovascular activity, e.g the 
hypothalamic influence on renin secretion (Zehr and Feigl, 1973) and on release 
of adrenomedullary catecholamines (Nathan and Reis, 1975) 
Apart from the electrophysiological evidence in favour of a role of the CNS in 
cardiovascular control mentioned above, recent contributions along more phar­
macological lines of research have also provided evidence in favour of this con­
cept. In the following two paragraphs several aspects of the two major lines of 
evidence in this respect — central noradrenergic neurones in cardiovascular con­
trol and the CNS as a site of action of antihypertensive drugs — will be briefly 
discussed. For more details the reader may consult several recent reviews 
(Schmitt, 1971, Kobinger, 1973, van Zwieten, 1973, 1975 a, Chalmers, 1975, 
Haeusler, 1975). 
4.1 Central noradrenergic neurones and cardiovascular control 
The distribution of central monoanunergic neurones has largely been elucidated 
after the introduction of histochemical techniques to visualize monoamines or 
their synthetic enzymes (Fuxe, 1965, Ungerstedt, 1971,Hokfelt et al , 1974). 
Also the recently described very sensitive radioisotopic assay technique for 
cdtecholammes has greatly enhanced knowledge on the distribution of central 
monoamines (Kobayashi et al , 1974, Palkovits et al, 1974, Κοριη et al , 1974, 
Saavedra et al , 1974) 
In cardiovascular control especially the noradrenergic neurones have been impli­
cated so far, whereas recently also some attention has been given to adrenaline 
respectively serotonin containing neurones (Bolme et al., 1974, Chalmers, 1975) 
However, evidence in favour of a role of these latter two neuron types is still too 
scanty and will therefore not be discussed here 
The most conspicuous central noradrenergic fibres are (1) the descending bulbo­
spinal fibres which have cell bodies in the medulla and nerve terminals in both 
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the ventral hom and the lateral column and dorsal horn of the spinal cord; (2) a 
descending pathway originating in the locus coeruleus with short axonal 
processes ramifying locally around lower brainstem nuclei; (3) an ascending 
pathway originating in the locus coeruleus innervating the cortex, the hippo­
campus and the cerebellum and (4) an ascending pathway with cell bodies 
scattered throughout the medulla and pons, innervating the lower brainstem, the 
mesencephalon, the hypothalamus and the limbic system (cf. fig. 2). 
Several techniques can be used to study the possible involvement of central 
noradrenergic neurones in cardiovascular control: A. The endogenous amounts 
of noradrenaline and the activity of the noradrenaline-metabolizing enzymes can 
be measured after inducing — usually in rats — one of several types of hyper­
tension. Among these types are: DOCA-saline hypertension, in which unine-
phrectomized rats are treated with desoxycorticosterone (DOCA) and are given 
1% sodium chloride to drink to develop hypertension; renal hypertension, in 
which rats are made hypertensive by unilateral renal wrapping with contralateral 
nephrectomy or by partial unilateral renal infarction with contralateral neph­
rectomy; neurogenic hypertension, in which animals are made hypertensive by 
deafferentation of the arterial barorecept or reflexes either by bilateral section of 
the carotid sinus and aortic nerves or by central deafferentation after bilateral 
lesioning of the nucleus tractus solitarii; spontaneous hypertension (in rats), in 
which hypertension gradually develops as a consequence of a genetic disposition 
(for review: Chalmers, 1975); B. The activity of central noradrenergic neurones 
can be changed by the administration of drugs that change endogenous levels of 
noradrenaline; С Drugs acting on postsynaptic receptors normally stimulated by 
noradrenaline can be administered intravenously, intravertebrally etc. 
Each of these approaches has been used to assess the involvement of central 
noradrenergic neurones in cardiovascular control. 
Ad. A. The first approach — the study of central noradrenaline metabolism in 
hypertensive animals — has provided some data which have been explained as 
evidence favouring such involvement. In certain types of experimental hyper­
tension — mainly of the neurogenic, DOCA-saline and genetic type — differences 
in the noradrenaline metabolism in several parts of the brain have been found in 
comparison with that of control animals (Yamori et al., 1970; Lew, 1975). 
Especially the marked decrease in noradrenaline levels in the hypothalamus 
during the development of spontaneous hypertension may indicate a role of 
hypothalamic noradrenergic neurones in the genesis of this form of hypertension 
(Lew, 1975). However, up to now results of these studies have suffered much 
from a great variability in noradrenaline biosynthetic enzyme activities in differ­
ent control groups of normotensive animals (Lovenberg et al., 1973) or the 
variability in the noradrenaline metabolism at different times of the day or night 
(Lew, 1975). Moreover, another disadvantage of this approach up to now has 
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been that potential changes were measured in large regions of the brain, each of 
which may contain several populations of catecholaminergic neurones subserving 
different or even opposing functions (Chalmers, 1975). Finally, different central 
noradrenaline metabolism in hypertensive animals does not necessarily imply 
that central noradrenergic neurones trigger the development of hypertension or 
maintain it; such difference may also reflect a CNS reaction to the hypertension 
established and maintained by factors outside the CNS. 
Ad. B. Experiments following the second approach - changing the activity of 
central noradrenergic neurones — have up to now mostly been done by using 
6-hydroxydopamine as a tool to destroy noradrenergic neurones or by treating 
animals with I^ -dopa to increase neuronal noradrenaline amounts. 
Intraventricular or intracisternal injection of 6-hydroxydopamine into rabbits, 
cats or rats produces a fall in blood pressure and heart rate for several hours. 
This effect has been explained on the basis of a mimetic action of 6-hydroxy-
dopamine at central noradrenergic receptors mediating inhibition of sympathetic 
nerve activity (Haeusler et al., 1972; Chalmers and Reid, 1972;Takishita, 1975; 
Chalmers, 1975). Thereafter blood pressure returns to normal, whereas endo-
genous noradrenaline levels in the brain may remain below control level for a 
prolonged period. Also long-term treatment with 6-hydroxydopamine fails to 
cause a significant change in blood pressure. 
Intracisternal administration of 6-hydroxydopamine prevents the development 
of neurogenic hypertension in sino-aortic denervated or nucleus tractus solitarii 
lesioned rats (Chalmers and Wurtman, 1971;Doba and Reis, 1974 b), but not in 
rats with other types of hypertension (Chalmers, 1975). This observation has 
been interpreted as evidence for the existence of bulbo-spinal noradrenergic 
fibres that facilitate the increase in blood pressure in animals with neurogenic 
hypertension (Chalmers, 1975). However, a serious drawback of these studies in 
which large amounts of 6-hydroxydopamine were injected intracisternally or 
intraventricularly is that after such treatment noradrenergic as well as dopamin-
ergic and possibly also adrenergic neurones at different levels of the brain may 
be affected. This was not checked in most of these studies. 
In order to obtain more detailed knowledge concerning the organization of 
central noradrenergic neurones experiments should be preferred in which small 
amounts of 6-hydroxydopamine are injected locally at circumscribed sites of the 
brain (Ungerstedt, 1971). Up to now such experiments have indicated the exist-
ence of a noradrenergic synapse at the level of the nucleus tractus solitarii 
mediating decrease in blood pressure (Doba and Reis, 1974 b) and a noradren-
ergic synapse at the level of the posterior hypothalamus mediating increase in 
blood pressure (Philippu et al., 1973; Haeusler, 1975). This local injection tech-
nique has so far not been used in measuring the development of blood pressure 
over a longer period of time. 
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Ldopa in combination with a peripheral decarboxylase inhibitor injected peri­
pherally or L-dopa alone injected intraventncularly into normotensive rats, cats 
or dogs or spontaneous hypertensive rats causes invariably a long-lasting decrease 
in blood pressure and heart rate and a decrease in sympathetic nerve activity 
(Henning and Rubenson, 1970, Schmitt et al., 1972, Yamon et al., 1972, Baum 
and Shropshire, 1973, Watanabe et al., 1974). This effect can be blocked by a 
adrenergic receptor antagonists (Schmitt et al., 1972). Moreover, the effect is 
abolished by inhibition of central decarboxylase activity, indicating that the 
cardiovascular effects of L-dopa are caused by its metabolites dopamine or nor­
adrenaline (Henning and Rubenson, 1970, Yamon et al., 1972, Watanabe et al., 
1974). Again, as was the case for the 6-hydroxydopamine experiments, these 
data do not allow conclusions concerning the differential role of the different 
central catecholaminergic neurones, since L-dopa used at the doses it was, ad­
ministered peripherally or intraventncularly, is an unselective drug that can in­
crease the activity of catecholaminergic synapses at several levels of the CNS. 
Ad. C. The third approach to assess the role of central noradrenergic neurones in 
cardiovascular control has been the use of drugs potentially interfering with the 
noradrenergic receptors located on postsynaptic neurones This can be done by 
the intracerebral administration of the natural agonist (i с noradrenaline) or by 
injecting drugs that stimulate or block these receptors The results obtained with 
some of the most commonly used agents in this respect — Clonidine and a 
methyldopa and its derivative α-methylnoradrenaline - will be discussed in the 
next paragraph on the CNS as a site of action of antihypertensive drugs 
The central effects of the natural noradrenergic receptor agonist - noradrenaline 
- are generally associated with a fall in sympathetic nerve activity, blood 
pressure and heart rate (Nashold et al., 1962, Share and Melville, 1963, 
Smookler et al., 1966, Toda et al., 1969, Schmitt and Fénard, 1971, Baum and 
Shropshire, 1973) By means of stereotactic injections the two major sites of 
action in this respect have been shown to be located in the medulla oblongata at 
the level of the nucleus tractus solitari! (de Jong, 1974) and m the diencephalon 
at the level of the anterior hypothalamic/preoptic region (see chapter 5). In both 
cases an α rather than a β adrenergic receptor has been implicated in the media­
tion of this response, although there may be slight differences in the respective 
receptors (see chapter 6) Apart from these two sympatho-mhibitory noradren­
ergic synapses a third, sympatho-stimulatory noradrenergic synapse has been 
shown at the level of the postenor hypothalamus by Philippu and co-workers 
(Przunteket al, 1971, Philippu et al, 1973 and 1974) 
Not much work has yet been published regarding central cardiovascular effects 
of adrenergic receptor antagonists Intracisternal injections oí large amounts of 
phentolamine and phenoxybenzamme, which can be regarded as typical a-adren-
ergic receptor blocking agents, cause a fall in blood pressure and heart rate in 
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vagotoini¿cd rats (Ito and Schanberg, 1974). There is, however, up to now no 
evidence to support that this action is caused by an interaction of these drugs 
with central α-adrenergic receptors. Central cardiovascular effects of /3-adrenergic 
receptor blocking agents have not been very thoroughly investigated so far. 
Intraventricular injections of huge amounts of propranolol cause a biphasic 
change of blood pressure, consisting of an initial increase followed by a small 
prolonged decrease of blood pressure accompanied by a bradycardia (Srivastava 
et al., 1973; Day and Roach, 1973; Reid et al., 1974). The hypotensive response 
may, however, not be related to the /3-adrenergic receptor blocking capacity of 
this drug (Kelliher and Buckley, 1970; see also: van Zwieten, 1975 a). 
In summary, (1) noradrenergic neurones show a relatively wide pattern of 
distribution in the CNS and many of these neurones terminate in regions from 
which cardiovascular function can be influenced as evidenced by the data dis­
cussed in the introduction of this chapter. This stresses the potential complexity 
of the possibilities with which central noradrenergic neurones can influence 
cardiovascular function; (2) although studies using pharmacological tools to in­
fluence the activity of these neurones have not yet provided evidence for a role 
of central noradrenergic neurones in the maintenance of resting blood pressure, 
they do indicate that changing the activity of noradrenaline synapses may cause 
acute changes in cardiovascular parameters. As was discussed in the introduction 
to this chapter an important function of CNS mechanisms influencing cardio­
vascular activity seems to be the organization of complex behavioural-somato-
visceral action patterns. Therefore, in stead of being involved in the maintenance 
of resting blood pressure, central noradrenergic neurones may have a modulatory 
role (cf. Kobinger, 1974; Kobinger and Pichler, 1974); and (3) localized phar­
macological manipulation at sites where noradrenergic neurones terminate, indi­
cates that stimulation of noradrenergic receptors at several levels of the CNS 
leads to different effects: sympatho-inhibitory effects by stimulation at the level 
of the nucleus tractus solitarii and the anterior hypothalamic/preoptic region 
and sympatho-stimulatory effects by stimulation at the level of the posterior 
hypothalamus. Possibly also in the spinal cord there are noradrenergic receptors 
stimulation of which induces sympathetic stimulation. 
4.2 The CNS as a site of action of antihypertensive drugs 
The presence in the CNS of noradrenergic synapses and receptors mediating 
sympathetic inhibition should provide an interesting concept for the design of 
antihypertensive drugs. In fact, the history is just the reversed way: first there 
were the antihypertensive drugs and thereafter the concept of CNS sympatho-
inhibitory synapses was developed. This history needs not be repeated here as 
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most of its aspects have been reviewed already by the authors who originally 
developed this concept (Schmitt, 1971, Kobinger, 1973, van Zwieten, 1973, 
1975 a) 
The two major antihypertensive drugs in this respect are Clonidine and a-methyl-
dopa The mechanism of antihypertensive action of Clonidine has now been 
shown to be a centrally induced inhibition of sympathetic activity The anti­
hypertensive effect of a-methyldopa is of more complicated nature the reduc­
tion in sympathetic activity induced by this agent is probably of peripheral as 
well as central origin However, in the acute hypotensive effect of a-methyldopa 
a centrally mediated fall in sympathetic nerve activity via the α methyldopa 
metabolite α-methylnoradrenaline is clearly indicated The centrally mediated 
reduction of sympathetic nerve activity after both Clonidine and a-methylnorad-
renaline has been suggested to be caused by stimulation of central α-adrenergic 
receptors by these agents (cf Schmitt, 1971, Kobinger, 1973, van Zwieten, 
1973, 1975 a) However, two aspects of this mechanism of action of Clonidine 
and a-methyldopa are still under debate the localization of the receptors 
mediating the sympathetic inhibition and the pharmacological nature of these 
receptors The rest of this paragraph will be devoted to a discussion of the 
literature pertaining to these two aspects of the mechanism of hypotensive ac­
tion of Clonidine and a-methyldopa 
SITb O l A.CTION 
Early attempts to localize the noradrenergic receptors stimulated by Clonidine 
and a-methyldopa have been done with decerebration techniques whereby trans-
sections were made at several levels of the brainstem of cats or rabbits 
(Hukuhara et al, 1968, Schmitt and Schmitt, 1969, Shaw et al, 1971) The size 
of the hypotension induced by Clonidine was not reduced after transsection at 
the level of the mesencephalon, the pons or the area between the pons and 
mesencephalon Also the clomdine-induced decrease in splanchnic and renal dis­
charges was not reduced by such transsections (Hukuhara et al, 1968, Schmitt 
and Schmitt, 1969) However, Clonidine induced somewhat less bradycardia in 
such decerebrated animals (Shaw et al, 1971, Hukuhara et al, 1969) Trans­
section of the spinal cord at the C-l level completely abolished the hypotensive 
and bradycardiac effect of Clonidine (Schmitt and Schmitt, 1969) These data 
suggest an important site of action of Clonidine in the medulla oblongata Similar 
approaches in rats and cats have indicated the same site for the hypotensive 
action of α methyldopa (Nijkamp, 1975) and L-dopa (Henning et al, 1972, 
Schmitt et al, 1973 a) 
However, transsection expenments have so far been rather one-sided approaches 
in the localization of drug-induced effects in the CNS With these transsection 
techniques it has been possible to measure drug-induced cardiovascular effects in 
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the medullary region isolated from the higher centres of the brain, but it has so 
far not been possible to measure the involvement of higher brain centres under 
conditions that they were isolated from the medullary centres. Therefore, the 
relevance of transsection techniques as an estimation for the differential involve­
ment of different centres of the brain must not be over-estimated (cf. Hilton and 
Spyer, 1971; Hilton, 1974, 1975). 
Another early indication for a medullary site of action of Clonidine was the fact 
that in cats Clonidine is more active when injected into a vertebral artery than 
after injection into a carotid artery (cf. van Zwieten, 1975 a). The pontomedul-
lary region mainly receives blood from the vertebral artery as evidenced by 
experiments using microspheres labelled with 1-125 and Nb-95 (Reneman et al., 
1974). 
Recently techniques claiming more detailed localization have been used to assess 
where in the medulla oblongata Clonidine may exert its a-adrenergic fall in blood 
pressure and heart rate. Superfusion of the motor nucleus of the vagus of cats 
with Clonidine induces bradycardia, whereas superfusion of the medullary 
pressor area elicits a fall in systemic blood pressure (Sinha et al., 1975). 
Clonidine superfusion of the cat nucleus tract us solitarii — the area proposed 
originally as the primary site of action of Clonidine (Schmitt, 1971) - does not 
influence blood pressure, although this treatment blocks the pressor response to 
posterior hypothalamic stimulation (Philippu et al., 1973). Topical application 
of concentrated Clonidine solutions to the floor of the fourth ventricle of cats 
produces hypotension and bradycardia (Dhawan et al., 1975). However, neither 
the superfusion experiments nor the topical application experiments allow 
precise estimation of the dose applied and the area to which a drug spreads. 
Recently de Jong (1975) showed that after stereotactic injection of Clonidine 
into the nucleus tractus solitarii of rats no decrease in blood pressure and heart 
rate was observed, whereas the same author (de Jong, 1974; de Jong et al., 1975 
a and b) showed that noradrenaline as well as α-methylnoradrenaline very 
effectively lower blood pressure and heart rate after stereotactic administration 
into this nucleus. This would agree with the observation of Laubie (1975) that 
bilateral lesions of the nucleus tractus solitarii or the surrounding "depressor" 
area of the medulla in cats do not change the hypotensive and bradycardiac 
actions of Clonidine. Schmitt et al. (1973 b) earlier reported already that massive 
lesions in the "depressor" area of cats - of which the nucleus tractus solitarii 
forms a part - only partly reduces the decrease in splanchnic nerve activity 
induced by Clonidine. 
Another medullary site of action of Clonidine has been proposed by Bousquet 
and Guertzenstein (1973) and Bloch et al. (1973). These authors showed that 
Clonidine administration to the ventral surface of the brainstem of cats onto the 
chemosensitive zone causes a fall in blood pressure and heart rate. However, this 
action cannot be mimicked by noradrenaline (Bloch et al., 1973). This lack of 
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effectiveness of noradrenaline combined with the fact that several agents having 
local-anaesthetic properties produce hypotension when applied to this region 
(Bousquet et al., 1975) suggest a local-anaesthetic rather than an a adrenergic 
effect of Clonidine at this site. 
In summarizing these data concerning possible medullary sites where antihyper­
tensive agents may cause decrease in blood pressure and heart rate, it must be 
concluded that in the case of Clonidine neither in the cat nor in the rat a 
medullary α-adrenergic receptor site has been described yet that can mediate 
these effects. With respect to the hypotensive effect of α-methyldopa, an 
û-adrenergic receptor stimulation by its metabolite a-methylnoradrenaline at the 
level of the nucleus tractus solitari! of rats is indicated (de Jong, 1975, de Jong et 
al., 1975 a, Nijkamp, 1975). Possibly Clonidine causes some of its effects apart 
from the decrease in blood pressure and heart rate by an action on these latter 
α-adrenergic receptors, e.g. its blockade of pressor responses induced by posterior 
hypothalamic stimulation (Philippu et al., 1973, Dhawan et al., 1975) and its 
facilitatory effect upon the cardio-inhibitory component of the baroreceptor 
reflex (Kobinger and Walland, 1972 a, Kobinger and Pichler, 1975). 
Apart from a medullary site of action several authors have indicated that some 
of the central cardiovascular effects of Clonidine may be caused by a forebram 
site of action (Shaw et al., 1971, Klevans et al., 1973, Philippu et al., 1973 and 
1974). 
Philippu et al. (1974) showed that at the level of the posterior hypothalamus of 
cats low doses of Clonidine enhance the pressor response to electrical stimulation 
of this nucleus due to α-adrenergic receptor stimulation by Clonidine Intra­
venous injections of Clonidine in cats significantly reduce pressor responses pro­
duced by electrical stimulation of the dorso-lateral medullary reticular forma­
tion. After mesencephalic decerebration this effect is reversed (Klevans et al., 
1973). This reversal has been explained on the basis of a forebram stimulation of 
sympatho-inhibitory neurones by Clonidine (Klevans et al., 1973). Körner and 
co-workers, finally, studied the effects of intravenous Clonidine injections upon 
reflex autonomic function in the rabbit (Shaw et al., 1971, Komer, 1974) In 
earlier studies these authors had shown already that for normal cardiovascular 
reflex function medullary as well as diencephalic circuits are essential (Komer 
and Shaw, 1971, Uther et al., 1970, cf. introduction to this chapter). In these 
studies they showed that various medullary and diencephalic centres can be 
regarded as interneuronal links for altering excitability of autonomic effector 
neurones to afferent input from arterial baro- and chemoreceptors (Komer and 
Shaw, 1971) Clonidine blocks a number of reflex elements, partly by a medul-
lary, partly by a diencephalic action 
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PHARMACOLOGICAL NATURE OF THE RECtPTOR MEDIATING THE 
CENTRAL CARDIOVASCULAR EFFbCTS OF CLONIDINE AND (IME 
THYLDOPA 
The second aspect of the central mechanism of action of Clonidine and a-methyl-
dopa still under debate is the nature of the receptor mediating the centrally 
induced cardiovascular effects 
So far, this receptor has been indicated as an "α-adrenergic" one in view of the 
early evidence obtained. Such evidence was based upon the pharmacological 
mechanism of action of Clonidine in the periphery, its mechanism of action with 
respect to some central non-cardiovascular effects and the ability of some classic­
al α-ddrenergic receptor blocking agents to antagonize its central cardiovascular 
effects 
In the periphery Clonidine causes a number of a-sympathomimetic effects such 
as increase in blood pressure, contraction of the mctatating membrane decrease in 
spleen volume, vascular constriction of the perfused isolated rabbit ear and 
constriction of isolated aortic and pulmonary artery strips (Hoefke and 
Kobinger, 1966, Kobinger and Walland, 1967, Constantine and McShane, 1968; 
Boibsier et al, 1968, Rand and Wilson, 1968, Autret et al., 1971, Starke et al., 
1975). These actions were shown to be due to a direct effect of Clonidine and 
they are very similar to those of related imidazolines which were shown to be 
potent and specific «-adrenergic receptor stimulants by Mujic and van Rossum 
(1965) in a detailed paper on the pharmacodynamics of imidazoline derivatives. 
However, only a limited number of studies have been performed according to 
the approach used by Mujic and van Rossum (1965) who expressed the activity 
of the imidazolines in terms of their intrinsic activity and affinity at peripheral α 
adrenergic receptors. In those studies in which such approach was used (Constan­
tine and McShane, 1968, Starke et al., 1975, see also chapter 7) Clonidine was 
found to have a low intrinsic activity and a relatively low affinity for the 
α-adrenergic receptors of isolated rabbit aorta or pulmonary artery strips. 
A number of central effects of Clonidine have been shown to be of classical 
α-adrenergic receptor stimulatory nature, e g clonidine-induced mtrahypothalam-
ic stimulation of food intake in rats (Broekkamp and van Rossum, 1972), cloni-
dine-induced increase in flexor-reflex activity in the rat (Andén et al , 1970) and 
clonidine-induced facilitation of vagal reflex bradycardia in dogs (Kobinger and 
Walland, 1972 b). In all these cases the effects of Clonidine were antagonized by 
classical a adrenergic receptor blocking agents such as phentolamine Moreover, 
in the case of eating behaviour and the vagal reflex bradycardia the effects were 
mimicked by the classical α-adrenergic receptor stimulating imidazolines oxy-
metazolme and naphazoline (Broekkamp and van Rossum, 1972, Kobinger, 
1974,Struyker Boudier and Broekkamp-Brouwer, unpublished observations). 
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Several other central effects of Clonidine are not antagonized by the classical a 
adrenergic receptor blocking agent phentolamine These are the centrally 
mediated sedative effects of Clonidine (Delbarre and Schmitt, 1971) and the 
centrally mediated sympatho-inhibitory effects (Schmitt and Schmitt, 1970) In 
a further analysis Schmitt and co-workers have been able to show that two other 
α-adrenergic receptor blocking agents — piperoxane and yohimbine - are good 
antagonists of these two central effects of Clonidine (Schmitt et al., 1971, 
1973 с, Delbarre and Schmitt, 1971). On the basis of these results Schmitt and 
co-workers proposed that the central α-adrenergic receptors involved in the 
sedative and the sympatho-inhibitory effects of Clonidine have properties in 
common with the peripheral ones but are slightly different from these (Schmitt, 
1971, Delbarre and Schmitt, 1971, Schmitt et al, 1973c) A major drawback in 
the further classification of the central α adrenergic receptors stimulated by 
Clonidine has been the fact that upon intravenous and even intravertebral, intra-
cistemal or intraventricular injection drugs will have to pass a number of 
physico-chemical barrieres before they reach their putative receptors These 
barriers may be more decisive in the possible lack of activity of drugs than their 
potential inability to stimulate or block central α-adrenergic receptors pharmaco-
dynamically. 
Still, on the basis of such studies some characterization has been done. It was 
mentioned already that phentolamine — and also phenoxybenzamine — are poor 
antagonists at the level of the receptor stimulated by Clonidine, whereas piperox­
ane and yohimbine seem to be better antagonists A second remarkable property 
of the central a adrenergic receptor mediating the sympatho-inhibitory effect of 
Clonidine is the fact that a range of tricyclic antidepressant drugs act as compe-
tative antagonists at these receptors (van Zwieten, 1975b) Finally, only a limit­
ed number of imidazolines are able to act as agonists whereas a number of 
2-amino-imidazolines and also the related 2-aiTuno-thiazine derivative xylazine 
seem to mimiek the sympatho-inhibitory activity of Clonidine (Stahle, 1974, 
Hoefke et al., 1975, Finch, 1975) the classical 2-methyl-imidazolines oxymeta-
zolme and naphazohne are ineffective (Schmitt and Fenard, 1971, van Zwieten, 
1975 a), whereas these latter agents are potent agonists at peripheral a-adren-
ergic receptors (Mujic and van Rossum, 1965). In this respect experiments in 
which potential agonists and antagonists are administered as close to the recep­
tor site as possible to avoid the physicocheirucal barrieres are clearly indicated. 
Such experiments can best be performed using the technique of the stereotactic 
injections at those sites where Clonidine produces an α-adrenergic receptor 
mediated inhibition of sympathetic nerve activity, given that attention is paid to 
solvent effects, diffusion of the drugs and dose-response characteristics 
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Conclusion 
The studies discussed in this chapter have clearly suggested a role for the CNS 
in cardiovascular control. Electrophysiological studies have indicated an inte-
grative role for the CNS in proprioceptive cardiovascular reflex activity as well as 
in the initiation of somatovisceral-behavioural adaptive action patterns in which 
cardiovascular elements form an integral aspect. Moreover, these studies have 
shown that several bulbar as well as suprabulbar nuclei are indispensable in this 
respect. Little attention has so far been given to the role of the CNS in the 
long-range control of blood pressure, which will be a necessity if the involvement 
of the CNS in hypertensive disease is to be estimated (cf. Guyton et al., 1972, 
1974; van Rossum, 1975). In this respect the function of the hypothalamus as a 
brain region involved in the control of both hemodynamic and endocrine 
systems may be of special interest. 
Pharmacological studies have recently greatly contributed to the insight of CNS 
control of cardiovascular activity. In these studies especially central noradren-
ergic receptors have been suggested to be of relevance in the mode of action of 
certain antihypertensive drugs, viz. Clonidine and a-methyldopa. However, the 
precise sites of action of these drugs and the pharmacological nature of the 
receptor via which they produce their cardiovascular effects are still under de-
bate. The following chapters are devoted to the presentation of a series of 
experiments intended as a contribution to this discussion. 
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CHAPTER 5 NORADRENALINE-INDUCED CARDIOVASCUL-
AR EFFECTS AFTER INTRAHYPOTHALAMIC 
INJECTION IN RATS 
Introduction 
Noradrenaline causes a fall in blood pressure and heart rate when injected into 
the brain ventricles of several species, e.g. cats (Nashold et al., 1962; Share and 
Melville, 1963; Smookler et al., 1966; Schmitt and Fénard, 1971), rabbits (Toda 
et al., 1969) and rats (Baum and Shropshire, 1973). These effects have been 
suggested to be caused by an effect of noradrenaline upon neurones in the lower 
brainstem at the level of the nucleus tractus solitarii (de Jong, 1974) or upon 
neurones in higher brain structures (Nashold et al., 1962; Schmitt and Fénard, 
1971). 
One of the likely sites with respect to the higher brain structures is the hypo-
thalamus since this bnin region plays an important role in cardiovascular control 
(cf. chapter 4); it is richly innervated by noradrenergic neurones (Fuxe, 1965; 
Ungerstedt, 1971) and it contains high amounts of endogenous noradrenaline 
(Glowinski and Iversen, 1966; Palkovits et al., 1974). We therefore decided to 
perform a series of experiments in which noradrenaline was injected stereo-
tactically into the hypothalamus of rats. Results of such experiments will be 
reported in this chapter. 
5.1. Methods and materials 
A N I M A L S 
Male Wistar rats were used in all experiments. The weight of the animals ranged 
from 180-250 g. 
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STFREOTACTIC OPFRATION 
In order to allow intracerebral or intraventricular injections a stainless steel 
cannula system was implanted stereotactically into the rats under pentobarbital 
(NembutalR) anaesthesia (55 mg/kg, ι p.). The cannula system consists of 2 ele­
ments (fig. 23) (1) An outer cannula of which the pipe that is implanted into 
the cerebral tissue has a total diameter of 0 8 mm. This outer cannula is fixed to 
the skull with dental cement (PaladurR), (2) A stylette extending 0.5-1 mm 
below the tip of the outer cannula to minimize destruction of brain tissue 
around the tip of the cannula. This stylette can be removed to allow drug 
injections. Cannulae were implanted using a stereotactic device developed by the 
Technical Department of the Medical Faculty of the University of Nijmegen. 
Stereotactic coordinates were chosen according to the rat brain atlas of Komg 
and Klippel (1963) using a correction for the differences in weight of the rats 
The size of this correction was determined in pilot-expenments 
In a number of experiments one cannula was aimed at the lateral ventricle to 
facilitate intraventricular injections. In other experiments one cannula was aimed 
at the hypothalamus of one hemisphere of the brain, such experiments will be 
referred to further as "unilateral" experiments. A third group of experiments 
was performed in animals having 2 cannulae symmetrically aimed at the hypo­
thalamus of each brain-hemisphere, such experiments will be further referred to 
as "bilateral" expenments. 
STtREOTACTIC 1NJFCTIONS 
For intraventricular or intrahypothalamic injections the stylette was removed 
from the cannula system. Drug solutions were then injected with a 5 μΐ Hamilton 
syringe with an adjustable screw on the needle, such that drug solutions could be 
administered at the desired site of the brain (fig. 23). 
The volume injected was always 1 μΐ, unless otherwise stated This 1 μ\ was 
injected over a period of 3 - 5 seconds. 
For a detailed discussion of the stereotactic technique for localized brain injec­
tions the reader may consult several reviews (Myers, 1971, Routenberg, 1972). 
Although this technique is used for some decades now it is relatively new in the 
field of cardiovascular research. Its use poses several specific problems In order 
to be able to draw conclusions concerning the specificity of a drug-induced 
effect after stereotactic application a number of criteria have to be fulfilled 
attention has to be given to possible effects induced by solvents, attention has to 
be given to dose-response characteristics of drug-induced effects, attention has to 
be given to the possible spread of a drug within the CNS and also to its uptake 
into the cerebral circulation which may transport the drug rapidly to peripheral 
sites (detailed discussion Myers, 1971, Routenberg, 1972) Especially the last 
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FIG. 23: Л. Cannula system for intracerebral stereotactic injections, consisting of an outer 
cannula and a removable stylette. B. Microliter syringe for stereotactic injections. Note the 
adjustable screw on the needle of the syringe, allowing injection at the desired depth in the 
brain. 
mentioned aspect is of major importance in the study of cardiovascular effects 
of stereotactically injected adrenergic agents as many of these drugs influence 
cardiovascular function at very low doses when injected into the peripheral 
circulation. Myers et al. (1971) have studied the distribution of a 1 μΐ ,4C-nor-
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adrenaline solution (containing approximately !0 nmol noradrenaline) injected 
intrahypothalamically. They found that more than 90% of the total radioactivity 
injected remained within the hypothalamus for at least 30 - 45 minutes. Only 
small amounts of radioactivity were found in ventricular perfusates (ca. 2%). In 
some animals slight amounts of radioactivity were found in venous blood, in 
others no significant radioactivity could be detected intravenously. This latter 
finding indicates that in a limited portion of the animals noradrenaline had 
leaked into the peripheral circulation. 
Similar experiments were performed in our laboratory with 14C-clonidine 
(Wijffels, unpublished observations). In these experiments autoradiographic 
methods were used to visualize the distribution of radioactivity. These experi-
ments have indicated that only very slight amounts of Clonidine appear outside 
the hypothalamic area within 15 minutes after injecting Clonidine intrahypothal-
amically. 
In conclusion, in evaluating drug-induced cardiovascular effects after stereotactic 
injections one has to compare effects induced by the intravenous route of ad-
ministration with those observed after the intracerebral route of administration. 
If the intracerebral route of administration leads to cardiovascular effects similar 
to those observed after intravenous injections one has to compare the respective 
doses needed to induce these effects. In the case that intracerebrally much 
higher doses are needed to induce these effects than intravenously, it is highly 
probable that the cardiovascular effects are caused by leakage of the drug into 
the circulation rather than by a brain-specific action. 
HISTOLOGY 
The site of injection in the brain was checked at the end of the experiment. Rats 
were sacrificed under pentobarbital anaesthesia and perfused with ca. 20 ml 
0.9% NaCl followed by ca. 30 ml of a 10% formaldehyde solution. The brains 
were then removed gently and these were kept in a 4% formaldehyde solution 
for a period of at least 7 days. The site of the cannula tip was then localized by 
making consecutive sections of the brain and comparing these with those of the 
atlas of König and Klippel (1963). 
CARDIOVASCULAR OPERATION 
Arterial blood pressure was recorded from the right carotid artery via a poly-
ethylene cannula which was connected to a Statham Ρ 23 Ac or Statham Ρ 23 
Db pressure transducer. These pressure transducers were connected to a Grass 7P 
Polygraph for registration of the arterial pulse. Heart rate was measured from the 
lead II peak of the electrocardiogram which was fed to a cardiotachometer 
constructed by W.F.M. van Amerom of the Department of Pharmacology, Uni-
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versity of Nijmegen. The cardiotachometer was also connected to the polygraph. 
In a number of animals the left jugular vein was cannulated to facilitate intra­
venous injections In the case of intravenous injections the volume of injection 
was 0 1 ml drug solution followed by 0.2 ml 0.9% NaCl The total intravenous 
injection lasted 30 - 40 sec. 
EX PL· RIMFNTAL PROCEDURE 
The stereotactic operation was followed immediately by the cardiovascular pre­
paration. The whole operative procedure usually took 30 - 40 minutes per rat. 
After this period rats were given another 20 mg/kg pentobarbital (i.p.) de­
pending upon the depth of anaesthesia The body temperature of the rats was 
kept above 36° С by means of a heating lamp. If no injection was given blood 
pressure and heart rate remained constant usually for a period of at least 1 - 2 
hours Not more than 3 intracerebral or intraventricular injections were given per 
rat. In the case of intravenous injections the maximal number of injections per 
animal was 6 
For each series of experiments the average value of the pre-injection systolic 
blood pressure and heart rate is given. Blood pressure is given in mm Hg and 
heart rate in beats/mmute (b/m) The average pre-injection blood pressure in a 
group of more than 100 rats was systolic 135 ± 16 mm Hg (mean ± S.D.) and 
diastolic 99 + 12 mm Hg (mean ± S.D ). Average pre-injection heart rate in this 
group was 396 ± 28 b/m (mean ± S.D ). 
Drug effects are given as means ± standard error of the mean ( S E M ) . Effects 
are measured as the change in blood pressure or heart rate in comparison with 
the pre-injection levels. The absolute size of the effects is given and compared 
with that of the control group, unless the average pre-injection blood pressure 
and heart rate value differs much from that of the control group. In that case 
absolute changes as well as relative changes are given Significances were cal­
culated using the Student's t-test. 
5 2 Localization 
In a first series of experiments a cannula was implanted unilaterally into each of 
56 rats. Cannulae tips were aimed at a number of sites throughout the dience-
phalon in posterior-anterior direction ranging from the mammilary region to the 
preoptic region, in medial-lateral direction from the periventricular area to the 
lateral hypothalamic area, in ventral-dorsal direction from the ventromedial 
hypothalamic nucleus to the lower thalamic area (fig. 24). In each of these 56 
experiments a fixed dose of 40 nmol noradrenaline was injected stereotactically. 
Two groups of animals could be distinguished on the basis of the heart rate 
changes observed after 40 nmol noradrenaline (A) a group of 35 rats in which 
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I IG 24 Sagittal sections through the rat brain according to the atlas of König and Klippel 
(1963) indicating the 56 sites where 40 nmol noradrenaline were injected 
• Sites where this dose induced no change in blood pressure and heart rate A Sites where 
noradrenaline caused a transient increase in blood pressure without attecting heart rate * 
Sites where noradrenaline induced a long lasting lall of both blood pressure and heart rate 
ha nucleus anterior hypothalami, hdd nucleus dorsomediahs hypothalami, pars dorsali;,, 
hdv nucleus dorsomediahs hypothalami, pars ventrahs, hi nucleus lateralis hypothalami, 
hp nucleus posterior hypothalami, hvm nucleus ventromedialis hypothalami pol 
nucleus preopticus lateralis, pom nucleus preopticus mediahs 
40 nmol noradrenaline induced no or only a minor (< 25 b/m) change in heart 
rate. The sites of injection of these animals were located throughout the hypo-
thalamic area (indicated in fig. 24 by dots and triangles), (B) a group of 21 rats 
in whtch 40 nmol noradrenaline caused a fall in heart rate > 30 b/m The sites of 
injection in these animals were located in a relatively small region of the dience-
phalon, viz. in the anterior hypothalamic/preoptic area (indicated by stars in fig 
24) This area will further be mentioned the АН/PO region and the diffuse area 
where noradrenaline is ineffective with respect to heart rate changes will further 
be indicated as the rest of the hypothalamic area (RHA) 
The bradycardia induced by 40 nmol noradrenaline in the АН/PO region started 
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immediately after injection, was maximal after 10 - 20 minutes and lasted for 30 
- 60 minutes (fig. 25B). The mean maximal bradycardia in this group of 21 rats 
was 81 ± 8 b/m (table VIH). 
In group A - no change in heart rate — 40 nmol noradrenaline caused a transient 
increase in blood pressure in 21 rats and no change in pressure in 14 rats (table 
VIII). The sites from which an increase was observed lay scattered throughout 
the hypothalamic area (indicated in fig. 24 with triangles). There was no particu­
lar region specially sensitive with respect to this noradrenaline-induced pressor 
effect. 
In group В — long-lasting bradycardia — the injection of 40 nmol noradrenaline 
led to a decrease in blood pressure within 2-12 minutes after injection. Systolic 
and diastolic pressure were reduced to an equal degree (fig. 25B). Maximal de­
crease was observed 1 0 - 3 0 minutes after the injection and blood pressure 
remained below pre-injection level for 30 - 60 minutes. The mean maximal fall in 
systolic blood pressure for this group of rats amounted to 15 ± 2 mm Hg. In 10 
of the 22 animals in group В the hypotension was preceded by a transient 
В 
200 
mmHg 100 
0J 
500 
b/mm 400 
300 
200 
mmHg 100 
0 J 
400-1 
b/mm 300-
20' 60' 
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40 N Mol 
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200 J 40NMol 1min 
I-'IG. 25. Cardiovascular effects of 40 nmol noradrenaline injected into the hypothalamus ol 
rats. A. Effects of 40 nmol noradrenaline injected into the posterior hypothalamus. В 
Effects of 40 nmol noradrenaline injected into the anterior hypothalamic/preoptic region. 
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TABU·. Vili 
Mean maximal change (±5.Ь.М.) in systolic blood pressure (mm Hg) and heart rate (b/m) after injection of 40 nmol noradrenaline into 
the anterior hypothalamic/preoptic region (АН/PO) or into the remaining hypothalamic area (RHA). 
Treatment N Mean heart rate Mean maximal N Mean syst, blood Mean maximal Mean maximal 
just before in- change in pressure just be- initial increase decrease in 
jection heart rate fore injection in syst. b.p. syst. b.p. 
133 0 0 
140 + 2 5 + 8 0 
130 0 1 7 ± 2 
136 + 2 1 ± 5 - 1 3 ± 3 
Noradrenaline Í 14 
40 nmol, RHA 35 403 + 8 ±5 i 
(group A) I 21 
Noradrenaline Г 12 
40 nmol, AH/PO 21 382 - 8 1 + 8 i 
(group H) 10 
increase in blood pressure, similar to that observed in a number of rats in group 
A (table VIII). In the other 12 rats of group В no increase in blood pressure was 
observed. The maximal degree of hypotension in these latter 12 animals (17 ± 2 
mm Hg) is not significantly different from that in the former 10 animals of 
group В ( 13 ± 3 mm Hg). 
This series of experiments indicates that depending upon the site of injection the 
following cardiovascular effects can be obtained by intrahypothalamic ad­
ministration of 40 nmol noradrenaline: (1) no effect, from a number of sites 
located diffusely throughout the hypothalamic area; (2) a transient increase in 
blood pressure not accompanied by a change in heart rate, also from a number 
of sites diffusely throughout the hypothalamic area; (3) long-lasting hypotension 
and bradycardia, from a number of sites located in a small region within the 
hypothalamic area, viz. the anterior hypothalamic/preoptic region (AH/PO). 
5.3. Dose-response characteristics 
Dose-response studies in the case of intracerebral injection experiments cannot 
be done in the classical way whereby the effects of increasing doses of a 
substance are measured in one and the same preparation. The stereotactic tech­
nique only allows a limited number of injections over a certain period of time 
(cf. Myers, 1971; Routenberg, 1972). In our experiments we never made more 
than 3 injections during a period of 2 hours. A second or third injection was 
only given if the effect of the first respectively the second had disappeared. 
Dose-response data were obtained by taking together effects of identical doses 
injected into different animals. 
Three groups of dose-response experiments were made: (1) in a total of 16 rats 
0.9% NaCl (1 μΐ) or different doses of noradrenaline (3, 15 and 100 nmol) were 
injected into the АН/PO region in which 40 nmol noradrenaline induced a 
pattern of change in cardiovascular activity consisting of a long-lasting fall in 
blood pressure and heart rate as described in 52; (2) in a total of 8 rats 0.9% 
NaCl (2 χ 1 μΐ) and noradrenaline ( 2 x 3 and 2 x 1 5 nmol) were injected 
bilaterally into the АН/PO region; (3) in a total of 12 rats 0.9% NaCl (1 μΐ) or 
different doses of noradrenaline (15 and 100 nmol) were injected into the rest of 
the hypothalamic area (RHA) in which 40 nmol noradrenaline induced either no 
change in cardiovascular activity or a transient increase in blood pressure. The 
results of these three groups of experiments are summarized in table IX (cf. also 
fig. 26 and 27). In this table the effects of 40 nmol NA as described in 5.2. have 
also been included. 
In the first group (unilateral АН/PO injections) 1 ді 0.9% NaCl (n=12) and 3 
nmol noradrenaline (n=6) did not affect resting blood pressure and heart rate, 
except for 1 rat in which 3 nmol noradrenaline caused a transient increase in 
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TABLE IX 
Mean maximal change (± S.E.M ) in systolic blood pressure (mm Hg) and heart rate (b/m) after injection of different doses of 
noradrenaline unilaterally (UNI.) or bilaterally (BIL.) into the anterior hypothalamic/preoptic region (АН/PO) or the rest of 
the hypothalamic area (RHA) of rats. 
Treatment N Mean systolic Mean maximal Mean maximal Mean heart rate Mean maximal 
b.p. just be- initial increase decrease in just before in- change in heart 
fore injection m syst. b.p. syst. b.p. jection rate 
(no. of rats) 
0 9%NaCl 1 μΐ UNI. AH/PO 12 
NA 3 nmol UNI. AH/PO 6 
NA 15 nmol UNI. AH/PO 8 
NA 40 nmol UNI. AH/PO 21 
NA 100 nmol UNI. AH/PO 7 
0.9% NaCl 2 χ 1 μΐ BIL. AH/PO 5 
NA 2 χ 3 nmol BIL. AH/PO 5 
NA 2 χ 15 nmol BIL. AH/PO 5 
0 9% NaCl 1 /il UNI. RHA 10 
NA 15 nmol UNI. RHA 5 
NA 40 nmol UNI RHA 35 
NA 100 nmol UNI. RHA 9 
138 
139 
134 
133 
141 
123 
132 
138 
131 
148 
137 
134 
0 
+ 12(1)* 
+ 18(1) 
+ 21 ± 5 ( 1 0 ) 
+ 32 ± 5 ( 6) 
0 
0 
0 
0 
0 
+ 25 ± 8 ( 2 1 ) 
+ 34 ± 6 ( 9) 
0 
0 
- 6 ± 2 * * 
- 1 5 ± 2 * * * 
- 2 6 ± 3 * * * 
0 
- 8 ± 3 * 
- 23 ± 4 * * * 
0 
0 
0 
- 2 ± 2 
402 
362 
367 
382 
402 
369 
378 
378 
378 
415 
403 
398 
0 
0 
- 2 8 + 7*** 
- 81 ± 8*** 
- 101 ± 1 2 * * * 
0 
- 26 ± 6** 
- 107 ± 1 0 * * * 
0 
+ 4 + 4 
+ 8 ± 5 
+ 1 4 ± 1 0 
No significance levels are indicated in this column in view of the fact that only in a limited no. of animals blood pressure 
was increased. 
* . P < 0 . 0 5 
** P < 0 . 0 1 
* * * P < 0 . 0 0 1 
Significance in the difference with 0.9% NaCl control groups. 
blood pressure (table IX). After the injection of both 15 nmol (n=8) and 100 
nmol (n=7) noradrenaline a long-lasting fall in blood pressure and heart rate was 
observed Both the hypotension and the bradycardia were much larger after 100 
nmol than after 15 nmol (26 ± 3 mm Hg and 6 ± 2 mm Hg respectively 101 ± 12 
b/m and 28 + 7 b/m). Not only the size of these effects was related to the dose 
of noradrenaline injected, but also the duration of the effects (fig. 26). 
In 1 of the 8 rats in which 15 nmol noradrenahne was injected and in 6 of the 7 
rats treated with 100 nmol noradrenahne a transient increase in blood pressure 
preceding the hypotension was observed (table IX). 
These data indicate a dose-dependency in the size of the fall in blood pressure 
and heart rate induced by different doses noradrenahne injected into the AH/PO 
region (cf. fig 26 and 30). Moreover, these data indicate that only with the high 
dose of 100 nmol a consistent initial mcrease in blood pressure is obtained. 
In the second group (bilateral АН/PO injections) 2 χ 1 μΐ 0 9% NaCl (n=5) did 
not affect resting blood pressure and heart rate. Both 2 x 3 nmol (n=5) and 2 χ 
15 nmol (n=5) noradrenaline induced hypotension and bradycardia Heart rate 
started to fall immediately after injection and maximal bradycardia was observed 
10-20 minutes after injection. Blood pressure started to fall 2 - 6 minutes after 
injection and hypotension and heart rate returned to control levels 45 - 70 
minutes after injection (figure 27). The maximal degree of hypotension and 
bradycardia was larger after 2 x 1 5 nmol than after 2 x 3 nmol noradrenaline (23 
± 4 mm Hg and 8 ± 3 mm Hg respectively 107 ± 10 b/m and 26 ± 6 b/m). In 
none of these cases an initial increase in blood pressure was observed. 
These data indicate that after bilateral administration noradrenahne induces a 
fall in blood pressure and heart rate at much lower doses than after unilateral 
injections (cf. table IX). 
In the third group of rats (unilateral RH A injections) 1 μΐ 0.9% NaCl (n=10) and 
15 nmol noradrenahne (n=5) did not affect resting blood pressure and heart rate. 
The high dose of 100 nmol noradrenahne (n=9) caused an immediate increase in 
blood pressure m all animals without affecting heart rate significantly. 
These data indicate that only after the high dose of 100 nmol a consistent 
pressor effect can be obtained by injecting noradrenahne into the RHA. No 
decrease in blood pressure and heart rate can be obtamed by injecting 15 - 100 
nmol noradrenahne into this area. 
5.4. Intravenous and intraventricular noradrenaline injections 
In order to be able to draw conclusions concerning the specificity of a drug-
induced effect after its stereotactic injection into a certain bram region, its 
intracerebral effects have to be compared with those observed after intravenous 
and intraventricular administrations as it is known that small amounts of drugs 
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injected into brain tissue may be taken up into the general circulation or may be 
transported to the brain ventricles (cf. 5.1.)· Therefore the following two series 
of experiments were performed: (1) in 7 rats noradrenaline was injected intra­
venously in doses varying from 0.03 - 30 nmol; (2) in 8 rats 1 μ] 0.9% NaCl and 
15 and 40 nmol noradrenaline was injected into the lateral brain ventricle. The 
data of these two series of experiments are summarized in table X. 
TABLE X 
Mean maximal change (± S.E.M.) in systolic blood pressure (mm Hg) and heart rate after 
injection of different doses of noradrenaline intravenously or intraventricularly. 
Treatment 
intravenous 
NA 0.03 nmol 
NA 0.1 nmol 
NA 0.3 nmol 
NA 1 nmol 
NA 3 nmol 
NA10 nmol 
intraventricular 
0.9% NaCl 1 μΐ 
NA 15 nmol 
NA 40 nmol 
N 
3 
6 
5 
3 
6 
6 
4 
4 
5 
Mean syst. b.p. 
just before in­
jection 
131 
136 
134 
142 
139 
139 
123 
134 
137 
Mean maximal 
change in syst. 
b.p. 
0 
+ 6 ± 6 
+ 3 8 ± 8 
+ 51 ± 1 0 
+ 6 6 ± 1 2 
+ 7 8 ± 6 
+ 3 ± 3 
0 
- 8 ± 3 
Mean heart rate 
just before in­
jection 
412 
404 
399 
393 
401 
400 
382 
379 
400 
Mean maximal 
change in heart 
rate 
+ 10± 8 
+ 13± 6 
- 32 ± 1 5 
- 38 + 19 
- 96 ± 2 4 
- 120 ± 2 6 
+ 8± 5 
0 
- 45 ± 9 
Upon intravenous injection noradrenaline causes an immediate dose-dependent 
increase in arterial blood pressure. Systolic blood pressure is generally increased 
more than diastolic pressure. 0.5 - 5 minutes after noradrenaline injections both 
systolic and diastolic blood pressure had returned to pre-injection levels. At low 
doses of noradrenaline the blood pressure rise was accompanied by a slight 
tachycardia, whereas at the higher doses the pressor effect was accompanied by a 
short-lasting bradycardia. These changes in heart rate lasted 2 - 7 minutes. 
These data are in agreement with the typical α-sympathomimetic peripheral prop­
erties of noradrenaline. The bradycardia at the high doses is of reflex nature in 
contrast to the centrally induced bradycardia which is long-lasting and also 
occurs in absence of a pressor effect. 
In the second series of experiments 0.9% NaCl and two different doses norad­
renaline were injected into the lateral brain ventricle. Neither 1 μΐ 0.9% NaCl 
(n=4) nor 15 nmol noradrenaline (n=4) affected resting blood pressure and heart 
rate significantly. After intraventricular injection of 40 nmol noradrenaline 
(n=5) a small, but significant hypotension and bradycardia was observed. Both 
hypotension and bradycardia were maximal 15-20 minutes after injection and 
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lasted about 40 minutes However, this intraventricular effect of 40 nmol norad­
renaline is significantly smaller (P < 0 05) than that induced by the same dose 
injected into the АН/PO region (cf. table X). 
This series of experiments indicates that intraventricular noradrenaline injections 
produce hypotension and bradycardia, but the effect is less than that observed 
after injection of noradrenaline into the АН/PO region. The hypotension and 
bradycardia observed after intraventricular noradrenaline injections can be ex­
plained on the basis of penetration of noradrenaline into the hypothalamus 
Discussion 
When injected into the hypothalamic area noradrenaline induces (1) no change 
in blood pressure and heart rate, (2) a transient pressor effect without changes in 
heart rate or (3) a long lasting hypotension and bradycardia. 
The pressor effect can be elicited throughout the hypothalamic area and there is 
no region specially sensitive with respect to the ehcitation of this response In 
view of (a) this lack of localization, (b) the fact that slight amounts of intra-
cerebrally injected noradrenaline may be taken up into the peripheral circulation 
(Myers et al., 1971) and (с) the fact that noradrenaline is a pressor substance 
when injected intravenously at doses some 300 times lower than those needed 
intrahypothalamically, we suggest that this pressor effect is caused by leakage of 
noradrenaline into the peripheral circulation, although the present experiments 
cannot exclude other mechanisms In contrast to this pressor effect, noradrena-
hne-induced long-lasting hypotension and bradycardia seem to be brain-specific 
effects these effects cannot be induced by peripheral routes of administration 
of noradrenaline and can only be elicited from a specific region within the 
hypothalamic area The size of both hypotension and bradycardia is related to 
the dose of noradrenaline injected. Moreover, the threshold dose to induce hypo­
tension and bradycardia is some 5 times lower in the case of bilateral injections 
than in the case of unilateral noradrenabne injections. 
The decrease in blood pressure and heart rate after injection of noradrenaline 
into the АН/PO region could theoretically be caused by vasoconstriction of 
hypothalamic blood vessels by noradrenaline However, such effect does not 
seem very likely in view of the fact that oxymetazolme — a vasoconstrictor 
substance equipotent to noradrenaline (Mujic and van Rossum, 1965) — does 
not mimic these effects when injected into the same area at doses several times 
higher than those at which noradrenaline causes a fall in blood pressure and 
heart rate (cf. chapter 7). Therefore an effect of noradrenaline on hypothalamic 
neurones influencing cardiovascular activity seems to be the mechanism via 
which noradrenaline causes its intrahypothalamic depressor effects 
After intraventricular injections of noradrenabne a fall in blood pressure and 
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FIG. 28: Sagittal sections through the rat brain according to the atlas of König and Klippel 
(1963) indicating the area from which hypotension and bradycardia can be obtained by 
stereotactic injections of noradrenaline. F. Columna formas; ha nucleus anterior hypo-
thalami; hl : nucleus lateralis hypothalami; hvm : nucleus ventromediabs hypothalami, pol . 
nucleus preopticus lateralis; pom : nucleus preopticus medialis, st : Nucleus interstitiahs 
striae terminahs. 
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heart rate has been observed in cats (Nashold et al., 1962; Share and Melville, 
1963; Smookler et al., 1966; Schmitt and Fénard, 1971), rabbits (Toda et al., 
1969) and rats (Baum and Shropshire, 1973; this study). The data reported in 
this chapter indicate that the anterior hypothalamic/preoptic region of the 
diencephalon may be a site where noradrenaline acts to produce this effect. The 
extent of the noradrenaline-sensitive region is summarized in figure 28. 
This brain area contains high amounts of endogenous noradrenaline (Glowinski 
and Iversen, 1966; Palkovits et al., 1974), so it is tempting to speculate that 
endogenous АН/PO noradrenaline may play a role in certain aspects of central 
cardiovascular control. In fact, an indication for such a role has already come 
from experiments in which the hypothalamic regulation of body temperature 
was studied. It has been proposed that АН/PO noradrenaline would be involved 
in triggering heat-loss mechanisms (Feldberg and Myers, 1964; Myers, 1970; 
Bligh, 1973). The thermoregulatory effectors for heat-loss consist - depending 
upon the species involved — of evaporative mechanisms, mechanisms for the 
inhibition of muscular activity and conduction and convection changes in the 
skin (Bligh, 1973). Intrahypothalamic noradrenaline induces its immediate hypo­
thermic effects probably to an important extent via peripheral vasodilation 
(Rudy and Wolf, 1971). This indicates that cardiovascular regulation and ther­
moregulation may be functionally linked in the АН/PO region of the dience­
phalon via noradrenergic mechanisms that modulate peripheral autonomic ac­
tivity. 
Studies in which the anterior hypothalamic/preoptic region was stimulated elec­
trically have also provided evidence in favour of the concept of sympathetic and 
parasympathetic modulation by neurones in this area of the brain (Löfving, 
1961; Folkow et al., 1964; Hilton and Spyer, 1971). These studies have revealed 
that stimulation of the area ventral and caudal to the anterior commissure in cats 
—coinciding with the АН/PO region in the rat — elicits pattern of cardiovascular 
change consisting of a fall in blood pressure, heart rate and vascular resistance 
and a potentiation of reflex bradycardia induced by baroreceptor activation 
(Folkow et al., 1964; Klevans and Gebber, 1970; Hilton and Spyer, 1971). 
Observations in our laboratory (Broekkamp-Brouwer and Struyker Boudier, to 
be published) indicate that electrical stimulation of this region in the rat also 
produces a fall in blood pressure and heart rate at relatively low stimulus in­
tensities (bipolar stimulation; 5 second trains of 20 - 50 pulses/second; pulse 
duration 0.1 - 0.5 msec; pulse current: 50 - 200 μΑ). 
Other evidence in favour of a sympatho-modulatory role of the АН/PO region 
comes from the recent work of Nathan and Reis (1975) who showed that 
electrolytic lesions of the anterior hypothalamus of rats produce fulminating 
arterial hypertension, tachycardia and hyperthermia via activation of the 
sympathetic nervous system. 
In view of the fact that noradrenaline mimics the effects of electrical stimulation 
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of the AH/PO region rather than the effects observed after lesioning this area, it 
may be suggested that noradrenaline activates АН/PO neuronal activity. Such 
activation has indeed been found in studies in which noradrenaline was applied 
iontophoretically onto АН/PO neurones (Jell, 1974). 
The presence of noradrenaline-sensitive sites in the CNS which can modulate peri­
pheral autonomic activity might be of great importance in the mechanism of 
action of several antihypertensive drugs, e.g. α-methyldopa and Clonidine 
(Schmitt, 1971 ; Kobinger, 1973; van Zwieten, 1973, 1975a). The data reported 
in this chapter indicate that the АН/PO region may be one of the sites where 
these drugs act to produce their cardiovascular effect. In the next chapter ex­
periments will be presented in which the cardiovascular effects of Clonidine and 
the a-methyldopa metabolite a-methylnoradrenaline were measured after intra-
hypothalamic injection to see whether such action does indeed occur. 
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CHAPTER 6 NATURE OF THE RECEPTOR MEDIATING THE 
CARDIOVASCULAR EFFECTS OF INTRAHYPO-
THALAMIC NORADRENALINE 
Introduction 
The data reported in chapter S have indicated that noradrenaline can induce a 
specific pattern of cardiovascular change when injected into the anterior hypo­
thalamic/preoptic region of the rat. This pattern consists of a long-lasting fall in 
blood pressure and heart rate. These noradrenaline-induced effects have been 
suggested to be mediated by receptors located on hypothalamic neurones ca­
pable of influencing cardiovascular function. 
In this chapter expenments will be reported that were aimed at a pharmacologic­
al analysis of these receptors. We therefore investigated whether classical a- or 
Д-adrenergic receptor antagonists could block the noradrenaline-induced effects 
and whether classical a- or /3-adrenergic receptor stimulating agents could mimic 
the noradrenaline-induced effects Moreover, we investigated the intrahypo-
thalamic effects of the a-methyldopa metabolite α-methylnoradrenaline and 
Clonidine to see whether the hypotension and bradycardia observed after peri­
pheral injections of these antihypertensive agents could be mediated by the 
hypothalamic receptors. 
6.1. Materials and methods 
The stereotactic and cardiovascular methods used in the studies described in this 
chapter are identical to those described in 5 1. Only the results of injections into 
the АН/PO region (fig 28) are taken into consideration. 
The following drugs were used in the expenments described in this chapter (- ) 
phenylephrine hydrochloride (Boehnnger Ingelheim), (—) isoprenaline sulphate 
(Sigma), dopamine hydrochloride (Koch-Light), (- ) adrenahne bitartrate 
(Boehnnger Ingelheim), phcntolamine (RegitineR, CIBA), (±) piperoxane hydro-
chlonde (Brocades), (-) propranolol hydrochloride (ICI), ( ) α-methylnorad-
renahne hydrochloride (Sterlmg-Winthrop), Clonidine hydrochloride 
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(Boehringer-Ingelheim). Drugs were dissolved freshly in 0.9% NaCl except for 
phentolamine which was injected as the commercially available form of 
RegitineR. Doses given in the text refer to nmol of the salt injected. 
6.2. Phentolamine, (±) piperoxane and (—) propranolol 
In a total of 38 rats a standard dose of 40 nmol noradrenaline (unilateral) was 
injected 15-20 minutes after ipsilateral pretreatment of the АН/PO region with 
3 μΐ 0.9% NaCl; 53 nmol phentolamine (in 1.5 μΐ); 106 nmol phentolamine (in 3 
μΐ); 53 nmol piperoxane (in 1.5 μΐ); 34 nmol propranolol (in 1 μΐ); 51 nmol 
propranolol (in 1.5 μΐ) or 102 nmol propranolol (in 3 μΐ). Each rat obtained only 
one of these pretreatments. Results of these experiments are summarized in 
table XI and XII and figure 29. 
TABLE XI 
Mean maximal change (± S.E.M.) in systolic blood pressure (mm Hg) and heart rate (b/m) 
after injection of 0.9% NaCl (3 μΐ) or different doses of phentolamine (PHENT.), 
piperoxane (PIP.) or l-propranolol (PROP.) into the АН/PO region of the rat. 
Treatment N Mean syst. b.p. Mean maximal Mean heart rate Mean maximal 
just before in- change in syst, just before in- change in heart 
0.9% NaCl 3 μ 1 
PHENT. 53 nmol 
PHENT. 106 nmol 
PIP. S3 nmol 
PROP. 34 nmol 
PROP. 51 nmol 
PROP. 102 nmol 
6 
5 
6 
6 
5 
4 
6 
jection 
132 
140 
135 
130 
144 
139 
128 
b.p. 
- H ± 2 
- | - 8 ± 3 
+ 5 ± 4 
+ 4 + 3 
0 
- 4 ± 2 
- 8 ± 4 
jection 
380 
395 
411 
376 
388 
381 
408 
rate 
+ 8 ± 4 
- 1 2 ± 1 0 
- 1 6 ± 1 2 
- 1 1 + 8 
+ 6± 5 
- 2 8 ± 1 4 * 
- 9 6 ± 1 7 · * * 
Significance in the difference with 0.9% NaCl controls. 
In table XI the effects of local injections of the adrenergic receptor blockers 
themselves are summarized. Neither 0.9% NaCl nor phentolamine (53 and 106 
nmol), piperoxane (53 nmol) or the low dose of propranolol (34 nmol) affected 
resting blood pressure and heart rate significantly during the 15-20 minutes after 
their respective injection. There was a tendency for a reduction in heart rate 
after both phentolamine and piperoxane, but the size of this reduction did not 
differ very significantly (0.05 < P <0.1) from that of 0.9% NaCl controls. After 
the two higher doses of propranolol (51 and 102 nmol) a more significant fall in 
heart rate was observed (table XI). The bradycardia after 51 nmol propranolol 
lasted 1 0 - 2 0 minutes and reached an average maximum of 28 ±14 b/m. The 
122 
Decrease in blood pressure (mmHg) 
20 π 
16 
12 
θ -
4 -
•¡ГС 
u u u i - -'- — : 
Decrease in heart rate ( b/m) 
ico 
во 
6 0 
4 0 
20 
^ 5 
ι 
I N T 1 
I 
Sal 
3 F I 
Phent 
bJnmol 
Phent 
106nmol 
Pip 
53nmol 
Prop 
34nmol 
Prop 
51nmol 
Prop 
102nmol 
PRETREATMENT 
FIG. 29. Mean maximal change (± S.E.M.) in systohc blood pressure (upper part) and heart 
rate (lower part) after injection of 40 nmol noradrenaline into the anterior hypothalamic/ 
preoptic region (АН/PO) of rats pretreated locally with 0.9%NaCl (saline) or different doses 
of phentolamine (Phent.), piperoxane (Pip.) or propranolol (Prop.), bach pretreatment is 
given m 4 - 6 rats circa 20 minutes before the administration of noradrenaline. x P<P.05, 
x x
. P<p.01, significance in the difference with 0.9%NaCl controls. See also table XII. 
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TABLE XII 
Mean maximal change (± S.Γ.M.) in systolic blood pressure (mm Hg) and heart rate (b/m) expressed both as absolute and 
relative change after injection of noradrenaline (40 nmol) into the ЛН/РО region in rats pretreated locally with 0.9% NaCl 
or different doses of the d-adrenergic receptor blocking agents phentolamine (PHENT.) or pipcroxane (PIP.) or the /3-adren-
ergic receptor blocking agent propranolol (PROP.). 
Pretreatment 
0 9% NaCl 3 μΐ 
PUIN Г. S3 nmol 
PHLNT. 106 nmol 
PIP. 53 nmol 
PROP. 34 nmol 
PROP 51 nmol 
PROP 102 nmol 
N 
6 
5 
6 
6 
5 
4 
6 
Mean syst. b.p. 
just before in­
jection 
132 
146 
138 
133 
144 
138 
121 
Mean maximal change 
in syst 
absolute change 
- 11 ± 2 
- 1 4 ± 5 
- 3 ± 2 * 
+ 2±3* 
- 1 6 ± 4 
- 11 ± 3 
- 5 ± 3 
b.p. 
% change 
- 8.3 ±1.5 
- 9.6 + 3.4 
- 2.2 ± 1 4 * 
+ 1.5 ± 3 . 0 * 
- 11.1 ±2.8 
- 7.8 ±2.2 
- 4.1 ±2.5 
Mean heart rate 
just before in­
jection 
382 
392 
405 
374 
390 
376 
316 
Mean maximal change 
in heart rate 
absolute change 
- 7 1 ± 8 
- 90 ± 12 
- 4 0 + 8* 
- 7 ± 1 2 * * 
- 8 9 ± 1 5 
- 5 4 ± 9 
- 39 ± 1 0 * 
% change 
- 18.6 ±2.1 
- 23.0 ±3.1 
- 9.9 ± 2 . 0 * 
- 1.9 ± 3 . 2 * * 
- 22 8 ± 3 8 
- 14.4 ±2.4 
- 12.3 ±3.2 
Significance in the difference with 0.9% NaCl controls. 
bradycardia observed after 102 nmol propranolol amounted to 96 ± 17 b/m 
This bradycardia reached maximum 10 - 20 minutes aiter injection. In this series 
of experiments we were not able to determine the duration of propranolol (102 
nmol) induced bradycardia because of the noradrenaline injections which were 
given 1 5 - 2 0 minutes after the injection of propranolol However, in a few 
experiments (n=4) in which noradrenaline was not injected it was observed that 
heart rate remained below pre-injection level for more than 1 hour 
In table XII the effects of 40 nmol noradrenaline injected 15-20 minutes after 
intrahypothalamic injection of 0 9% NaCl or the adrenergic receptor antagonists 
are summarized In this table not only the absolute changes are given, but also 
the relative changes in view of the large differences in the pre-injection values for 
blood pressure and heart rate especially for the propranolol pretreated rats. 
15 - 20 minutes after 3 μΐ 0 9% NaCl 40 nmol noradrenahne caused a fall in 
blood pressure of 11 ±2 mm Hg and a fall in heart rate of 71 ±8 b/m The size 
of these effects is not significantly different from those obtained by injection of 
40 nmol noradrenaline into not-pretreated rats (15 ± 2 mm Hg respectively 81 
± 8 b/m, cf table X). After pretreatment with 53 nmol phentolamine no signif­
icant reduction was observed in the size of the hypotension and bradycardia 
induced by 40 nmol noradrenahne. However, after the higher dose of phentol­
amine (106 nmol) 40 nmol noradrenaline only caused a fall in blood pressure of 
3 ± 2 mm Hg and a heart rate fall of 40 ± 8 b/m The size of these effects is 
significantly smaller than that in control rats. 
Pretreatment with 53 nmol piperoxane even caused a complete block of the 
hypotension and bradycardia induced by АН/Ю injections of noradrenahne. 
After propranolol pretreatment noradrenaline-mduced fall in blood pressure and 
heart rate was not significantly reduced in the case of the lower two doses of 
propranolol (34 and 51 nmol) The change in heart rate after pretreatment with 
51 nmol propranolol was smaller than that in 0.9% NaCl controls (54 ±9 b/m 
respectively 71 ± 8 b/m), but the difference between the two is not very signif­
icant (0.1 < Ρ < 0.2). Pretreatment with 102 nmol propranolol caused a not 
very significant reduction of noradrenaline-induced fall m blood pressure (5 ± 3 
mm Hg, significance in the difference with saline controls 0 1 < Ρ < 0 2), but a 
more significant reduction in the size of the bradycardia induced by noradren­
ahne (39 + 10 b/m, significance in the difference with sahne controls 0.02 < Ρ 
< 0 05). However, if the change in heart rate is expressed as percentage in 
companson with the pre-injection level a less significant difference in the fall in 
heart rate after noradrenaline is obtained (0.1 < Ρ < 0 2). 
In summary, this series of experiments indicates that the alpha-adrenergic re­
ceptor antagonists phentDlamine and piperoxane do not change resting blood 
pressure and heart rate when injected unilaterally into the АН/PO region of rats, 
but do antagonize the fall in blood pressure and heart rate induced by noradren­
aline administration to this area Piperoxane seems to be more potent in this 
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respect since it blocks the effects or noradrenaline completely at a dose at which 
phentolamine causes no reduction of noradrenaline-induced effects. Doubling 
the dose of phentolamine leads to a significant, but only partial degree of 
antagonism. In this respect it is interesting that in peripheral adrenergic phar­
macology piperoxane and phentolamine are both competitive α-adrenergic re­
ceptor antagonists and that phentolamine is circa 3 times more potent than 
piperoxane (van Rossum, 1965). 
Finally, the high dose of propranolol causes a significant fall in blood pressure 
and heart rate and it reduces the effects of noradrenaline. Experiments with 
other ß-adrenergic receptor antagonists, especially those lacking local-anaesthetic 
properties should be performed to allow conclusions concerning the mechanism 
of action of propranolol in this respect. 
6.3. Dopamine, phenylephrine, isoprenaline and adrenaline 
For a further analysis of the adrenoceptor involved in the АН/PO noradrenaline-
induced fall in blood pressure and heart rate, a series of experiments were 
performed in which the specific α-adrenergic receptor agonist phenylephrine (3, 
30 and 70 nmol), the specific /3-adrenergic receptor agonist isoprenaline (3, 12 
and 30 nmol) and the a- and ß-adrenergic receptor agonist adrenaline (0.3, 3 and 
30 nmol) were injected into the АН/PO region of the rat. Moreover, 2 doses 
dopamine (30 and 70 nmol) were injected to investigate the possible involve­
ment of dopaminergic mechanisms. Only results of injections made into the 
АН/PO region indicated in figure 28 were taken into account. Results of these 
experiments are summarized in fig. 30 and table XIII. 
Dopamine did not affect resting blood pressure and heart rate significantly (table 
XIII) when injected into the АН/PO region. 
The low dose of the α-adrenergic receptor stimulant phenylephrine - 3 nmol — 
did not change these parameters either. However, the higher doses — 30 and 70 
nmol — induced a long-lasting fall in both blood pressure and heart rate. These 
effects were very similar to those of noradrenaline: maximal bradycardia and 
hypotension were observed 10-20 minutes after injection and the effects lasted 
30 - 40 minutes. No initial increase in blood pressure was observed after these 
doses phenylephrine. 
The lower 2 doses of the /3-adrenergic receptor stimulant isoprenaline - 3 and 12 
nmol — did not affect resting blood pressure and heart rate significantly. How­
ever, 30 nmol isoprenaline caused a slight, but significant fall in blood pressure 
which lasted for 1 - 3 minutes. Heart rate was increased for 10 - 15 minutes. The 
hypotension observed after isoprenahne differed from that observed after norad­
renaline and phenylephrine in the sense that these latter 2 drugs produced a 
gradual, long-lasting fall in blood pressure. However, the cardiovascular effects 
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Decrease in blood pressure (mmHg) 
o (-)Adrenaline 
α (-) a -Methyl NA 
m (-)Noradrenaline 
Δ (-) Phenylephrine 
+ Clonidine 
nmol 
FIG. 30. Dose-response characteristics of the decrease in blood pressure (upper part) and 
heart rate (lower part) after injection of adrenaline, o-methylnoradrenahne, noradrenaline, 
phenylephrine or Clonidine into the anterior hypothalamic/preoptic region of the rat. 
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TABLb XIII 
Mean maximal change (± S.b.M.) in systolic blood pressure (mm Hg) and heart rate (b/m) 
after the injection of different doses dopamine, phenylephrine, isoprenaline and adrenaline 
into the АН/PO region in rats. 
Treatment N Mean syst. b.p. Mean maximal Mean heart rate Mean maximal 
just before in- change in syst just before in- change in heart 
0.9% NaCll μ ΐ 
dopamine 30 nmol 
dopamine 70 nmol 
phenylephrine 3 nmol 
phenylephrine 30 nmol 
phenylephrine 70 nmol 
isoprenaline 3 nmol 
isoprenaline 1 2 nmol 
isoprenaline 30 nmol 
adrenaline 0 3 nmol 
adrenaline 3 nmol 
adrenaline 30 nmol 
* P<0.05 
** P < 0 . 0 1 
*** · P < 0 . 0 0 1 
12 
7 
7 
5 
5 
5 
6 
5 
4 
8 
7 
8 
jection 
138 
147 
138 
126 
127 
132 
144 
138 
140 
125 
133 
128 
Significance in the dilf 
b.p. 
0 
+ 4 ± 2 
- 3 ± 2 
+ 2 ± 2 
- 5 + 4 
- 1 4 ± 3 * * * 
- 5 ± 5 
- 6 ± 4 
- 1 4 ± 5 * 
- 8 ± 3 * 
- 1 4 ± 3 * * * 
· - 21 ± 2 * * * 
crence with 0 9% 
jection 
402 
393 
416 
401 
395 
394 
362 
373 
383 
428 
405 
427 
NaCI controls. 
rate 
0 
- 7 ± 3 
- 8 ± 4 
0 
- 34 ± 9** 
- 9 0 ± 1 7 * * * 
+ 12± 8 
- 10± 6 
+ 3 6 ± 1 0 * * 
- 2 3 ± 6* 
- 5 8 ± 1 0 * * * 
- 1 3 0 ± 1 1 * * * 
induced by 30 nmol isoprenaline intrahypothalamically are quite similar to those 
observed after intravenous injections of isoprenaline at doses some 300 times 
lower (Houben and Struyker Boudier, unpublished observations). Therefore, 
leakage of some intrahypothalamically injected isoprenaline into the peripheral 
circulation seems to be the most likely explanation for this effect. 
The a- and j3-adrenergic receptor stimulant adrenaline caused a significant fall in 
blood pressure and heart rate already at a dose of 0.3 nmol. The hypotension 
and bradycardia observed after this dose of adrenaline lasted some 10 - IS 
minutes. With increasing doses a larger and long-lasting fall in blood pressure and 
heart rate was observed. At the dose of 30 nmol these effects lasted 30 - 40 
minutes. Frequently, the hypotension was preceded by a small (< 15 mm Hg) 
increase in blood pressure. In order to evaluate whether leakage of adrenaline 
into the peripheral circulation could contribute to its intrahypothalanuc effects, 
this compound was injected intravenously into 5 rats in doses of 0.03 - 1 nmol. 
When adrenaline is injected via this route it causes a typical α-sympathomimetic 
increase in blood pressure accompanied by a slight tachycardia at low doses and 
a reflex bradycardia at higher doses (cf. table XIV). These effects lasted 1 - 5 
minutes maximally. 
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TABLE XIV 
Mean maximal change (± S Ε M ) in systolic blood pressure (mm Hg) and heart rate (b/m) 
after intravenous injection of different doses adrenaline in rats 
Dose 
0 03 nmol 
0 1 nmol 
0 3 nmol 
1 nmol 
N 
3 
4 
4 
4 
Mean syst b ρ 
just before in 
jection 
134 
134 
136 
139 
Mean maximal 
change in syst 
bp 
+ 2 ± 2 
+ 1 7 ± 6 
+ 50 + 9 
+ 7 1 ± 5 
Mean heart rate 
just before in­
jection 
404 
405 
400 
400 
Mean maximal 
change m 
heart rate 
+ 8 ± 5 
- 1 2 ± 7 
- 2 0 ± 1 1 
- 1 8 0 + 30 
This senes of expenments with dopamine and adrenergic receptor stimulants 
indicates that a-adrenergic rather than /3-adrenergic or dopaminergic receptor 
stimulation is the pharmacological mechanism via which intrahypothalamic 
noradrenaline causes bradycardia and hypotension. When dose-response curves 
are compared (fig 30) it appears that phenylephrine is slightly less potent than 
noradrenaline in inducing hypotension and bradycardia, but that adrenaline is 
some 10-15 times more potent. This latter finding is surprising as adrenaline is 
almost equipotent with noradrenaline when tested on peripheral a-adrenergic 
receptors (van Rossum, 1965). 
6.4. o-Methylnoradrenaline and Clonidine 
Intrahypothalamic injections of a-methylnoradrenalme have been included in this 
study as it has been suggested that the hypotension and bradycardia induced by 
df-methyldopa and Clonidine are caused by central α-adrenergic receptor stimula­
tion. In the case of α-methyldopa its metabolite a-methylnoradrenahne has been 
suggested to be the receptor stimulant and in the case of Clonidine a direct 
receptor stimulation by this agent itself has been proposed (cf. chapter 4). 
o-Methylnoradrenaline was injected in doses ot 1, 3 and 15 nmol unilaterally into 
the АН/PO region. It caused a fall in blood pressure and heart rate the size of 
which depended upon the dose injected (table XV). Both blood pressure and 
heart rate started to fall immediately after injection. Maximal hypotension and 
bradycardia were observed 15 - 30 minutes after injection and the effects lasted 
1-2 hours (fig. 31). No increase in blood pressure was observed after a-methyl­
noradrenalme. When injected bilaterally, a-methylnoradrenahne caused a signif­
icant fall m blood pressure and heart rate already at a dose of 2 χ 1.5 nmol 
(table XV). 
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FIG. 31: Cardiovascular effects of an injection of IS nmol O-methylnoradrenaline into the 
anterior hypothalamic/preoptic region of the tat. 
Clonidine was injected into the АН/PO region in doses from 1.5-40 nmol. It 
induced an immediate fall in blood pressure and heart rate, the size of which was 
related to the dose injected (table XV). Maximal hypotension and bradycardia 
were observed 10 - 45 minutes after injection. After l^-- 2 hours blood pressure 
and heart rate has usually returned to control levels. In 6 rats 2 χ 1.5 nmol 
Clonidine was injected bilaterally into the АН/PO region. This dose — although 
TABLE XV 
Mean maximal change (± S.E.M.) in systolic blood pressure (mm Hg) and heart rate (b/m) 
after unilateral or bilateral injection of different doses a-methylnoradrenaline (Or-methylNA) 
or Clonidine into the АН/PO region of rats. 
Treatment 
a-methylNA 1 nmol 
a-methylNA 5 nmol 
a-methylNA 15 nmol 
a-methylNA 2 χ 1.5 nmol 
a-methylNA 2 x 5 nmol 
domarne 1.5 nmol 
Clonidine 4 nmol 
Clonidine 15 nmol 
Clonidine 40 nmol 
Clonidine 2 χ 1.5 nmol 
clomdme 2 x 4 nmol 
N 
4 
5 
5 
4 
6 
8 
8 
9 
12 
6 
4 
Mean syst. b.p. 
just before in­
jection 
128 
132 
140 
136 
119 
137 
134 
142 
131 
137 
144 
Mean maximal 
change in syst. 
b.p. 
0 
- 1 2 ± 3 * * 
- 25 ± 4 * * * 
- 9 ± 2 * * 
- 2 2 ± 3 * * * 
- 2 ± 2 
- 1 9 ± 5 * * 
- 2 6 ± 2 * * * 
- 34 + 3*** 
- 18 ± 4 * * * 
- 3 0 ± 5 * * · 
Mean heart rate 
just before in­
jection 
391 
365 
384 
420 
406 
414 
386 
406 
393 
400 
385 
Mean maximal 
change in 
heart rate 
0 
- 4 4 ± 1 1 * * 
- 9 3 + 14*** 
- 3 6 ± 8** 
- 7 8 ± 1 0 * * * 
- 1 2 ± 1 0 
- 3 2 ± 7*** 
- 5 9 + 6*** 
- 7 9 ± 8*** 
- 4 0 ± 7*** 
- 7 2 ± 1 1 * * * 
** :P<0.01 
***.P<0.001 Significance in the difference with 0.9% NaCl controls (n=12, table VIII) 
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ineffective when given unilaterally — induced a significant, long-lasting fall in 
blood pressure and heart rate when given bilaterally. An initial increase in blood 
pressure was never observed after unilateral or bilateral injections of these doses 
of Clonidine 
This series of experiments shows that both a-methylnoradrenaline and Clonidine 
produce a long-lasting fall in blood pressure and heart rate when injected into 
the АН/PO region of the rat When dose-response curves are compared, it 
appears that both α-methylnoradrenahne and Clonidine are 3 - 5 times more 
potent than noradrenaline in inducing these effects (fig 30). 
Discussion 
The data reported in this chapter show that the α-adrenergic receptor agonist 
phenylephrine mimics intrahypothalamic noradrenaline effects rather than the 
^-adrenergic receptor agonist isoprenalme or the dopamine receptor stimulant 
dopamine. Also the antagonistic properties of the α-adrenergic receptor antag­
onists phentolamine and piperoxane point into the direction of an a- rather than 
a j3-adrenergic receptor in the mediation of intrahypothalamically induced car­
diovascular effects of noradrenaline. 
However, several data reported m this chapter do not agree entirely with the 
classification of this receptor as an α-adrenergic one (1) The j3-adrenergic re­
ceptor blocker propranolol attenuates the hypothalamic noradrenaline effects. 
This antagonism can be explained partly on the basis of the cardiovascular 
effects propranolol induces itself when injected intrahypothalamically and which 
may be caused by a local-anaesthetic effect of this agent, although an interaction 
of propranolol with the hypothalamic adrenergic receptor cannot be excluded. 
Further experiments with other /3-adrenergic receptor blockers will be necessary 
to allow conclusions whether a /3-adrenergic component is involved (2) Piperox­
ane is more potent antagonist of the intrahypothalamic noradrenaline effects 
than phentolamine, whereas on peripheral α-adrenergic receptors phentolamine 
is at least 3 times more potent than piperoxane (van Rossum, 1965) (3) a-Me-
thylnoradrenalme is 3 - 5 times more potent than noradrenaline intrahypothal­
amically, whereas this agent is some 10 times less active than noradrenaline on 
peripheral α-adrenergic receptors (van Rossum, 1965). One possible explanation 
for this difference in relative potencies could be that a-methylnoradrenaline is 
inactivated via metabolic routes more slowly than noradrenaline (Muscholl, 
1972) The longer duration of its effect can be considered as evidence in favour 
of such difference (4) Intrahypothalamic adrenaline induces cardiovascular 
effects at doses some 10-15 tunes lower than those needed to obtain similar 
effects with noradrenaline, whereas the difference in peripheral α-adrenergic 
potency of adrenaline and noradrenaline is not higher than a factor 2 - 3 (van 
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Rossum, 1965, Ariens, 1967) A less effective central metabolic inactivation for 
adrenaline does not seem likely as the duration of the adrenaline-induced effects 
is similar or even shorter than that of noradrenaline 
These discrepancies may indicate that the hypothalamic α-adrenergic receptors 
are somewhat different from the peripheral ones In this respect it is interesting 
that Schmitt et al (1970, 1971, 1973c) have reported that piperoxane - in 
contrast to phentolanune — is an effective antagonist of the central cardio­
vascular effects of Clonidine. Schmitt et al (1970, 1971, 1973c) have interpreted 
this observation as an indication for a difference between central and peripheral 
α-adrenergic receptors. 
Recently, de Jong (1974) and de Jong et al (197 Sa and b) have shown that norad­
renaline can also induce a fall in blood pressure at the level of the nucleus tractus 
solitari! in the lower brainstem These effects can be antagon.zed effectively by 
phentolamine, whereas adrenaline is equipotent with noradrenaline in inducing 
similar effects Moreover, Clonidine does not mimic the noradrenaline-induced 
cardiovascular effects at the level of the nucleus tractus sohtam (de Jong, 1975) 
On the basis of the above mentioned we suggest that the nucleus tractus solitari! 
α-adrenergic receptor is identical to the peripheral ones, characterized by re­
latively strong antagonistic activity of phentolamine, an almost equipotency in 
the agonistic activity of noradrenaline and adrenaline and a relative lack of 
agonistic activity of Clonidine The AH/PO α-adrenergic receptor is an a-adren-
ergic receptor different from the peripheral ones and is characterized by re­
latively strong antagonistic activity of piperoxane, relatively strong agonistic 
activity of Clonidine and a high degree of agonistic activity of adrenahne when 
compared with noradrenaline 
With respect to this latter AH/PO α-adrenergic receptor the recent suggestion of 
the existence of brain neurones containing adrenaline rather than noradrenaline 
as a neurotransmitter may be of importance (Hokfelt et al, 1974) as these 
neurones innervate inter aha the АН/PO region described in this study (cf figure 
2) If adrenaline is a neurotransmitter in this brain region one could speculate 
the presence of receptors more sensitive to adrenaline than noradrenaline 
Formally, such receptors would have to be classified as "adrenaline receptors" 
(Bolmeetal., 1974). 
It seems attractive to suggest that the special class of AH/PO α-adrenergic re­
ceptors stimulation of which causes decrease in blood pressure and heart rate are 
identical to such "adrenaline receptors" However, before such conclusion can 
be drawn more firmly a larger group of drugs have to be compared with respect 
to their activity on this receptor and their activity on a classical α-adrenergic 
receptor, because receptor specificity can only be based upon the following 
entena (a) the effect of the natural agonist (i с adrenaline) must be antagonized 
by drugs that at a certain dose-range in which they block the effect of this 
agonist do not block the effects of agonists at other receptors, (b) the effect 
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induced by the natural agonist must be mimicked by a set of compounds with a 
relative potency that differs from that at other receptors. In the next chapter the 
results of a series of experiments will be presented in which a number of imida­
zoline derivatives were studied as potential agonists at a classical α-adrenergic 
receptor and the hypothalamic "adrenaline receptor". 
Finally, results reported in this chapter show that both Clonidine and a-methyl-
noradrenaline can mimic the intrahypothalamically induced cardiovascular 
effects of adrenaline and noradrenaline. This stresses the potential importance of 
the АН/PO region as one of the sites of action of Clonidine and a-methylnorad-
renaline when injected peripherally apart from the previously suggested medullar 
sites of action. These agents may exert their full scala of cardiovascular activity 
probably via a multiple site of action within the CNS especially when given 
chronically. In fact, the distribution pattern of Clonidine in the CNS of gerbils 
and monkeys after intravenous injection of the C-14 labelled compound shows 
that Clonidine is distributed to several areas of the brain known to be involved in 
cardiovascular control, e.g. the pontomedullary area and the diencephalon 
(Wijffels, 1974). Studies in which the measurement of a variety of cardiovascular 
parameters is combined with selective stimulation or destruction of each of these 
areas, could reveal their respective role in CNS control of cardiovascular activity. 
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CHAPTER 7 PERIPHERAL AND CENTRAL a-ADRENERGIC 
ACTIVITY OF IMIDAZOLINE DERIVATIVES: A 
STRUCTURE-ACTIVITY-RELATIONSHIP STUDY 
Introduction 
The antihypertensive agent Clonidine belongs chemically to the class of the 
imidazoline derivatives: it is an example of a 2-arylamino-imidazoline (fig. 32a). 
Infra-red spectra have revealed that in solution the resonance structure with an 
exocyclic double bond is more stable; this resonance structure is that of a 
2-arylimino-imidazolidine (fig. 32b; Stähle, 1974;Wermuth et al., 1973). 
H R
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FIG. 32: Α. General structure of 2-amino-imidazolines; В. General structure of 2-imino-
imidazolidines; C. General structure of 2-methyl-imidazoünes. 
Some imidazoline derivatives exert α-sympatholytic activity — e.g. phentolamine 
and tolazoline — whereas other causes α-sympathomimetic effects, such as napha-
zoline, oxymetazoline and xylometazoline (Hartmann and Isler, 1939; Bovet and 
Bovet-Nitti, 1948). These latter three drugs are examples of 2-arylmethyl-imi-
dazoline derivatives. Mujic and van Rossum (1965) have shown that the 
α-sympathomimetic effects of naphazoline, oxymetazoline and xylometazoline 
are caused through direct α-adrenergic receptor stimulation by these agents. 
Moreover, they showed that these agents are devoid of ^-sympathomimetic ef­
fects (Mujic and van Rossum, 1965). 
Qonidine causes several typical α-sympathomimetic effects such as contraction of 
nictatating membrane, decrease in spleen volume, vasoconstriction as well as 
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increase in arterial blood pressure (Hoefke and Kobinger, 1966, Kobinger and 
Walland, 1967, Constantine and McShane, 1968,Boissieret al., 1968, Rand and 
Wilson, 1968, Starke et al., 1975). Moreover, Clonidine does not exert ^-adren­
ergic effects and therefore it seems to have similar pharmacodynamic properties 
as for instance naphazohne, oxymetazoline and xylometazolme (Mujic and van 
Rossum, 1965, Hoefke and Kobinger, 1966, Kobinger, 1973). However, the 
α-sympathomimetic increase in blood pressure after intravenous administration 
of Clonidine is followed by a prolonged hypotension accompanied by a long-
lasting bradycardia These latter two effects are not due to peripheral adreno­
lytic properties (Hoefke and Kobinger, 1966), but rather to a CNS effect of 
Clonidine (Kobinger, 1967, Schmitt et al, 1967, Sattler and van Zwieten, 1967, 
Sherman et al., 1968). This central effect has been suggested to be mediated via 
central α-adrenergic receptors (Andén et al., 1970, Schmitt et al., 1971, Bolme 
and Fuxe, 1971, reviews Schmitt, 1971, Kobinger, 1973, van Zwieten, 1973, 
1975a). 
A number of clomdine-hke 2-arylamino-imidazolmes have properties very similar 
to those of cloradme they mimic both the peripheral and central effects of 
Clonidine (Stahle, 1974, Hoefke et al., 1975). Moreover, the central potency of 
these compounds is correlated with their peripheral α-adrenergic stimulating 
potency in conjunction with their lipid solubility (Stahle, 1974, Hoefke et al., 
1975). 
After intravenous injection of the 2-arylmethyl-imidazolines naphazohne, oxy­
metazoline and xylometazolme no long-lasting hypotension and bradycardia was 
observed (Mujic and van Rossum, 1965). Moreover, oxymetazohne does not 
cause hypotension and bradycardia when injected into the vertebral artery of the 
cat (van Zwieten, personal commumcation) or when injected into the cisterna 
magna of cats or dogs (Schmitt and Fénard, 1971). In other words, 2-arylammo-
imidazolines and 2-arylmethyl-imidazohnes seem to share an ability to stimulate 
peripheral α-adrenergic receptors, but only the 2-arylamino-imidazolines cause 
cardiovascular effects mediated via central α-adrenergic receptors. 
There are two possible reasons for the lack of central cardiovascular activity of 
the 2-arylmethyl-imidazolines (1) the physico-chemical properties of these 
drugs prevent them from reaching the central adrenergic receptors mediating fall 
in blood pressure and heart rate, (2) central and peripheral adrenergic receptors 
differ in such a sense that the 2-arylmethyI-imidazobnes cannot act as agonists at 
the central adrenergic receptors mediating decrease in blood pressure and heart 
rate 
In this chapter experiments will be presented that were intended to investigate 
these possibilities In this chapter the chemical structures of the imidazoline 
derivatives used in this study will be presented as well as some of their physico-
chemical properties that might be of relevance in determining their penetration 
into the CNS when injected intravenously Moreover, expenments will be present-
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ed in which the peripheral α-adrenergic activity of the imidazolines was measured 
on the isolated intestinal smooth muscle of the rabbit. This isolated organ 
system was used since it was shown by van Rossum and co-workers that the 
α-adrenergic receptors of the rabbit intestine are the most specific noradrenaline 
receptors of a range of organs studied (van Rossum, 1965; van Rossum and 
Mujic, 1965; Mujic and van Rossum, 1965). Finally, experiments will be present­
ed in which the CNS cardiovascular effects of the imidazolines were measured 
after stereotactic injection into the anterior hypothalamic/preoptic region in the 
rat. This brain region was chosen since it was previously shown that adrenaline, 
noradrenaline and Clonidine cause a long-lasting change (see chapters 5 and 6) in 
cardiovascular parameters when injected into the anterior hypothalamic/preoptic 
region. It was suggested that this effect is mediated by receptors having similar 
properties as peripheral α-adrenergic receptors, but different in the sense that 
adrenaline is a relatively potent agonist and that piperoxane is a more (ratent 
antagonist than phentolamine. 
7.1. Materials and methods 
P H Y S I C O - C H E M I C A L P R O P E R T I E S O F T H E I M I D A Z O L I N E S 
The following physico-chemical properties of the imidazolines were determined: 
pK
a
 : The pK
a
 of each imidazoline was determined by titration of a 0.1 mMol 
solution of the salt of the drug in distilled water (25° C) according to Leffler et 
al. (1951) or by titration in ethanol-water according to Gutzbezahl and Grun-
wald (1953). In the latter case the pK
a
 in water could be extrapolated by using 
mixtures of different ethanol content. The pK
a
 of 2,6-dichlor-3-hydroxyphenyl-
amino-2-imidazoline (St 666), 3,4-dihydroxyphenylamino-2-imidazoline (DPI) 
and 2,6-dimethyl-3-hydroxy-4-t-butylphenylrnethyl-2-irnidazoline (oxymetazo-
line) could not be determined by either method in view of the presence of 
hydroxyl substituents in these molecules. Very refined Potentiometrie methods 
would be required to measure the pK^'s of such molecules (Sinistri and Villa, 
1962). 
Molar volume: The van der Waals volumes of the fragments of each molecule 
were taken from the compilation of Bondi (1964). The molar volume (MV) of 
each molecule was then calculated by summing the volumes of the fragments. 
Apparent Partition Coefficient (APC): The APC's in chloroform/water (25° C) 
were determined using Kolthoff buffers of various pH values. The concentration 
of the drugs in the aqueous phase was measured with a Zeiss spectrophotometer 
at the respective absorption maxima between 260 and 280 nm according to 
Hellenbrecht et al. (1973). The APC at pH 7.4 was graphically determined then. 
True Partition Coefficient (TPC): The TPC can be calculated from the pK
a
 and 
APC using the relation: TPC= APC (1 + 10PKa-PH). 
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R A B B I T I N T E S T I N K E X P E R I M E N T S 
The pendular movements of isolated pieces of rabbit jejenum were registered by 
means of a Ft 03B force transducer on a Grass 7P polygraph. The pieces of 
intestine were suspended in a Ringer solution of the following composition: 137 
meq Na+, 2.7 meq K+, 3.6 meq Ca* 2.1 meq Mg* 145 meq СГ 11.9 meq 
HCO3", 0.42 meq H 2 P0 4 " and 0.1% glucose. The α-adrenergic activity of the 
drugs was determined by measuring the effects of increasing doses of the 
respective drugs. Activity is expressed in terms of intrinsic activity and affinity 
according to van Rossum (1963). (-) Noradrenaline was used as the reference 
drug. In sufficiently high doses this drug causes 100% inhibition of pendular 
movements; therefore its intrinsic activity (i.a.) equals 1. The maximal % in­
hibition a drug induces is given as its i.a. This constant always has a value 
between 0 and 1. The affinity of a drug is expressed as its pD 2, i.e. the negative 
logarithm of the molar concentration that causes a response equal to 50% of the 
maximal response of that drug. 
CARDIOVASCULAR EXPERIMENTS 
The stereotactic and cardiovascular preparation of the rats was performed 
according to the methods described in chapter 5. Each animal received maximal­
ly 3 doses of a drug. The effectiveness of a drug is expressed as the minimal dose 
to induce a bradycardia of at least 40 b/minute lasting at least 20 minutes. 
Bradycardia rather than hypotension was chosen as cardiovascular parameter 
because it was found in previous experiments (chapter 5 and 6) that there is a 
clearer dose-response relationship in drug-induced bradycardia than in the hypo­
tension induced by intrahypothalamic injection of a drug (cf. fig. 30). 
QUANTIFICATION OF THE SAR PATTERN OF THE IMIDAZOLINES ON 
THE α-ADRENKRGlC RECEPTOR OF THE RABBIT INTESTINE 
The method of stepwise regression analysis was used to derive a set of equations 
correlating the biological activity expressed as pD2 with the physico-chemical 
properties of the imidazolines using an IBM 370/158 computer. Each equation 
was obtained by the method of least squares. For each equation the correlation 
coefficient (r) and the residual standard deviation (s) were calculated. The signif­
icance of a correlation was calculated with the F-test according to Dixon and 
Massey(1957). 
The method of stepwise regression analysis was developed originally by Mansch 
and co-workers (review: Mansch, 1973). It gives information concerning the 
significance of each individual parameter or combination of parameters in the 
correlation between chemical properties and biological activity of a series of 
137 
drugs. In the stepwise regression analysis described in this chapter, pD2 values on 
rabbit intestine α-adrenergic receptor were used as parameter for biological ac­
tivity; log MV was used as a first approximation of the steric (bulk) effect of the 
molecule; pK was used as a first approximation of substituent-associated elec­
tronic factors; log APC and log TPC were used as approximations for the 
lipophilic and hydrophilic character of the molecules. For details concerning the 
use of these parameters in a stepwise regression analysis the reader may consult 
the reviews of Lien (1969) and Hansch (1973). 
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FIG. 33: Chemical structures of the imidazoline derivatives used in this study. 
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D R U с; s 
Drugs used in this study were: ( -) noradrenaline hydrogen tartrate (Fluka) and a 
number of imidazoline derivatives: Clonidine, tramazoline, DPI and related St-
derivatives (Boehringer-Ingelheim); naphazoline and xylometazohne (CIBA); 
tetrahydrozoline (Pfizer); oxymetazoline (Merck) (figure 33). 
7.2. Physico-chemical properties of the imidazolines 
The physico-chemical properties of the imidazohnes are given in table XVI. 
TABLL XVI 
Physico-chemical constants of the imidazolines used in this study 
Compound 
Clonidine 
St 464 
St 91 
St 93 
St 600 
tramazoline 
naphazoline 
tetrahydroz. 
xylometaz. 
St 1913 
St 71 
DPI 
St 666 
oxymetaz. 
logMV 
1.85 
1.88 
1.98 
1.86 
1.80 
1.94 
1.91 
1.90 
2.07 
1.86 
1.94 
1.80 
1.88 
2.09 
pK
a
* 
8.05 
8.13 
10.86 
9.76 
9 98 
10.66 
10.35 
10.51 
10.2 
9.96 
10.7 
_ 
-
-
A P C a t p H 7 . 4 * 
4.95 
14.56 
0.123 
0.343 
0 059 
0.170 
0.52 
0.233 
3 64 
0.477 
0.427 
0.025 
0.0103 
0.345 
log A PC 
0.69 
1.16 
-0.91 
-0.46 
-1.23 
-0.77 
-0.28 
-0.64 
0.56 
-0.32 
-0.37 
-1.60 
-1.98 
-
TPC 
27 
88 
375 
80 
23 
310 
464 
303 
2297 
178 
866 
-
-
-
log TPC 
1.43 
1.94 
2.57 
1.90 
1.35 
2.49 
2.67 
2.48 
3.36 
2.50 
2.94 
_ 
_ 
-
*: Both pK
a
 and APC were determined from a minimum of 3 experiments. The average 
values are given in this table. The standard deviation in pK
a
 determinations was not larger 
than 2%, in the case of APC standard deviation never exceeded 5%of the mean value. 
7.3. Rabbit intestine o-noradrenergic receptor 
The results of the rabbit intestine expenments are summarized in table XVII. 
The values given in this table are the average values for each drug determined on 
at least 4 different pieces of rabbit intestine. In figure 34 and 35 dose-response 
characteristics of (-) noradrenaline and a number of imidazolines are given. 
Within the group of imidazolines only a limited number of drugs have an in­
trinsic activity equal to 1 (i.e. tramazoline, naphazoline, tetrahydrozoline, xylo-
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Percent mhiDition ol rabbit intestine 
100-
o t-)Noradrena ine 
Δ Naphazoline 
m · DPI 
η St 91 
A Clonidine 
о St 93 
FIG. 34 Dose-response characteristics of (-) noradrenaline and several imidazoline deri­
vatives. 
metazolme, DPI and oxymetazoline). The dose-response curves of these drugs 
are parallel to those of (-) noradrenaline (figures 34 and 35). A few compounds 
have a low intrinsic activity of 0.2 - 0.4 (i.e. Clonidine, St 464, St 93, St 1913 
and St 666). From the dose-response curves given in figs. 34 and 35 it can be 
concluded that these drugs reach a maximal plateau of activity at a certain dose 
and that the effect does not increase beyond this dose. In a few cases it was 
observed that the effect was even smaller after a higher dose than the one at 
which these drugs reach their maximal effect 
Two imidazolines (St 600 and St 71) had an intermediate ι a. of 0.5 - 0.6, 
whereas St 91 had an i.a. equal to 0.9. In fact the i.a. of St 91 was equal to 1 in 
3 expenments, whereas in 4 other experiments it inhibited pendular movements 
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Percent inhibition of rabbit intestine 
100 
o (-)Noradrenaiine 
A Tramazolme 
ж St 71 
• St 666 
A St 464 
FIG. 35 Dose-response characteristics of (-) noradrenaline and several imidazoline deri­
vatives 
only up to 70 - 90%. The dose-response curves of these agents are parallel with 
those of (—) noradrenaline, suggesting a common mode of action (figures 34 and 
35). 
Also with respect to pD2 values a range of values was obtained oxymetazolme 
having a high pD2 of 8.8 and St 464 having the lowest pD2 4.9. The high pDj 
value of oxymetazolme vs that of xylometazohne (8.8 respectively 6.0) stresses 
the fact that the presence of a 3-OH substituent in the phenyl moiety enhances 
peripheral α-adrenergic activity to a great extent (Mujic and van Rossum, 1965). 
The presence of a 3-OH group in DPI may also explain the relative potent 
agonistic activity of this drug when compared with, for instance, Clonidine and 
St 464 
141 
шж Шш ÉL IL i 
• • • • • 
З О х Ю "
7
 1 8 х Ю ' 7 6 О х Ю ' 7 1 8 х 1 0 ' 6 б О х Ю " 6 M 
(-)NA S t 9 1 St91 St91 St91 
З О х Ю "
7
 1 8 х Ю ' 7 6 0x10" 7 1 0 " 6 1 8 x 1 0 ' e M 
(-)NA DPI DPI DPI DPI 
З О х Ю "
7
 6 0 x 1 0 " 7 б О х Ю ' 6 Ю " 5 б О х Ю " 5 M 
(-)NA Clonidine Clonidine Clonidine Clonidine 
FIG. 36: Records of pendular movements of the rabbit intestine and inhibition of intestinal 
motility by St 91 in the upper row, DPI in the middle row and Clonidine in the lower row. 
(-) Noradrenaline is used as the reference drug. Note the low intrinsic activity of Clonidine. 
R F G R E S S I O N ANALYSIS 
The pD2 values of a number of imidazolines were correlated with different 
combinations of the physico-chemical parameters from table XVI by stepwise 
regression analysis. Only the values of the first 11 compounds of table XVI were 
taken into account, because two essential physico-chemical parameters tpK
a
 and 
TPC) of the remaining 3 imidazolines (DPI, St 666, oxymetazoline) could not be 
determined. Moreover, at least in the case of DPI and oxymetazoline the pre-
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TABLF XVII 
Intrinsic activity constants (i.a.) and pD2 values for drug-induced inhibition of the pendul­
ar movements of rabbit intestine and minimal dose required to induce bradycardia > 40 
beats/mm after intrahypothalamic injection in the rat. 
Compound 
Clonidine 
St 464 
St 91 
St 93 
St 600 
tramazobne 
naphazoUne 
tetrahydroz. 
xylometaz. 
St 1913 
St 71 
DPI 
St 666 
oxymetazoline 
(-)noradr. 
Rabbit intestine 
i.a. 
0.4 
0.2 
0.9 
0.3 
0.5 
1 
1 
1 
1 
0.3 
0.6 
1 
0.3 
1 
1 
p D 2 
5.2 
4.9 
6.2 
5.6 
5.4 
6.2 
6.1 
5.6 
6.0 
5.6 
5.7 
5.8 
5.4 
8.8 
6 8 
Minimal dose to induce 
bradycardia > 40 b/m 
(nmol) 
7 
12 
> 50 
not determined 
50 
40 
> 1 0 0 
60 
> 1 0 0 
> 50 
> 1 0 0 
3 
20 
> 100 
20 
sence of the 3ΌΗ substituent seems to be an activity-enhancing factor which is 
not based upon either of the physico-chemical parameters taken into account in 
this study. In table XVIII the set of equations correlating pDj with one or more 
parameters is given. 
In correlating pD2 with one parameter the most significant correlation is obtain­
ed with pD2 vs. pKa (eq. 4; table XVIII). This equation explains 70% of the 
TABLX Х Ш 
Equations obtained from regression analysis describing the relation between pD2 values 
from rabbit intestine experiments and physico-chemical characteristics of the imidazolines 
1-11 from table XVI ( n = l l ) . г correlation coefficient, s standard deviation 
p D 2 = -1.238 + 3.626 log MV 
p D 2 = 4.624 +0.456 logTPC 
p D 2 = 5 .613-0.295 log APC 
p D 2 = 2.088+0.362 pK
a 
p D 2 = 2.347+0.164 log T P C + 0 . 2 9 8 pK
a 
pD2 = -0.870 + 1.876 log MV +0.299 pK
a 
г 
0.636 
0.668 
0.517 
0.837 
0.858 
0.888 
pDj = - 4 . 2 1 2 + 3.468 log MV +0.324 pK
a 
- 0.119 (log TPC) 2 +0.320 log TPC 0.900 
s 
0.341 
0 329 
0.378 
0.242 
0.241 
0.216 
0.236 
no. eq. 
(D* 
(2)* 
(3) 
(4)** 
(5)+ 
(7) + 
significance level in correlations: * . 0.01 < P < 0 . 0 5 , * * : 0 001 < P < 0 0 1 ; * no signific­
ant improvement; : improvement of eq. 4 at P = 0 I 
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variance in the pD2 values (r2 = 0.70). The addition of log TPC (eq. 5; table 
XVIII) does not improve significance (significance level in the difference between 
eq. 4 and 5: 0.25 < Ρ < 0.50; F = 1.22). In adding log MV (eq. 6; table XVIII) the 
improvement in the correlation is marginally significant (F = 3.40; Ρ = 0.10). 
Adding both log MV and log TPC does not further improve significance, not 
even when adding a square term for log TPC (significance level in the difference 
between eq. 6 and 7: 0.50 < Ρ < 0.75; F = 0.395). 
From this analysis it may be concluded that the difference in pD2 values of 
imidazolines at the α-adrenergic receptor of the rabbit intestine can be explained 
at least partly on the basis of the difference in pK
a
: the degree of dissociation of 
the imidazoline base. Within the range of compounds studied it does so in such a 
sense that the higher pK
a
, the larger pD2 (cf. fig. 37). Moreover, within the 
group of compounds studied an increase in molar volume also seems to be an 
activity-enhancing factor. 
pD2 o< imidazolines on rabbit -
intestine .ι-adrenergic receptor 
6 5 π 
pD2=2 0 8 8 * 0 362pKa 
г =0 837 
s = 0 242 
0 0 0 1 < P < 0 01 6 0 
5 5 
5 0 
8 0 9 0 100 110 
ρ Ka 
FIG. 37: pK
a
 of the first 11 imidazolines from table XVI plotted against the pDi of these 
compounds on the rabbit intestine tt-adrenergic receptor. 
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7.4 Intrahypothalamic adrenergic receptor 
The results of the experiments in which the cardiovascular effects of the imida­
zolines were measured after intrahypothalamic injection are summarized in table 
XVII Results are based upon a minimum of 5 experiments per drug. 
After intrahypothalamic injection only a limited number of the imidazolines 
induced bradycardia. DPI was the most potent of the active drugs inducing a fall 
in heart rate of more than 40 b/m already at a dose of 3 nmol. Clonidine, St 
464, St 666, tramazohne, St 600 and tetrahydrozoline were also effective in 
decreasing order of potency (Table XVII). Naphazoline, xylometazobne, St 71 
and oxymetazoline were without effect even in doses up to 100 nmol. St 91 and 
St 1913 were not active in doses up to 50 nmol, higher doses were not tested in 
this expenment. 
We have not attempted to correlate central cardiovascular activity of the imida­
zolines with the physico-chemical parameters of the drugs because only a limited 
number of compounds were active at the doses tested. The use of even higher 
doses is not meaningful in these stereotactic experiments since at such high doses 
drugs may easily leak away from the site of injection and cause effects elsewhere 
in the brain (cf. Myers, 1971, Routenberg, 1972). However, even without 
quantifying the SAR profile for intrahypothalamic effects, it can be concluded 
from the data presented in table XVII that structural requirements for hypo­
thalamic adrenergic activity are quite different from those for rabbit intestine 
adrenergic activity, imidazoline derivatives having good central activity (i.e. St 
464, St 666 and Clonidine) are peripherally weak a-adrenergic receptor stimu­
lants, whereas the reverse is the case for oxymetazoline, xylometazoline, napha­
zoline and St 91. 
Discussion 
A number of imidazoline derivatives belong to the most specific α-adrenergic 
receptor stimulating agents known. The effects these drugs induce when injected 
peripherally are purely those of directly acting α-sympathicomimetics (Mujic 
and van Rossum, 1965). The cardiovascular effects of these drugs when injected 
intravenously therefore consist of an immediate increase in blood pressure, 
usually accompanied by a short reflex bradycardia. However, early observations 
by Hutcheon et al. (1958, 1964) revealed a secondary hypotensive and long-
lasting heart rate lowering effect by tetrahydrozoline and a number of 2-amino-
imidazohne derivatives. In fact, Clonidine — also a 2-amino-imidazoline — is one 
of the most powerful hypotensive agents used in present cardiovascular therapy. 
The hypotension and bradycardia induced by Clonidine are now generally 
accepted to be caused by an effect upon the central nervous system. It can be 
145 
speculateci that the depressor effects of the other 2-ammo-imidazolines and 
tetrahydrozohne are brought about by stimulation of these same central re­
ceptors via which Clonidine causes its hypotension and bradycardia. This 
receptor has been proposed to be an α-adrenergic one (Schmitt, 1971 .Kobinger, 
1973, van Zwieten, 1973, 1975a, see also chapter 4). However, it is remarkable 
that hypotension and bradycardia have not been observed after intravenous 
injection of 2-arylmethyl-imidazolincs. One could suggest that these drugs do 
not penetrate into a lipoid tissue like the brain and therefore do not reach the 
central α-adrenergic receptors mediating sympathetic depression. On the basis of 
the data reported in this chapter it can be concluded that differences in bpo-
phylicity cannot be the only reason for the lack of hypotensive action of the 
2-arylmethyl-imidazolines In fact, the APC's for oxymetazolme, naphazolme 
and xylometazolme are larger than those for St 600, whereas the latter agent 
produces a clomdine-hke hypotension and bradycardia when injected intra­
venously (Hoefke et al., 1975) and is even a clinically useful antihypertensive 
agent (Kho et al., 1975). 
In the previous chapter it was suggested already that hypothalamic and peri­
pheral α-adrenergic receptors may be different. The results with the imidazoline 
derivatives reported in this chapter strenghten this hypothesis. When comparing 
the SAR profiles of the imidazolines tor rabbit intestine vs. hypothalamic adren­
ergic activity the following conclusions can be made (a) the degree of disso­
ciation of imidazoline base is of major importance in determining rabbit intestine 
α-noradrenergic activity. This means that the charge distribution through the 
imidazoline part of the molecule may be of importance in determining agonistic 
activity. This would be in agreement with previous suggestions concerning the 
ionic nature of the interaction between the nitrogen of the catecholamines and 
the a-noradrenergic receptor (Belleau, 1967), (b) Increasing the volume of the 
non-imidazoline part of the molecules is an activity-enhancing factor with 
respect to rabbit intestine adrenergic activity. The increase in activity in this 
respect could reflect a greater amount of hydrophobic interaction of this part of 
the molecule with the receptor sitc,(c) The presence of a 3-OH substituent m 
the phenyl moiety of the imidazolines is an activity-enhancing factor with respect 
to rabbit intestine adrenergic activity as was suggested before (Mujic and van 
Rossum, 1965), (d) Although the APC of the imidazolines has been shown to be 
an important factor determining the centrally mediated cardiovascular effects of 
these drugs when injected intravenously (Stahle, 1974, Hoefke et al , 1975), this 
is no longer the case if the drugs are injected mtracerebrally, ι e beyond the 
blood-brain barrier, (e) Although on basis of the data reported in this study it 
cannot be concluded which molecular characteristics determine the central 
bradycardiac activity of the imidazolines, it seems that the presence of a 
nitrogen atom between the imidazoline and the phenyl moieties is of great 
importance for central α-adrenergic activity m contrast to the periphery where 
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both —N= and —C— derivatives are active. Stähle (1974) has reported that 
changing the bridge from -N= into -CH2-N=, -NH-N= or -CH=N-N= also 
causes a drastic reduction in central hypotensive activity. The reason for the 
relatively good central activity of the —N= derivatives may be that exocyclic 
—N= in the imidazolines will stabilize resonance structure. This has been shown 
to be an activity-enhancing factor in other series of CNS acting drugs (Lien et al., 
1973). 
In conclusion, the data reported in this chapter confirm our previous (cf. chapter 
6) hypothesis that the AH/PO α-adrenergic receptors mediating decrease in blood 
pressure and heart rate differ from classical α-adrenergic receptors. In the previous 
chapter it was suggested that hypothalamic α-adrenergic receptors may be 
"adrenaline receptors". On the basis ot the present data Clonidine would have to 
be classified as a typical "adrenaline receptor" stimulant. There is yet no dear-
cut evidence for the existence of "adrenaline receptors" in peripheral autonomic 
pharmacology. If such receptors could be shown to exist they could provide a 
simple test system for evaluating possible adrenaline receptor stimulating or 
blocking properties of drugs. In this respect it might be of interest to analyse 
adrenergic effects in amphibians, as adrenaline rather than noradrenaline is the 
main catecholamine of the central as well as the peripheral nervous system of 
these animals (Bogdanski et al., 1963). 
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SUMMARY 
This thesis consists of two sections which have in common that in both the 
interactions of drugs with neuronal catecholamine receptors are studied. 
SECTION I is aimed at a molecular pharmacological analysis of neuronal dopa-
mine receptors. Chapter ] contains a review of the models used in the study of 
dopamine receptors. The studies discussed in detail are those concerning the 
mammalian vascular dopamine receptor, the dopamine receptors in evertebrate 
ganglia and dopamine sensitive adenylate cylase Moreover, in this chapter some 
recent advances in the study of mammalian central nervous system dopamine 
receptors are discussed. These advances have been made by the introduction of 
microiontophoretic injections of drugs onto dopamine sensitive neurones on the 
one side and by the use of stereotactic techniques to inject drugs into circum-
scribed, dopamine sensitive brain areas on the other side. This survey reveals that 
the original classification of apomorphine as a typical dopamine receptor stimu-
lant and halopendol as a typical dopamine receptor blocker could not be con-
firmed in several studies. 
In chapter 2 materials and methods used in the study of dopamine receptors in 
the ganglia of the snail Helix aspersa are described Arguments are presented for 
the use of this preparation for a molecular pharmacological analysis of dopamine 
receptors dopamine is the only catecholamine present in the ganglia of thus 
snail, dopamine acts as an inhibitory as well as excitatory neurotransmitter in 
snails, the electrophysiological activity of Helix aspersa neurones can be 
measured intracellularly and the neurones remain functionally intact for several 
hours after the isolation of the ganglia Furthermore, in this chapter the dose-
response characteristics of dopamine-induced inhibition as well as excitation are 
described. Finally, the effects of the anticholinergic agent atropine and the 
antiadrenergic agents phentolamme and propranolol are presented. These agents, 
unless given at high doses, do not influence dopamine-inhibition or excitation. 
This indicates that the dopamine-induced effects may be mediated by dopamine 
specific receptors 
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Chapter 3 is dedicated to the presentation and discussion of a series of expen-
ments in which a number of potential dopamine receptor stimulants or blockers 
were tested for their effects on dopamine sensitive Helix aspersa neurones Sever­
al groups of drugs were tested as such dopamme-like phenylethylamine deri­
vatives, imidazoline derivatives, apomorphme, pinbedil, ergot alkaloids and 
neuroleptic agents The effects obtained with these groups of drugs confirm the 
conclusion that dopamine receptors in Helix aspersa ganglia are dopamine 
specific receptors This conclusion is based upon the fact that dopamine-induced 
inhibition and excitation can be selectively antagonized by drugs that at doses in 
which they block dopamme effects, do not antagonize effects of agonists at 
other (e.g cholinergic, adrenergic) receptors Moreover, dopamine-induced 
effects are mimicked by a set of compounds with a relative potency that differs 
from that at other receptors The second conclusion derived in this chapter is 
that dopamine receptors mediating neuronal inhibition respectively excitation 
have different pharmacological properties This conclusion is based upon the 
observation that several drugs or groups of drugs interact with only one of these 
receptors neuroleptic agents specifically block dopamine-induced excitations, 
ergometnne blocks dopamine-induced inhibitions at doses 10-15 times lower 
than those needed to block excitations, apomorphme mimics dopamine-induced 
excitations whereas it blocks the inhibitions and (3>4-dihydroxyphenylammo)-2-
imidazoline only mimics dopamine-induced inhibitions Finally, in this chapter 
the implications of the existence of two pharmacological distinct types of 
dopamine receptors, DA-I and DA-Ε receptors, are discussed from the point of 
view of the topography of dopamine receptors as well as with respect to the 
possibilities of the design of new, potential clinically useful dopaminergic drugs 
The investigations reported in SECTION II of this thesis focus upon the role of 
mammaban central nervous system adrenergic receptors in the mechanism of 
action of antihypertensive drugs Chapter 4 contains a survey of data from the 
literature pertaining to the role of the central nervous system in cardiovascular 
control. Electrophysiological studies have indicated an integrative role for the 
central nervous system in proprioceptive cardiovascular reflex activity as well as 
in the initiation of somato-visceral adaptive action patterns in which cardio­
vascular elements form an integral aspect Moreover, these studies have shown 
the involvement of several bulbar as well as suprabulbar nuclei Recent pharma­
cological studies have also contributed to the insight of central nervous system 
control of cardiovascular activity In this respect especially central noradrenergic 
mechanisms have been implicated. These mechanisms have been suggested to be 
involved in the mode of action of certain antihypertensive drugs, viz Clonidine 
and α-methyldopa. The survey on the mechanism of action of these two anti­
hypertensive drugs reveals that the site of action of these drugs within the 
central nervous system is still unknown Also the pharmacological nature of the 
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receptor via which these drugs produce their cardiovascular effects is still un­
certain. 
In chapter 5 experiments are presented in which the cardiovascular effects of 
noradrenaline injected stereotactically into the hypothalamus of rats were 
measured Attention is given to the possibilities and bmitations of the technique 
of stereotactic inicction in cardiovascular expenments The results from the 
experiments described in this chapter indicate the presence of noradrenaline 
sensitive mechanisms in the antcnor hypothalamic/preoptic region of the rat. 
Stimulation of these mechanisms with noradrenaline induces an immediate, long-
lasting fall in arterial blood pressure and heart rate. The size and duration of 
these effects depend upon the dose of noradrenaline injected These observations 
are discussed with respect to the possible role of endogenous hypothalamic 
noradrenaline in cardiovascular control. 
Chapter 6 is devoted to a pharmacological analysis of the receptor mediating the 
cardiovascular effects of mtrahypothalamic noradrenaline. Phenylephrine, in 
contrast to isoprcnahne, mimics the noradrenaline-induced effects This indicates 
that noradrenaline stimulates an a- rather than a Д-ddrenergic receptor However, 
several results do not agree entirely with the classification of this receptor as an 
a-adrenergic one fcspecially the relatively potent antagonistic activity of 
piperoxane when compared with phentolamine and the relatively high agonistic 
activity of adrenaline are remarkable These results are discussed in view of the 
presence of adrenaline-containing neurones in the hypothalamus of the rat. 
Furthermore, in this chapter expenments are presented that show that Clonidine 
and the a-methyldopa metabolite α-methylnoradrenaline can mimic the norad­
renaline or adrenaline-induced effects when injected into the anterior hypo­
thalamic/preoptic region. These findings suggest that this region is one of the 
possible sites of action of these drugs when injected peripherally. 
Chapter 7 contains a structure-activity relationship study of 14 clonidme-like 
aryhmidazolines. The activity of these agents was tested on the rabbit intestine 
α-adrenergic receptor and on the hypothalamic adrenergic receptor mediating 
decrease m blood pressure and heart rate after injection of noradrenaline or 
adrenaline. The results obtained indicate a marked difference in the structure-
activity relationship profile for agonistic activity at these respective adrenergic 
receptors. With respect to agonistic α-adrenergic activity on the rabbit intestine 
it was found that imidazolines having a high pK
a
, e g xylometazolinc and 
naphazolme, have a higher affinity and intrinsic activity than imiddzolmes with a 
relatively low pK
a
, such as Clonidine For hypothalamic adrenergic activity the 
presence of a nitrogen bridge between the aryl and the imidazoline moieties is an 
activity enhancing factor. These data are discussed in view of the possible differ­
ences between central and peripheral a-adrenergic receptors 
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SAMENVATTING 
Dit proefschnft bestaat uit twee secties waarin de interaktie van farmaca met 
neuronale catecholamine receptoren centraal staat. 
SECTIE I is gewijd aan een moleculair farmacologische analyse van neuronale 
dopamine receptoren. Hoofdstuk 1 bevat een overzicht van de modellen die 
gebruikt worden bij de bestudering van dopamine receptoren. De studies die in 
detail worden besproken hebben betrekking op de dopamine receptoren in het 
vasculaire systeem van zoogdieren, de dopamine receptoren in ganglia van m-
vertebraten en dopamine gevoelig adenyl cyclase. Bovendien worden in dit 
hoofdstuk een aantal meuwe ontwikkelingen besproken op het gebied van de 
bestudering van dopamine receptoren in het centraal zenuwstelsel van zoog-
dieren. Deze nieuwe ontwikkelingen zijn enerzijds het gevolg van de introduktie 
van de techniek van de micro-iontoforetische injectie van farmaca op dopamine 
gevoelige neuronen en anderzijds het gevolg van de toepassing van stereotactische 
injecties van farmaca in distincte, dopamine gevoehge hereengebieden. Uit dit 
literatuuroverzicht blijkt dat de oorspronkelijke classificatie van apomorphine 
als dopamine receptor stimulant en halopendol als dopamine receptor blokker in 
een aantal studies niet bevestigd kon worden. 
In hoofdstuk 2 worden de methodes besproken die gebruikt zijn bij de bestude-
nng van dopamine receptoren in de ganglia van de slak Helix aspersa De redenen 
worden besproken voor het gebruik van dit preparaat voor een moleculair farma-
cologische analyse van dopamine receptoren dopamine is het enige cate-
cholamine in de ganglia van deze slak, dopamine is zowel inhibitoire als excita-
toire neurotransmitter in slakken, bij Helix aspersa neuronen is het mogelijk de 
electrofysiologische aktiviteit van neuronen intracellulair te meten en de 
neuronen blijven functioneel intact gedurende een aantal uren na isolatie van de 
ganglia. Bovendien worden in dit hoofdstuk de dosis-aktiviteit karakteristieken 
beschreven van de door dopamine geïnduceerde inhibitie of excitatie. Tot slot 
worden de effecten beschreven van de antichohnerge stof atropine en de anti-
adrenerge stoffen phentolamine en propranolol Deze farmaca beïnvloeden de 
dopamine effecten niet, tenzij ze in relatief hoge doseringen worden toegediend. 
Dit duidt erop dat de dopamine effecten mogelijk tot stand komen via dopamine 
specifieke receptoren. 
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Hoofdstuk 3 is gewijd aan de presentatie van een serie experimenten waarin de 
effecten van een aantal potentiële dopamine receptor stimulantia of blokkers 
zijn getest op dopamine gevoelige Helix aspersa neuronen. Verschillende groepen 
farmaca zijn als zodanig getest phenylethylamine derivaten verwant aan dopa-
mine, imidazoline derivaten, apomorphine, pinbedil, ergot alkaloïden en neuro-
leptica. De effecten van deze stoffen bevestigen de conclusie dat dopamine 
receptoren in Helix aspena ganglia dopamine specifiek zijn Deze conclusie is 
gebaseerd op het feit dat de inhibitie en excitatie geïnduceerd door dopamine 
selectief kunnen worden geantagoneerd door stoffen die, in doseringen waarin ze 
de dopamine effecten blokkeren, de effecten van agomsten op andere receptoren 
(bijv. cholmerge, adrenerge) niet blokkeren. Bovendien worden de dopamine 
effecten nagebootst door een sene stoffen met een relatieve werkzaamheid die 
verschilt van die op andere receptoren. De tweede conclusie die getrokken wordt 
in dit hoofdstuk is dat er verschillen bestaan in de dopamine receptoren betrok-
ken bij neuronale inhibitie of excitatie. Deze conclusie is gebaseerd op de obser-
vatie dat verschillende farmaca of groepen farmaca slechts met een van deze twee 
types receptoren interacteren neuroleptica blokkeren specifiek de door dopa-
rrune veroorzaakte excitaties; ergometnne blokkeert de door dopamine geïndu-
ceerde inhibities in dosenngen 10-15 keer lager dan die waarin het de excitaties 
blokkeert, apomorphine bootst de excitaties na en blokkeert de inhibities en 
(3,4-dihydroxyphenyl-amino)-2-imidazoline bootst uitsluitend de inhibities na. 
Tot slot worden in dit hoofdstuk de implicaties van het bestaan van 2 verschil-
lende types dopamine receptoren — DA-1 en DA-b receptoren besproken, 
zowel in het licht van de topografie van dopamine receptoren als met betrekking 
tot de mogelijkheden voor de ontwikkeling van nieuwe, mogelijk klinisch bruik-
bare dopaminerge farmaca. 
Het onderzoek dat gepresenteerd wordt in SECTIE II van dit proefschrift is 
vooral gencht op de rol van adrenerge receptoren in het centraal zenuwstelsel 
van zoogdieren bij het werkingsmechanisme van antihypertensiva. Hoofdstuk 4 
bevat een overzicht van de literatuur die betrekking heeft op de rol van het 
centraal zenuwstelsel bij de cardiovasculaire controle Electrofysiologische 
studies hebben aangetoond dat het centraal zenuwstelsel een integratieve rol 
speelt zowel bij de propnoceptieve cardiovasculaire reflex activiteit als bij de 
initiatie van somato-viscerale adaptieve actie patronen waarvan cardiovasculaire 
elementen een integraal aspect uitmaken Bovendien hebben deze studies aange-
toond dat hierbij verschillende bulbaire en suprabulbaire kernen betrokken zijn. 
Recent farmacologisch onderzoek heeft ook bijgedragen tot het inzicht dat het 
centraal zenuwstelsel een rol speelt bij de cardiovasculaire regulatie In dit ver-
band is de aandacht speciaal gericht geweest op centrale noradrenerge mechanis-
men. Er is gesuggereerd dat deze mechanismen betrokken zijn bij het werkings-
mechanisme van sommige antihypertensiva, in het bijzonder Clonidine en 
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α-methyldopa. Uit de literatuur over het werkingsmechanisme van deze twee 
antihypertensiva blijkt dat de precieze plaats binnen de hersens waar deze stof­
fen hun effect uitoefenen nog onbekend is. Bovendien bestaat er onzekerheid 
over de farmacologische aard van de receptoren via welke deze farmaca hun 
cardiovasculaire effecten veroorzaken. 
In hoofdstuk 5 worden experimenten gepresenteerd waarin cardiovasculaire 
effecten werden gemeten na stereotactische injectie van noradrenaline in de 
hypothalamus van de rat. Er wordt ingegaan op de mogelijkheden en beperkin­
gen van de stereotactische techniek bij cardiovasculaire experimenten. De resul­
taten die verkregen zijn uit de experimenten gepresenteerd in dit hoofdstuk 
duiden erop dat er zich in het antérieur hypothalamische/preoptische gebied 
noradrenaline gevoelige mechanismen bevinden. Als deze mechanismen worden 
gestimuleerd met noradrenahne, treedt er een onmiddellijke, langdurige daling 
op van de artende bloeddruk en hartfrequentie De grootte en de duur van deze 
effecten hangen af van de dosis noradrenaline die wordt geïnjecteerd. Deze 
resultaten worden besproken in het licht van de mogelijke rol van endogeen 
hypothalamisch noradrenaline bij de cardiovasculaire regulatie. 
Hoofdstuk 6 is gewijd aan een farmacologische analyse van de receptoren die 
betrokken zijn bij de cardiovasculaire effecten van intrahypothalamisch toe-
gediend noradrenahne. In tegenstelling tot isoprenabne bootst phenylephrine de 
door noradrenahne veroorzaakte effecten na. Dit duidt erop dat noradrenaline 
eerder een α- dan een j3-adrenerge receptor stimuleert. Een paar resultaten zijn 
echter niet volledig in overeenstemming met de classificatie van deze receptor als 
a-ddrenerge. In dit verband valt vooral op het relatief sterke antagonisme van 
piperoxaan in vergelijking met phentolamine en de relatief sterke agomstische 
aktiviteit van adrenaline. Deze gegevens worden besproken in het licht van de 
aanwezigheid van adrenaline bevattende neuronen in de hypothalamus van de 
rat. In dit hoofdstuk worden bovendien experimenten gepresenteerd waaruit 
blijkt dat Clonidine en de metabohet van a-methyldopa — het a-methylnoradre-
naline — de door noradrenaline en adrenahne veroorzaakte effecten nabootsen 
als deze stoffen in het anteneur hypothalamisch/preoptische gebied worden 
geïnjecteerd. Deze gegevens suggereren dat dit gebied een van de mogelijke wer-
kingsplaatsen is van deze antihypertensiva na penfere toediening 
Hoofdstuk 7 bevat een structuur-activiteits relatie onderzoek van 14 aan cloni-
dine verwante arylimidazohnes. De activiteit van deze stoffen werd gemeten op 
de a-adrenerge receptor van de darm van het konijn en op de hypothalamische 
adrenerge receptor die betrokken is bij de door noradrenahne en adrenaline 
veroorzaakte bloeddruk en hartfrequentie daling. De resultaten tonen een duide-
lijk verschil aan in het structuur-activiteits profiel van deze farmaca voor agonis-
159 
tische werking op deze respectievelijke adrenerge receptoren Voor agomstische 
aktiviteit op de a-adrenerge receptor in de darm van het konijn werd gevonden 
dat imidazolines met een hoge pK
a) zoals xylometazoline en naphazolme, een 
hogere intrinsieke activiteit en affiniteit hebben dan stoffen met een relatief lage 
pK
a
, zoals Clonidine. Voor hypothalamische adrenerge aktiviteit werd gevonden 
dat de aanwezigheid van een stikstof brug tussen de aryl en imidazoline skeletten 
een aktiviteits verhogende factor is. Deze resultaten worden besproken in het 
licht van mogelijke verschillen tussen centrale en periphere α-adrenerge recep­
toren. 
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